Optimized Factor VIII gene

Codon-optimized nucleic acid molecules enhance Factor VIII expression in non-homologous systems, addressing high manufacturing costs and poor expression levels, leading to improved treatment efficacy and reduced administration frequency for hemophilia.

KR103047300B1Inactive Publication Date: 2026-11-11BIOVERATIV THERAPEUTICS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020187025354
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-10-18
Filing Date
2017-01-31
Publication Date
2026-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies face challenges in efficiently expressing Factor VIII protein in non-homologous systems due to high manufacturing costs and poor expression levels, which are inhibited by cis-active genes and matrix attachment-like sequences, leading to frequent and inconvenient therapeutic regimens for hemophilia patients.

Method used

Development of codon-optimized nucleic acid molecules encoding N-terminal and C-terminal portions of the Factor VIII polypeptide, with high sequence identity, to enhance expression and stability, and inclusion of signal peptides and tissue-specific promoters to increase FVIII activity in subjects.

Benefits of technology

The optimized nucleic acid molecules significantly increase FVIII expression levels, providing a more efficient and cost-effective treatment for hemophilia by reducing the frequency of administration and improving therapeutic outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112018095721096-PCT00012_ABST
    Figure 112018095721096-PCT00012_ABST
Patent Text Reader

Abstract

The present disclosure provides a codon-optimized factor VIII sequence, a vector comprising the codon-optimized factor VIII sequence and a host cell, a polypeptide encoded by the codon-optimized factor VIII sequence, and a method for preparing said polypeptide. The present disclosure also provides a method for treating a bleeding disorder, e.g., hemophilia, comprising the step of administering the codon-optimized factor VIII nucleic acid sequence or the polypeptide encoded thereby to a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Reference to the list of sequences submitted electronically

[0002] The contents of the electronically submitted sequence list in an ASCII text file (name: 2159_469PC02_SequenceListing_ST25.txt; size: 204,138 bytes; and creation date: January 31, 2017) are incorporated herein by reference in their entirety. Background Technology

[0003] The blood coagulation pathway involves, in part, the formation of the enzyme complex (Xase complex) of Factor VIIIa (FVIIIa) and Factor IXa (FIXa) on the surface of platelets. FIXa is a serine protease with relatively weak catalytic activity in the absence of its carrier, FVIIIa. The Xase complex cleaves Factor X (FX) into Factor Xa (FXa), which eventually interacts with Factor Va (FVa) to cleave prothrombin and produce thrombin. A hemophilia is a bleeding disorder caused by mutations and / or deletions in the FVIII (FVIII) gene that result in a deficiency of FVIII activity (Peyvandi). et al. 2006). In some cases, patients have reduced levels of FVIII in the presence of FVIII inhibitors, such as anti-FVIII antibodies.

[0004] A. Hemophilia is characterized by spontaneous massive bleeding and excessive bleeding. Over time, recurrent bleeding into the muscles and joints, usually beginning in infancy, leads to hemophilic arthrosis and irreversible joint damage. This damage is progressive and can result in severely limited joint mobility, muscle atrophy, and chronic pain (Rodriguez-Merchan, EC, Semin. Thromb. Hemost. 29:87-96 (2003) (the full text thereof is incorporated herein by reference).

[0005] The disease can be treated by alternative therapies that target the restoration of FVIII activity to 1% to 5% of normal levels to prevent spontaneous bleeding (e.g., literature [Mannucci, PM, et al., N. Engl. J. Med. [See 344:1773-9 (2001)] (the full text thereof is incorporated herein by reference). Plasma-derived and recombinant FVIII products are available to treat hemorrhagic episodes as needed or to prevent the occurrence of hemorrhagic episodes by providing prophylactic treatment. Based on the half-life of these products (10 to 12 hours) (White GC, et al., Thromb. Haemost. 77:660-7 (1997); Morfini, M., Haemophilia 9 (suppl 1):94-99;discussion 100 (2003)), therapeutic regimens commonly require frequent intravenous administration 2 to 3 times a week for prophylaxis and 1 to 3 times daily for treatment as needed (Manco-Johnson, MJ, et al., N. Engl. J. Med. 357:535-544 (2007) (the full text of each of these is incorporated herein by reference). Such frequent administration is inconvenient and expensive.

[0006] A major obstacle to providing low-cost recombinant FVIII protein to patients is the high cost of commercial manufacturing. FVIII protein is poorly expressed in non-homologous expression systems, being of a smaller secondary to tertiary scale than similarly sized proteins. (Lynch et al., Hum. Gene. Ther. ; 4:259-72 (1993). Poor expression of FVIII is partially inhibited by cis-active genes in the FVIII coding sequence that inhibit FVIII expression, e.g., transcription slicer genes (Hoeben et al., Blood 85:2447-2454 (1995)), matrix attachment-like sequences (MAR) (Fallux et al., Mol. Cell. Biol.16:4264-4272 (1996)), and transcriptional extension inhibitory gene (Koeberl et al., Hum. Gene. Ther. It is due to the existence of ; 6:469-479 (1995)).

[0007] Advances in the inventors' understanding of the biology of FVIII expression have led to the development of more potent FVIII variants. For example, biochemical studies have demonstrated that the FVIII B domain is not required for FVIII carrier activity. Deletion of the B domain resulted in a 17-fold increase in mRNA levels and a 30% increase in secreted protein compared to full-length wild-type FVIII. (Toole et al., Proc Natl Acad Sci USA 83:5939-42 (1986)). This led to the development of B domain-deleted (BDD) FVIII protein concentrate, which is now widely used in clinics. However, recent studies indicate that full-length and BDD hFVIII misfolds in the ER lumen, causing activation of the unfolded protein response (UPR) and apoptosis in mice and hepatocytes.

[0008] Therefore, there is a demand in the field for FVIII sequences that are efficiently expressed in non-homologous systems.

[0009] A codon-optimized nucleic acid molecule encoding a polypeptide having FVIII activity is disclosed. In one embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding an N-terminal portion of a factor VIII (FVIII) polypeptide and a second nucleic acid sequence encoding a C-terminal portion of an FVIII polypeptide; the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 58 to 2277 and 2320 to 1791 of SEQ ID NO. 3 or (ii) nucleotides 58 to 2277 and 2320 to 1791 of SEQ ID NO. 4; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.

[0010] The present disclosure also provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide; wherein the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 or (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.

[0011] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 1. In other embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 2. In one embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 70. In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 71.

[0012] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 3.

[0013] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 4.

[0014] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 5.

[0015] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 6.

[0016] In some embodiments, the present disclosure provides a method for increasing the expression of a polypeptide having FVIII activity in a subject, the method comprising the step of administering an isolated nucleic acid molecule or vector disclosed herein to a subject requiring such an expression, and the expression of the polypeptide is increased for a reference nucleic acid molecule comprising SEQ ID NO. 16 or a vector comprising a reference nucleic acid molecule.

[0017] In some embodiments, the present disclosure provides a method for treating a bleeding disorder comprising the step of administering a nucleic acid molecule, vector, or polypeptide disclosed herein to a subject requiring treatment for the bleeding disorder.

[0018] embodiments

[0019] E1. An isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of a factor VIII (FVIII) polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide; wherein the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 58 to 2277 and 2320 to 1791 of SEQ ID NO. 3 or (ii) nucleotides 58 to 2277 and 2320 to 1791 of SEQ ID NO. 4; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.

[0020] E2. An isolated nucleic acid molecule, wherein the first nucleotide sequence of E1 comprises nucleotides 58 to 1791 of SEQ ID NO. 3 or nucleotides 58 to 1791 of SEQ ID NO. 4.

[0021] E3. An isolated nucleic acid molecule having at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 4.

[0022] E4. An isolated nucleic acid molecule, wherein the second nucleotide sequence in E1 or E2 comprises nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 4.

[0023] E5. An isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide; wherein the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 or (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.

[0024] E6. In E5, the second nucleic acid sequence comprises nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 5 or nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 6, an isolated nucleic acid molecule.

[0025] E7. An isolated nucleic acid molecule having at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 1791 of SEQ ID NO. 5 or nucleotides 58 to 1791 of SEQ ID NO. 6.

[0026] E8. An isolated nucleic acid molecule, wherein the first nucleic acid sequence comprises nucleotides 58 to 1791 of sequence no. 5 or nucleotides 58 to 1791 of sequence no. 6.

[0027] E9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 1.

[0028] E10. In E9, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 1, an isolated nucleic acid molecule.

[0029] E11. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 2.

[0030] E12. An isolated nucleic acid molecule, wherein the nucleotide sequence of E10 comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 2.

[0031] E13. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 70.

[0032] E14. An isolated nucleic acid molecule, wherein the nucleotide sequence of E13 comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 70.

[0033] E15. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 71.

[0034] E16. An isolated nucleic acid molecule, wherein the nucleotide sequence of E15 comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence number 71.

[0035] E17. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 3.

[0036] E18. An isolated nucleic acid molecule, wherein the nucleotide sequence of E17 comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 3.

[0037] E19. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 4.

[0038] E20. An isolated nucleic acid molecule, wherein the nucleotide sequence of E19 comprises nucleotides 58 to 2277 and 2320 to 4374 of nucleotide sequence no. 4.

[0039] E21. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 5.

[0040] E22. In E21, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of nucleotide sequence no. 5, an isolated nucleic acid molecule.

[0041] E23. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 6.

[0042] E24. An isolated nucleic acid molecule, wherein the nucleotide sequence of E23 comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 6.

[0043] E25. An isolated nucleic acid molecule, wherein in any one of E1 to E24, the nucleotide sequence further comprises a nucleic acid sequence encoding a signal peptide.

[0044] E26. In E25, the signal peptide is an isolated nucleic acid molecule, which is an FVIII signal peptide.

[0045] E27. In E25 or E26, the nucleic acid sequence encoding the signal peptide is a codon-optimized, isolated nucleic acid molecule.

[0046] E28. In any one of E25 to E27, the nucleic acid sequence encoding the signal peptide comprises: (i) nucleotides 1 to 57 of SEQ ID NO. 1; (ii) nucleotides 1 to 57 of SEQ ID NO. 2; (iii) nucleotides 1 to 57 of SEQ ID NO. 3; (iv) nucleotides 1 to 57 of SEQ ID NO. 4; (v) nucleotides 1 to 57 of SEQ ID NO. 5; (vi) nucleotides 1 to 57 of SEQ ID NO. 6; (vii) nucleotides 1 to 57 of SEQ ID NO. 70; (viii) nucleotides 1 to 57 of SEQ ID NO. 71; or (ix) an isolated nucleic acid molecule having at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with nucleotides 1 to 57 of sequence number 68.

[0047] E29. In any one of E1 to E28, the isolated nucleic acid molecule comprises one or more characteristics selected from the group consisting of:

[0048] (a) The human codon adaptation index of a nucleic acid molecule or a part thereof is increased for sequence number 16;

[0049] (b) The frequency of the optimal codon of the nucleotide sequence or a part thereof increases for sequence number 16;

[0050] (c) The nucleotide sequence or a portion thereof contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in Sequence No. 16;

[0051] (d) The relative frequency of use of synonymous codons in the nucleotide sequence or a part thereof is increased for sequence number 16;

[0052] (e) The number of effective codons in the nucleotide sequence or a part thereof is reduced for sequence number 16;

[0053] (f) The nucleotide sequence contains fewer MARS / ARS sequences (sequence numbers 21 and 22) than sequence number 16;

[0054] (g) The nucleotide sequence contains fewer destabilizing genetic elements (sequence numbers 23 and 24) compared to sequence number 16; and

[0055] (h) Any combination of these.

[0056] E30. An isolated nucleic acid molecule comprising, in any one of E1 to E29, a non-homologous nucleotide sequence.

[0057] E31. In E30, the non-homologous nucleotide sequence is an isolated nucleic acid molecule encoding a non-homologous amino acid sequence that is a half-life extender.

[0058] E32. An isolated nucleic acid molecule in which the non-homologous amino acid sequence in E30 or E31 is an immunoglobulin constant region or a part thereof, transferrin, albumin, or PAS sequence.

[0059] E33. An isolated nucleic acid molecule in which, in E30 or E31, the non-homologous amino acid sequence is the Fc region.

[0060] E34. An isolated nucleic acid molecule, wherein in any one of E30 to E33, the non-homologous amino acid sequence is connected to the N-terminus or C-terminus of the amino acid sequence encoded by the nucleotide sequence, or is inserted between two amino acids in the amino acid sequence encoded by the nucleotide sequence.

[0061] E35. In E34, the non-homologous amino acid sequence is an isolated nucleic acid molecule inserted between two amino acids at one or more insertion sites selected from Table 3.

[0062] E36. An isolated nucleic acid molecule encoding a monomer-dimer hybrid molecule containing FVIII, in any one of E30 to E35.

[0063] E37. In any one of E1 to E36, the FVIII polypeptide is an isolated nucleic acid molecule that is full-length FVIII or FVIII with a B domain deleted.

[0064] E38. An isolated nucleic acid molecule that is operatively linked to at least one transcription control sequence in any one of E1 to E37.

[0065] E39. A vector comprising any one of the nucleic acid molecules of E1 to E38.

[0066] E40. In E39, the vector is a virus vector.

[0067] E41. A host cell containing a nucleic acid molecule of any one of E1 to E32 or a vector of E39 or E40.

[0068] E42. In E41, the host cells are selected from the group consisting of CHO cells, HEK293 cells, BHK21 cells, PER.C6 cells, NS0 cells and CAP cells.

[0069] E43. A polypeptide encoded by any one of the nucleic acid molecules of E1 to E37 or by a vector of E39 or E40, or produced by a host cell of E41 or E42.

[0070] E44. A method for producing a polypeptide having FVIII activity, comprising the steps of: culturing a host cell of E41 or E42 under conditions in which a polypeptide having FVIII activity is produced; and recovering the polypeptide having FVIII activity.

[0071] E45. A method in which the expression of a polypeptide having FVIII activity in E44 is increased for host cells cultured under the same conditions containing a reference nucleotide sequence including SEQ No. 16.

[0072] E46. A method for increasing the expression of a polypeptide having FVIII activity in a subject, comprising the step of administering an isolated nucleic acid molecule of any one of E1 to E38 or a vector of E39 or E40 to a subject requiring the same, wherein the expression of the polypeptide is increased with respect to a reference nucleic acid molecule comprising SEQ No. 16 or a vector comprising a reference nucleic acid molecule.

[0073] E47. A method for increasing the expression of a polypeptide having FVIII activity, comprising the step of culturing a host cell of E41 or E42 under conditions in which the polypeptide having FVIII activity is expressed by a nucleic acid molecule, wherein the expression of the polypeptide having FVIII activity is increased for a host cell cultured under the same conditions comprising a reference nucleic acid sequence including SEQ No. 16.

[0074] E48. A method in which, in any one of E44 to E47, the expression of the FVIII polypeptide is increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, or at least about 100 times.

[0075] E49. A method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing host cells of E41 or E42 under conditions in which a polypeptide having FVIII activity is produced by a nucleic acid molecule, wherein the yield of the polypeptide having FVIII activity is increased for host cells cultured under the same conditions comprising a reference nucleic acid sequence comprising SEQ No. 16.

[0076] E50. A method for treating a bleeding disorder comprising the step of administering any one of E1 to E38 nucleic acid molecules, a vector of E39 or E40, or a polypeptide of E43 to a subject requiring it.

[0077] E51. In E50, the bleeding disorder is characterized by a deficiency in FVIII.

[0078] E52. In E50, the bleeding disorder is hemophilia, method.

[0079] E53. In E50, the bleeding disorder is A hemophiliac, method.

[0080] E54. A method in which, in any one of E50 to E53, plasma FVIII activity at 24 hours after administration is increased compared to a subject administered with a reference nucleic acid molecule comprising SEQ No. 16, a vector comprising the reference nucleic acid molecule, or a polypeptide encoded by the reference nucleic acid molecule.

[0081] E55. In E54, plasma FVIII activity increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, or at least about 100 times.

[0082] E56. In E39 or 40, the vector is a lentivirus vector.

[0083] E57. A vector comprising, in any one of E39, E40 and E56, a tissue-specific promoter, a tissue-specific enhancer, or both a tissue-specific promoter and a tissue-specific enhancer.

[0084] E58. In E57, a tissue-specific promoter and / or tissue-specific enhancer selectively increase the expression of a transgene in liver cells, a vector.

[0085] E59. In E57 or E58, the tissue-specific promoter comprises a promoter sequence selected from the group consisting of mouse tyretin promoter (mTTR), endogenous human factor VIII promoter (F8), human alpha-1-antitrypsin promoter (hAAT), human albumin minimal promoter and mouse albumin promoter.

[0086] E60. In any one of E57 to E59, the tissue-specific promoter is a vector comprising an mTTR promoter.

[0087] E61. A method for treating a bleeding disorder comprising the step of administering any one of E56 to E60 vectors to a subject requiring it. Brief explanation of the drawing

[0088] FIGS. 1a through 1j provide codon-optimized nucleotide sequences (SEQN 17) encoding Factor VIII with a B domain deletion. FIG. 1a shows the nucleotide sequence of coFVIII-3 (SEQN 1). FIG. 1b shows the nucleotide sequence of coFVIII-4 (SEQN 2). FIG. 1c shows the nucleotide sequence of coFVIII-5 (SEQN 70). FIG. 1d shows the nucleotide sequence of coFVIII-6 (SEQN 71). FIG. 1e shows the nucleotide sequence of coFVIII-52 (SEQN 3). FIG. 1f shows the nucleotide sequence of coFVIII-62 (SEQN 4). FIG. 1g shows the nucleotide sequence of coFVIII-25 (SEQN 5). Figure 1h shows the nucleotide sequence of coFVIII-26 (sequence number 6). Figures 1i and 1j show the nucleotide and amino acid sequences of B domain deleted (BDD-FVIII) (sequence numbers 16 and 17, respectively). Figures 2a through 2j illustrate the codon usage frequency bias adjustments in codon-optimized nucleotide sequences encoding BDD-FVIII. Figure 2a shows the relative frequencies of codons in wild-type nucleotide sequences (before codon optimization) encoding BDD-FVIII, e.g., unoptimized BDD-FVIII. The Human Codon Adaptation Index (CAI) of the unoptimized BDD-FVIII sequence is 74%. Figure 2b shows the relative frequencies of codons in the coFVIII-1 variant sequence with a human CAI of 88%. Figure 2c shows the relative frequencies of codons in the coFVIII-3 variant sequence with a human CAI of 91%. Figure 2d shows the relative frequencies of codons in the coFVIII-4 variant sequence with a human CAI of 97%. Figure 2e shows the relative frequencies of codons in the coFVIII-5 variant sequence with 83% human CAI. Figure 2f shows the relative frequencies of codons in the coFVIII-6 variant sequence with 83% human CAI. Figure 2g shows the relative frequencies of codons in the coFVIII-52 variant sequence with 91% human CAI. Figure 2h shows the relative frequencies of codons in the coFVIII-62 variant sequence with 91% human CAI. Figure 2i shows the relative frequencies of codons in the coFVIII-25 variant sequence with 88% human CAI. Figure 2j shows the relative frequencies of codons in the coFVIII-26 variant sequence with 88% human CAI. FIG. 3 provides a plasmid map of FVIII-303 containing coFVIII-1 in the pcDNA3 backbone under the control of an ET-enhanced tyretin exchange promoter, which is positioned upstream of the coFVIII-1 translation start site and includes a synthetic enhancer, an mTIR enhancer, and an mTIR promoter. Figure 4 shows a graph of FVIII plasma activity in HemA mice after hydro-injection of 5 µg of FVIII-303 (coFVIII-1; circles) or 5 µg of FVIII-311 (BDD-FVIII; squares). FVIII plasma activity is determined by FVIII-specific colorimetric assays at 24, 48, and 72 hours after injection. Relative activity levels at 72 hours, normalized to the expression level of FVIII-311, are plotted. Figure 5 shows a plasmid map of pLV-coFVIII-52 containing coFVIII-52 in a lentivirus plasmid under the control of an ET promoter, which is positioned upstream of the coFVIII-52 translation start site and includes a synthetic enhancer, an mTTR enhancer, and an mTTR promoter. Figures 6a to 6c show graphs of FVIII plasma activity in HemA mice after hydro-injection of various nucleotide-coding FVIIIs. FVIII plasma activity is determined by FVIII-specific colorimetric assays at 24, 48, and 72 hours after injection. Figure 6a shows FVIII plasma activity in HemA mice after hydro-injection of 5 µg of LV-coFVIII-1 (filled circle), 5 µg of LV-coFVIII-3 (triangle), 5 µg of LV-coFVIII-4 (inverted triangle), 5 µg of LV-coFVIII-5 (diamond), or 5 µg of LV-coFVIII-6 (empty circle). Figure 6b shows FVIII plasma activity in HemA mice after hydro-injection of 5 µg of LV-coFVIII-1 (circle), 5 µg of LV-coFVIII-25 (triangle), or 5 µg of LV-coFVIII-26 (inverted triangle). Figure 6c shows FVIII plasma activity in HemA mice after hydro-injection of 20 µg of LV-2116 (codon-unoptimized (WT) BDD-FVIII nucleotide sequence; empty circle), 20 µg of LV-coFVIII-1 (triangle), 20 µg of LV-coFVIII-52 (square), or 20 µg of LV-coFVIII-62 (filled circle). The relative activity levels at 72 hours are shown for each plasmid normalized to the expression levels of LV-coFVIII-1 (Figs. 6a, 6b, and 6c) and / or LV-2116 (Fig. 6c) as indicated. Figure 7 shows plasma FVIII activity in HemA mice 24 days after injection with a 1E8TU / mouse lentivirus vector containing coFVIII-1, coFVIII-5, coFVIII-52, coFVIII-6, or coFVIII-62, compared to an LV-2116 (BDD-FVIII) control, as measured by FVIII-specific colorimetric assay. Error bars represent standard deviations. FIGS. 8a through 8c provide various codon-optimized nucleotide sequences encoding BDD-FVIII fused to XTEN. FIG. 8a shows the nucleotide sequence of coFVIII-52-XTEN (SEQ No. 19), where the nucleotide sequence encoding XTEN having 144 amino acids ("XTEN 144 "; SEQ ID NO. 18; underlined) is inserted into the coFVIII-52 nucleotide sequence. FIG. 8b shows the nucleotide sequence of coFVIII-1-XTEN (SEQ ID NO. 20), where the nucleotide sequence encoding XTEN having 144 amino acids ("XTEN 144 "; SEQ ID NO. 18; underlined) is inserted into the coFVIII-1 nucleotide sequence. FIG. 8c shows the nucleotide sequence of coFVIII-6-XTEN (SEQ ID NO. 72), where the nucleotide sequence encoding XTEN having 144 amino acids ("XTEN 144 "; Sequence No. 18; underlined) is inserted into the coFVIII-6 nucleotide sequence (e.g., amino acid residue 745 corresponding to the mature FVIII sequence). FIG. 9 provides a plasmid map of pLV-coFVIII-52-XTEN containing coFVIII-52-XTEN in a lentiviral vector under the control of an ET promoter. A lentiviral vector containing each of the remaining codon-optimized nucleic acid molecules encoding a polypeptide having FVIII activity as described herein is constructed in the same manner as pLV-coFVIII-52-XTEN, in which the same XTEN sequence is inserted to replace the B domain of FVIII. Figures 10a and 10b show FVIII activity in HemA mice after injection with plasmid DNA (Fig. 10a) or lentiviral vector (Fig. 10b) containing various codon-optimized nucleotide sequences encoding BDD-FVIII. Fig. 10a shows 5 µg of FVIII-311 (codon-unoptimized, BDD-FVIII coding nucleotide sequence; square), 5 µg of FVIII-303 (coFVIII-1; small circle), or FVIII-306 (coFVIII-1-XTEN). 144 Figure 10 shows a graph of FVIII plasma activity in HemA mice after hydro-injection by (large circle). Relative activity at 72 hours, normalized to FVIII-311, is plotted for each plasmid. Figure 10 shows plasma FVIII activity in HemA mice at 21 days after injection of 1E8TU / mouse of lentiviral vectors containing coFVIII-52 or coFVIII-52-XTEN, compared to the LV-2116 (BDD-FVIII) control, measured by FVIII-specific colorimetric assay. Error bars represent standard deviation. Figure 11a shows the amino acid sequence of full-length mature human factor VIII. Figure 11b shows the amino acid sequence of full-length human von Willebrand factor (sequence number 44). Figures 11c and 11d show the amino acid and nucleotide sequences, respectively, of the XTEN polypeptide having 42 amino acids (XTEN AE42-4; sequence numbers 46 and 47, respectively). The amino acid sequences of various XTEN polypeptides having 144 amino acids are shown in FIG. 11e, FIG. 11g, FIG. 11i, FIG. 11k, FIG. 11m, FIG. 11o, FIG. 11q, FIG. 11s, FIG. 11u, and FIG. 11w (sequence numbers 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66, respectively), and the corresponding nucleotide sequences are shown in FIG. 11f, FIG. 11h, FIG. 11j, FIG. 11l, FIG. 11n, FIG. 11p, FIG. 11r, FIG. 11t, FIG. 11v, and FIG. 11x (sequence numbers 49, 51, 53, 55, 57, 59, 61, 63, 65, and 67, respectively). Figure 11y shows the nucleotide sequence of the ET promoter (Sequence No. 69). Figure 11z shows the nucleotide sequence for coFVIII-1 (Sequence No. 68) (see International Publication WO 2014 / 127215, Sequence No. 1). Figure 12a is a graph showing the plasma activity (IU / mL) of FVIII in 14-day-old HemA mice after IV administration of approximately 1.5 E10 TU / kg of LV-wtBDD-FVIII (circles), LV-coFVIII-6 (squares), or LV-coFVIII-6XTEN (triangles). Figure 12b is a graph showing the vector copy number (VCN) at 150 days after treatment in 14-day-old HemA mice administered IVly of approximately 1.5 E10 TU / kg of lentiviral vectors expressing wtBDD-FVIII, coFVIII-1, coFVIII-3, coFVIII-4, coFVIII-5, coFVIII-6, coFVIII-52, coFVIII-62, coFVIII-25, or coFVIII-26. Figure 12c is a graph showing FVIII plasma activity (IU / mL) at 21 days after treatment in 14-day-old HemA mice administered by IV of a lentivirus vector at a dose of about 1.5 E10 TU / kg expressing wtBDD-FVIII, coFVIII-1, coFVIII-3, coFVIII-4, coFVIII-5, coFVIII-6, coFVIII-52, coFVIII-62, coFVIII-25, or coFVIII-26. Figures 13a and 13b are graph displays illustrating FVIII plasma activity levels (Figure 13a) and anti-FVIII antibody levels (Figure 13b) in five HemA mice treated with a lentivirus expressing the coFVIII-5 variant. 14-day-old HemA litters are administered approximately 1.5 E10 TU / kg of a lentivirus expressing the coFVIII-5 variant by intravenous injection. Each mouse is designated by a number (i.e., 1, 2, 3, 4, and 5; Figures 13a and 13b). Figure 14 is a graph showing the correlation between LV-FVIII expression levels and the presence of anti-FVIII antibodies, as evidenced by FVIII plasma activity 21 days after lentivirus treatment. Each data point corresponds to a single HemA mouse. Each mouse receives a dose of 1.5 E10 TU / kg by intravenous injection of a lentivirus expressing one of the coFVIII variants disclosed herein. The horizontal line represents the mean FVIII plasma activity. Figure 15 is a graph showing the correlation between the vector copy number (VCN) per cell and the presence of anti-FVIII antibodies at 150 days after lentivirus treatment. Each data point corresponds to a single HemA mouse. Each mouse receives a dose of 1.5 E10 TU / kg by intravenous injection of a lentivirus expressing one of the coFVIII variants disclosed herein. The horizontal line represents the mean VCN. Figures 16a and 16b are graphs illustrating FVIII plasma activity levels (Figure 16a) and anti-FVIII antibody levels (Figure 16b) in two HemA mice (coFVIII-52-A and coFVIII-52-B) treated with a lentivirus expressing the coFVIII-52 variant. 14-day-old HemA litters are administered approximately 1.5 E10 TU / kg of the lentivirus expressing the coFVIII-52 variant by intravenous injection. Figures 16c and 16d are images showing RNA in situ hybridization staining (dark staining) for FVIII expression in liver tissues collected from the coFVIII-52-A (Figure 16c) and coFVIII-52-B (Figure 16d) mice of Figures 16a and 16b. Figure 17 is a graph showing long-term FVIII expression in HemA neonatal mice treated with lentiviruses expressing wild-type B domain-deleted FVIII (wtBDD-FVIII; triangle), coFVIII-52XTEN (circle), or coFVIII-6XTEN (inverted triangle) variants. Neonatal HemA mice are administered an intravenous injection of approximately 1.5 A10 TU / kg of lentivirus expressing wtBDD-FVIII, coFVIII-52XTEN, or coFVIII-6XTEN. FVIII plasma activity is measured over approximately 16 weeks. FIG. 18 shows 1.3 x 10⁻¹⁰ containing a nucleotide encoding factor VIII (SEQ No. 72; LV-coFVIII-6-XTEN) fused to XTEN. 9 This is a graph showing circulating FVIII levels in HemA canine neonates (S3 or K4) after administration of a transduction unit / kg lentivirus vector. Squares connected by solid lines represent the aPTT-S3 sample, and triangles connected by dashed lines represent the aPTT-K4 sample. The y-axis shows plasma FVIII activity as % of normal, where normal human FVIII activity is 100%. The x-axis shows the date after lentivirus treatment, where lentivirus treatment is administered on day 0. FIGS. 19a to 19c are graphs of whole blood hemostasis monitored by rotational thromboelastometry (ROTEM) assays for Naive HemA dogs (Fig. 19a), dogs S3 (Fig. 19b) 2 weeks after lentivirus treatment, and dogs K4 (Fig. 19c) 2 weeks after lentivirus treatment. For each of FIGS. 19a to 19c, coagulation time (CT) is indicated in seconds (s), thrombus formation time (CFT) is indicated in seconds (s), alpha angle (α) is indicated in degrees (°), amplitude after 5 minutes CT (A5) is indicated in millimeters (mm), amplitude after 20 minutes CT (A20) is indicated in millimeters (mm), and maximum thrombus stiffness (MCF) is indicated in millimeters (mm). FIG. 19d is a table summarizing the normal ranges for each of the parameters CT, CFT, α, A5, A2, and MCF shown in FIG. 19a to 19c. Specific details for implementing the invention

[0089] The present disclosure describes a codon-optimized gene encoding a polypeptide having Factor VIII (FVIII) activity. The present disclosure relates to a codon-optimized nucleic acid molecule encoding a polypeptide having Factor VIII activity, a vector comprising the optimized nucleic acid molecule and a host cell, a polypeptide encoded by the optimized nucleic acid molecule, and a method for producing such polypeptide. The present disclosure also relates to a method for treating a bleeding disorder, such as hemophilia, comprising the step of administering an optimized Factor VIII nucleic acid sequence, a vector comprising the optimized nucleic acid sequence, or a polypeptide encoded by it to a subject. The present disclosure meets a significant need in the field by providing an optimized Factor VIII sequence that demonstrates increased expression in host cells and an improved yield of Factor VIII protein in a method for producing recombinant Factor VIII, and which potentially yields greater therapeutic efficacy when used in gene therapy methods. In a given embodiment, the present disclosure describes an isolated nucleic acid molecule comprising a nucleotide sequence having sequence homology to a nucleotide sequence selected from sequence numbers 1 to 14, 70 and 71.

[0090] Exemplary works of the present disclosure are illustrated in the accompanying drawings and sequence list. To provide a clear understanding of the specification and claims, the following definitions are provided.

[0091] I. Definition

[0092] It should be noted that the term “one” or “one” group means one or more of the group: for example, “nucleotide sequence” is understood to represent one or more nucleotide sequences. Therefore, the terms “one” (or “one”), “one or more”, and “at least one” may be used interchangeably in this specification.

[0093] The term “about” is used herein to mean approximately, nearly, about, or a range thereof. When the term “about” is used in connection with a numerical range, it modifies the range by extending the boundary higher or lower than the stated numerical value. Generally, the term “about” is used herein to modify numerical values ​​higher or lower than the mentioned value by a variation of 10% above or below (higher or lower).

[0094] For the purposes of this disclosure, the term “isolated” refers to biological material (cells, polypeptides, polynucleotides, or fragments, variants, or derivatives thereof) removed from its original environment (the environment in which it exists in nature). For example, polynucleotides existing in nature in plants or animals are not isolated, but the same polynucleotides separated from adjacent nucleic acids existing in nature are considered “isolated.” No specific level of purification is required. Polypeptides produced by recombination and proteins expressed in host cells are considered, for the purposes of this disclosure, isolated as native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.

[0095] "Nucleic acid," "nucleic acid molecule," "oligonucleotide," and "polynucleotide" are used interchangeably and refer to phosphate ester polymer forms of ribonucleosides (adenosine, guanosine, uridine, or cytidine; "RNA molecule") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecule"), or any phosphoester analogues thereof, e.g., single-stranded forms, or double-stranded helical phosphothioates and thioesters. Double-stranded DNA-DNA, DNA-RNA, and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structures of the molecule and is not limited to any specific tertiary form. Accordingly, the term includes double-stranded DNA, plasmids, supercoiled DNA, and chromosomes, which are particularly found as linear or circular DNA molecules (e.g., restriction fragments). In describing the structure of a specific double-stranded DNA molecule, the sequence may be described herein in accordance with general relationships that give a sequence only in the 5'→3' direction along the untranscribed strand of DNA (i.e., the strand having sequence homology to mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone molecular biological manipulation. DNA includes, but is not limited to, cDNA, genomic DNA, plasmid DNA, synthetic DNA, and semi-synthetic DNA. A "nucleic acid composition" of the present disclosure comprises one or more nucleic acids as described herein.

[0096] As used herein, a “coding region” or “coding sequence” is a portion of a polynucleotide consisting of codons that can be translated into amino acids. A “stop codon” (TAG, TGA, or TAA) is not typically translated into an amino acid, but may be considered part of the coding region; however, any flanking sequence, e.g., promoters, ribosome binding sites, transcription terminators, introns, etc., is not part of the coding region. The boundaries of the coding region are typically determined by a start codon at the 5’ end coding for the amino terminus of the resulting polypeptide and a translation stop codon at the 3’ end coding for the carboxyl terminus of the resulting polypeptide. Two or more coding regions may exist in a single polynucleotide construct, for example, on a single vector, or in separate polynucleotide constructs, for example, on separate (different) vectors. Subsequently, a single vector may contain only a single coding region or may contain two or more coding regions.

[0097] A specific protein secreted by a mammalian cell is associated with a secreted signal peptide that is cleaved from the mature protein when the release of the protein chain growing across the rough endoplasmic reticulum is initiated. Those skilled in the art know that the signal peptide is generally fused to the N-terminus of the polypeptide and cleaved from the complete or "full-length" polypeptide to produce the secreted or "mature" form of the polypeptide. In a specific embodiment, the native signal peptide or a functional derivative of its sequence retains the ability to direct the secretion of the polypeptide operatively associated with it. Alternatively, a non-homologous mammalian signal peptide, for example, human tissue plasminogen activator (TPA) or mouse β-glucuronidase signal peptide, or a functional derivative thereof may be used.

[0098] The term "downstream" refers to a nucleotide sequence located at the 3' end of a reference nucleotide sequence. In a given embodiment, the downstream nucleotide sequence refers to a sequence following the starting point of transcription. For example, the translation start codon of a gene is located downstream of the starting site of transcription.

[0099] The term "upstream" means a nucleotide sequence located at the 5' side of a reference nucleotide sequence. In certain embodiments, the upstream nucleotide sequence means a sequence located on the 5' side of a coding region or at the starting point of transcription. For example, most promoters are located upstream of the starting site of transcription.

[0100] As used herein, the terms “gene regulatory region” or “regulatory region” refer to a nucleotide sequence located upstream (5’ non-coding sequence), within, or downstream (3’ non-coding sequence) of a coding region that influences the transcription, RNA processing, stability, or translation of the associated coding region. The regulatory region may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites, and stem-loop structures. When the coding region is intended for expression in eukaryotic cells, the polyadenylation signal and transcription termination sequence will typically be located at the 3’ of the coding sequence.

[0101] A polynucleotide encoding a gene product, e.g., a polypeptide, may include a promoter and / or other expression (e.g., transcription or translation) control gene elements operatively associated with one or more coding regions. In an operative association, the coding region for the gene product, e.g., a polypeptide, is associated with one or more regulatory regions in such a way that the expression of the gene product is placed under the influence or control of the regulatory region(s). For example, the coding region and the promoter are "operatively associated" if the induction of the promoter function causes the transcription of the mRNA encoding the gene product encoded by the coding region, and if the nature of the connection between the promoter and the coding region does not interfere with the ability of the DNA template being transcribed or the ability of the promoter to direct the expression of the gene product. Other expression control gene elements, other than promoters, e.g., enhancers, manipulators, repressors, and transcription termination signals, may also be operatively associated with the coding region to direct the expression of the gene product.

[0102] "Transcriptional control sequence" means a DNA regulatory sequence that provides for the expression of a coding sequence in a host cell, such as promoters, enhancers, terminators, etc. Various transcriptional control regions are known to those skilled in the art. These include, without limitation, transcriptional control regions functioning in vertebrate cells, such as promoter and enhancer segments from cytomegalovirus (immediately an initial promoter with intron-A), primate virus 40 (an initial promoter), and retroviruses (e.g., Rous sarcoma virus) (but not limited to these). Other transcriptional control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone, and rabbit β-globin, and other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcriptional control regions include tissue-specific promoters and enhancers, and lymphokine-inducible promoters (e.g., promoters inducible by interferon or interleukin).

[0103] Similarly, various translation control genetic elements are known to those skilled in the art. These include, but are not limited to, ribosomal binding sites, translation initiation and termination codons, and genetic elements derived from picornaviruses (particularly referred to as internal ribosomal entry sites or IRES, also called CITE sequences).

[0104] As used herein, the term “expression” means the process by which a polynucleotide produces a gene product, e.g., RNA or polypeptide. This includes, without limitation, the transcription of a polynucleotide into messenger RNA (mRNA), transfer RNA (tRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA), or any other RNA product, and the translation of mRNA into a polypeptide. Expression produces a “gene product.” As used herein, the gene product may be a nucleic acid, e.g., messenger RNA produced by the transcription of a gene, or a polypeptide translated from a transcript. The gene product described herein further comprises a nucleic acid having post-transcriptional modifications, e.g., polyadenylation or splicing, or a polypeptide having post-translational modifications, e.g., methylation, glycosylation, addition of lipids, association with other protein subunits, or proteolytic cleavage. As used herein, the term “yield” means the amount of polypeptide produced by the expression of a gene.

[0105] "Vector" refers to any vehicle for the cloning of nucleic acids and / or their transport into a host cell. A vector may be a replicon to which another nucleic acid segment can be attached to cause replication of the attached segment. "Replicon" refers to any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that acts as an autonomous unit of in vivo replication, that is, capable of replicating under its own control. The term "vector" includes both viral and non-viral vehicles for introducing nucleic acids into cells in vitro, extracellularly, or in vivo. A large number of vectors are known and used in the field, including, for example, plasmids, modified eukaryotic viruses, or modified bacterial viruses. Insertion of a polynucleotide into a suitable vector can be achieved by ligating a suitable polynucleotide fragment into a selected vector having complementary adhesive ends.

[0106] A vector may be engineered to code for a selectable marker or reporter that provides for the selection or identification of the cell to which the vector has been introduced. The expression of the selectable marker or reporter allows for the identification and / or selection of a host cell to introduce and express other coding regions contained in the vector. Examples of selectable marker genes known and used in the art include genes that confer resistance to ampicillin, streptavidin, gentamicin, kanamycin, hygromycin, non-alphafos herbicides, sulfonamides, etc.; and genes used as phenotypic markers, namely anthocyanin regulatory genes, isofentanyl convertase genes, etc. Examples of reporters known and used in the art include luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetylconvertase (CAT), β-galactosidase (LacZ), β-glucuronidase (Gus), etc. Selectable markers may also be conceived as reporters.

[0107] The term "selectable marker" refers to an identification factor, usually an antibiotic or chemical resistance gene that can be selected based on the effect of a marker gene, namely resistance to antibiotics, resistance to herbicides, colorimetric markers, enzymes, fluorescent markers, etc., wherein the effect is used to track the heritability of a nucleic acid of interest and / or to identify a cell or organism that has inherited the nucleic acid of interest. Examples of selectable marker genes known and used in the art include genes that confer resistance to ampicillin, streptavidin, gentamicin, kanamycin, hygromycin, non-alphafos herbicides, sulfonamides, etc.; and genes used as phenotypic markers, namely anthocyanin regulatory genes, isofentanyl convertase genes, etc.

[0108] The term “reporter gene” means a nucleic acid encoding a confirmation factor that can be identified based on the effect of the reporter gene, wherein the effect is used to track the heritability of the nucleic acid of interest and / or to identify the cell or organism that has inherited the nucleic acid of interest and / or to induce gene expression or measure transcription. Examples of reporter genes known and used in the art include luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetylconvertase (CAT), β-galactosidase (LacZ), β-glucuronidase (Gus), etc. Selectable marker genes may also be considered as reporter genes.

[0109] "Promoter" and "promoter sequence" are used interchangeably and refer to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. Generally, the coding sequence is located at the 3' end of the promoter sequence. A promoter may be derived entirely from a native gene, may consist of different genetic elements derived from different promoters found in nature, or may even include synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct gene expression in different tissues or cell types, at different developmental stages, or in response to different environmental or physiological conditions. Promoters that cause gene expression in most cell types are commonly referred to as "constitutive promoters." Promoters that cause gene expression in specific cell types are commonly referred to as "cell-specific promoters" or "tissue-specific promoters." Promoters that cause gene expression at a specific developmental or cell differentiation stage are commonly referred to as "developmental-specific promoters" or "cell differentiation-specific promoters." Promoters that cause or induce gene expression after cell exposure or treatment by substances, biological molecules, chemicals, ligands, light, etc., are commonly referred to as "inducible promoters" or "regulatory promoters." In most cases, since the precise boundaries of the regulatory sequence are not completely delimited, it is further recognized that DNA fragments of different lengths can have the same promoter activity.

[0110] The promoter sequence is typically bound at its 3' end by a transcription initiation site and extends upstream (in the 5' direction) to contain the minimum number of bases or genetic elements required to initiate transcription at a detectable level above the background. A transcription initiation site (conveniently defined, for example, by mapping by nuclease S1) and a protein binding domain (common sequence) responsible for binding by RNA polymerase will be found within the promoter sequence.

[0111] The terms "restriction endonuclease" and "restriction enzyme" are used interchangeably and refer to enzymes that bind and cleave specific nucleotide sequences within double-stranded DNA.

[0112] The term “plasmid” refers to an extrachromosomal genetic element that usually carries a gene that is not part of the cell’s central metabolism, typically in the form of a circular double-stranded DNA molecule. Such genetic elements may be linear, circular, or supercoiled, autonomous replication sequences, genome integration sequences, phages, or nucleotide sequences of single or double-stranded DNA or RNA derived from any source, in which multiple nucleotide sequences are linked or recombined in a unique configuration capable of introducing a DNA sequence and promoter fragment for a selected gene product along an appropriate 3’ untranslated sequence into the cell.

[0113] Eukaryotic viral vectors that may be used include, but are not limited to, adenovirus vectors, retrovirus vectors, adeno-associated virus vectors, poxviruses, e.g., vaccinia virus vectors, baculovirus vectors, or herpesvirus vectors. Non-viral vectors include plasmids, liposomes, electrically charged lipids (cytopectins), DNA-protein complexes, and biopolymers.

[0114] "Cloning vector" refers to a unit length of nucleic acid that replicates sequentially and a "replicon" comprising a replication origin, such as a plasmid, phage, or cosmid, to which another nucleic acid segment can be attached to cause replication of the attached segment. A given cloning vector may replicate in one cell type, e.g., bacteria, and be expressed in another, e.g., eukaryotic cells. A cloning vector typically comprises one or more sequences that can be used for the selection of cells containing the vector and / or one or more cloning sites for the insertion of the nucleic acid sequence of interest.

[0115] The term "expression vector" refers to a vehicle designed to allow the expression of an inserted nucleic acid sequence after insertion into a host cell. The inserted nucleic acid sequence is operatively positioned in association with the regulatory region as described above.

[0116] The vector is introduced into a host cell by methods widely known in the art, such as transfusion, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), the use of a gene gun, or by a DNA vector carrier.

[0117] As used herein, “culture,” “culture for,” and “culturing” mean culturing cells under in vitro conditions that allow for cell growth or division, or maintaining cells in a living state. As used herein, “cultured cells” means cells proliferated in vitro.

[0118] As used herein, the term “polypeptide” means a molecule composed of monomers (amino acids) connected in a straight line by amide bonds (also known as peptide bonds), intended to include a single “polypeptide” and plural “polypeptides.” The term “polypeptide” means any chain or chains of two or more amino acids and does not mean a specific length of the product. Accordingly, any other term used to mean peptide, dipeptide, tripeptide, oligopeptide, “protein,” “amino acid chain,” or chain or chains of two or more amino acids is included within the definition of “polypeptide,” and the term “polypeptide” may be used instead of or interchangeably with any of these terms. The term "polypeptide" is also intended to mean the product of post-expression modification of a polypeptide, including, without limitation, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or manufactured recombinant technologies, but are not necessarily translated from the specified nucleic acid sequence. They may be produced by any method, including chemical synthesis.

[0119] The term "amino acid" includes alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine ​​(Cys or C); glutamine (Gln or Q); glutamic acid (Glu or E); glycine (Gly or G); histidine (His or H); isoleucine (Ile or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V). Non-traditional amino acids are also within the scope of this disclosure, and norleucine, omitin, norvaline, homoserine and other amino acid residue analogs, e.g., the literature [Ellman et al. Includes those described in Meth. Enzym. 202:301-336 (1991)]. To generate these non-naturally occurring amino acid residues, the literature [Noren et al.The procedures of Science 244:182 (1989) and the literature of Ellman et al. may be utilized. Briefly, this procedure involves the chemical activation of repressor tRNA by non-naturally occurring amino acid residues, followed by in vitro transcription and translation of RNA. The introduction of non-traditional amino acids may also be achieved using peptide chemistry known in the art. As used herein, the term “polar amino acid” includes amino acids that have a net charge of zero but a non-zero partial charge in different parts of their side chains (e.g., M, F, W, S, Y, N, Q, C). These amino acids may participate in hydrophobic and electrostatic interactions. As used herein, the term “charged amino acid” includes amino acids that may have a non-zero net charge in their side chains (e.g., R, K, H, E, D). These amino acids may participate in hydrophobic and electrostatic interactions.

[0120] Fragments or variants of polypeptides, and any combination thereof, are also included in this disclosure. The terms “fragment” or “variant” include any polypeptide that possesses at least some of the characteristics of a reference polypeptide (e.g., FcRn binding affinity for an FcRn binding domain or Fc variant, coagulation activity for an FVIII variant, or FVIII binding activity for a VWF fragment) when referring to the polypeptide binding domain or binding molecule of this disclosure. The polypeptide fragments include proteolytic fragments and deletion fragments in addition to the specific antibody fragments otherwise described herein, but do not include naturally occurring full-length polypeptides (or mature polypeptides). Variants of the polypeptide binding domain or binding molecule of this disclosure include fragments as described above, and polypeptides having amino acid sequences altered by amino acid substitutions, deletions, or insertions. Variants may be naturally occurring or non-naturally occurring. Non-naturally occurring variants may be produced using mutagenic techniques known in the field. Variant polypeptides may include conservative or non-conservative amino acid substitutions, deletions, or additions.

[0121] "Conservative amino acid substitution" is the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine), are defined in the art. Therefore, when an amino acid in a polypeptide is replaced by another amino acid from the same side chain family, the substitution is considered conservative. In another embodiment, the string of amino acids may be conservatively replaced by a structurally similar string with a different composition and / or order of side chain family members.

[0122] The term "percentage of identity," as known in the art, is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences as determined by comparing sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as in such cases, as determined by a match between strings of these sequences. "Identity" refers to the literature [ Computational Molecular Biology (Lesk, AM, ed.) Oxford University Press, New York (1988); Biocomputing : Informatics and Genome Projects (Smith, D.W., ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I(Griffin, AM, and Griffin, HG, eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer This can be easily calculated by known methods, including (but not limited to) those described in [Gribskov, M. and Devereux, J., eds.] Stockton Press, New York (1991). A preferred method for determining identity is designed to provide the best match between the tested sequences. Methods for determining identity are coded in publicly available computer programs. Sequence alignment and the calculation of identity percentages are performed using sequencing software, such as the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc. (Madison, Wisconsin)), the GCG suite of programs (Wisconsin Package version 9.0, Genetics Computer Group (GCG) (Madison, Wisconsin)), BLASTP, BLASTN, and BLASTX (Altschul et al ., J. Mol . Biol . 215This may be performed using :403 (1990)) and DNASTAR (DNASTAR, Inc. (53715 Madison Street S. Park 1228, Wisconsin, USA)). Within the context of this application, where sequence analysis software is used for analysis, it will be understood that the results of this analysis are based on the “default values” of the mentioned program unless otherwise stated. As used herein, “default values” will mean any set of values ​​or parameters originally loaded by the software when initially set up. For the purpose of determining the identity (%) between the optimized BDD FVIII sequence of this disclosure and the reference sequence, the identity (%) is calculated using only the nucleotides in the reference sequence corresponding to the nucleotides in the optimized BDD FVIII sequence of this disclosure. For example, when comparing a full-length FVIII nucleotide sequence containing a B domain with the optimized B domain-deleted (BDD) FVIII nucleotide sequence of the present disclosure, identity (%) is calculated using a portion of alignment including the A1, A2, A3, C1, and C2 domains. Nucleotides in the portion of the full-length FVIII sequence coding for the B domain (which creates a large "gap" in alignment) will not be counted as a mismatch. Additionally, in determining the identity (%) between the optimized BDD FVIII sequence of the present disclosure, or a designated portion thereof (e.g., nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 3) and a reference sequence, the identity (%) will be calculated by aligning the number of matched nucleotides divided by the total number of nucleotides in the complete sequence of the optimized BDD-FVIII sequence, or the designated portion thereof, as described herein.

[0123] As used herein, “nucleotides corresponding to nucleotides in the optimized BDD FVIII sequence of the present disclosure” are identified by alignment of the optimized BDD FVIII sequence of the present disclosure to maximize identity with the reference FVIII sequence. The number used to identify equivalent amino acids in the reference FVIII sequence is based on the number used to identify corresponding amino acids in the optimized BDD FVIII sequence of the present disclosure.

[0124] A “fusion” or “chimeric” protein means a first amino acid sequence connected to a second amino acid sequence that is not naturally connected by nature. Amino acid sequences that are typically present in distinct proteins may be placed together in a fusion polypeptide, or amino acid sequences that are typically present in the same protein may be located in a new arrangement in the fusion polypeptide, for example, in the fusion of the Factor VIII domain of the present disclosure by the Ig Fc domain. A fusion protein is produced, for example, by chemical synthesis or by generating and translating a polynucleotide in which the peptide region codes in a desired relationship. A chimeric protein may further comprise a second amino acid sequence associated with the first amino acid sequence by covalent, non-peptide, or non-covalent bonds.

[0125] As used herein, the term “insertion site” refers to a location in the FVIII polypeptide, or in a fragment, variant, or derivative thereof, immediately upstream of the location where a non-homologous moiety may be inserted. The “insertion site” is designated by a number, the number being the number of amino acids in the mature native FVIII (SEQ No. 15; FIG. 11a) corresponding to the insertion site immediately N-terminus at the insertion site. For example, the phrase “a3 comprises a non-homologous moiety at the insertion site corresponding to amino acid 1656 of SEQ No. 15” indicates that the non-homologous moiety is located between two amino acids corresponding to amino acids 1656 and 1657 of SEQ No. 15.

[0126] As used herein, the phrase “immediately downstream of the amino acid” means a position immediately next to the terminal carboxyl group of the amino acid. Similarly, the phrase “immediately upstream of the amino acid” means a position immediately next to the terminal amine group of the amino acid.

[0127] As used herein, the terms “inserted,” “inserted,” “inserted into,” or grammatically related terms refer to the positions of non-homologous moiety in the recombinant FVIII polypeptide relative to positions in native mature human FVIII. As used herein, such terms refer to characteristics of the recombinant FVIII polypeptide relative to native mature human FVIII and do not indicate, imply, or suggest any method or process by which the recombinant FVIII polypeptide is prepared.

[0128] As used herein, the term “half-life” refers to the biological half-life of a specific polypeptide in vivo. Half-life may be expressed as the time required for half of the dose administered to a subject and / or other tissue in an animal to be cleared from circulation. When the clearance curve of a specific polypeptide is plotted as a function of time, the curve is typically biphasic, consisting of a rapid α-phase and a longer β-phase. The α-phase typically represents the equilibrium of the administered Fc polypeptide between the intravascular and extravascular spaces and is determined in part by the size of the polypeptide. The β-phase typically represents the catabolism of the polypeptide in the intravascular space. In some embodiments, FVIII and chimeric proteins containing FVIII are monophasic and, accordingly, do not have an alpha phase but only a single beta phase. Thus, in certain embodiments, the term half-life as used herein refers to the half-life of the polypeptide in the β-phase.

[0129] As used herein, the term “linked” means a first amino acid sequence or nucleotide sequence that is covalently or non-covalently linked to a second amino acid sequence or nucleotide sequence, respectively. The first amino acid or nucleotide sequence may be directly linked to or juxtaposed with the second amino acid or nucleotide sequence, or alternatively, an mediating sequence may covalently link the first sequence to the second sequence. The term “linked” means not only the fusion of the first amino acid sequence to the second amino acid sequence at the C-terminus or N-terminus, but also includes the insertion of the entire first amino acid sequence (or second amino acid sequence) into any two amino acids in the second amino acid sequence (or each first amino acid sequence). In one embodiment, the first amino acid sequence may be linked to the second amino acid sequence by a peptide bond or a linker. The first nucleotide sequence may be linked to the second nucleotide sequence by a phosphodiester bond or a linker. The linker may be a peptide or polypeptide (in the case of a polypeptide chain) or a nucleotide or nucleotide chain (in the case of a nucleotide chain) or any chemical moiety (in the case of both polypeptide and polynucleotide chains). The term "linked" is also indicated by a hyphen (-).

[0130] As used herein, the term “associated” means a covalent or non-covalent bond formed between a first amino acid chain and a second amino acid chain. In one embodiment, the term “associated” means a covalent, non-peptide bond or non-covalent bond. This association may be indicated by a colon, i.e., (:). In another embodiment, this means a covalent bond excluding a peptide bond. For example, the amino acid cysteine ​​includes a thiol group capable of forming a disulfide bond or a bridge with a thiol group at the second cysteine ​​residue. In most naturally occurring IgG molecules, the CH1 and CL regions are associated by a disulfide bond, and the two heavy chains are associated by two disulfide bonds at positions 239 and 242 using the Kabat numbering system (positions 226 or 229, EU numbering system). Examples of covalent bonds include, but are not limited to, peptide bonds, metallic bonds, hydrogen bonds, disulfide bonds, sigma bonds, pi bonds, delta bonds, glycosidic bonds, agnostic bonds, bent bonds, bipolar bonds, Pi backbones, double bonds, triple bonds, quadruple bonds, pentatrix bonds, sextatrix bonds, conjugation, superconjugation, aromatity, hapticity, or antibonds. Non-limiting examples of non-covalent bonds include ionic bonds (e.g., , cation-pi bond or salt bond), metallic bond, hydrogen bond (e.g. , It includes dihydrogen bonds, dihydrogen complexes, storage wall hydrogen bonds, or symmetric hydrogen bonds), van der Waals forces, London dispersion forces, mechanical bonds, halogen bonds, aurophilicity, lubrication, stacking, entropy forces, or chemical polarity.

[0131] As used herein, the term “monomer-dimer hybrid” means a chimeric protein comprising a first polypeptide chain and a second polypeptide chain associated with each other by disulfide bonds, wherein the first chain comprises a coagulation factor, e.g., factor VIII and a first Fc region, and the second chain comprises a second Fc region without a coagulation factor, is essentially composed of, or is composed of. A monomer-dimer hybrid construct is thus a hybrid comprising a monomeric mode having at least one coagulation factor and a dimeric mode having two Fc regions.

[0132] As used in this specification, hemostasis means the cessation or slowing of bleeding or heavy bleeding; or the slowing or slowing of blood flow through a blood vessel or part of the body.

[0133] As used herein, a hemostatic disorder refers to a genetic, congenital, or acquired condition characterized by a tendency toward massive bleeding due to an impaired ability or inability to form fibrin clots, either spontaneously or as a result of trauma. The three major forms are hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency or "Christmas disease"), and hemophilia C (factor XI deficiency, mild bleeding tendency). Other hemostatic disorders include, for example, von Willebrand disease, factor XI deficiency (PTA deficiency), factor XII deficiency, deficiency or structural abnormality in fibrinogen, prothrombin, factor V, factor VII, factor X, or factor XIII, and Bernard-Soulier syndrome, which is a defect or deficiency in GPIb. GPIb, the receptor for vWF, may be defective and has resulted in a lack of primary thrombus formation (primary hemostasis), an increased tendency to bleed, and Glanzman and Naegeli thrombocytopenia. In liver failure (acute and chronic forms), there is insufficient production of coagulation factors by the liver; this may increase the risk of bleeding.

[0134] The isolated nucleic acid molecules, isolated polypeptides, or vectors comprising isolated nucleic acid molecules of the present disclosure may be used prophylactically. As used herein, the term “prophylactic treatment” means the administration of the molecule prior to a hemorrhagic episode. In one embodiment, a subject requiring a general hemostatic agent is undergoing or about to undergo surgery. The polynucleotide, polypeptide, or vector of the present disclosure may be administered prophylactically before or after surgery. The polynucleotide, polypeptide, or vector of the present disclosure may be administered during or after surgery to control an acute hemorrhagic episode. Surgery may include, but is not limited to, liver transplantation, hepatectomy, dental procedures, or stem cell transplantation.

[0135] The isolated nucleic acid molecules, isolated polypeptides, or vectors of the present disclosure are also used for on-demand therapy. The term “on-demand therapy” means the administration of the isolated nucleic acid molecules, isolated polypeptides, or vectors in response to symptoms of a hemorrhagic episode or prior to an activity that may cause bleeding. In one embodiment, on-demand therapy may be given to a subject when bleeding begins, e.g., after an injury, or when bleeding is anticipated, e.g., prior to surgery. In another embodiment, on-demand therapy may be given prior to an activity that increases the risk of bleeding, such as contact sports.

[0136] As used herein, the term “acute hemorrhage” means an episode of bleeding regardless of the underlying cause. For example, the subject may have resistance due to trauma, uremia, hereditary bleeding disorders (e.g., factor VII deficiency), platelet disorders, or the development of antibodies against coagulation factors.

[0137] As used herein, "treat," "treat," and "treat" mean, for example, a reduction in the severity of a disease or condition; a reduction in the duration of the disease course; the alleviation of one or more symptoms associated with a disease or condition; the provision of a beneficial effect on a subject having a disease or condition without necessarily needing to cure the disease or condition; or a preventive measure against one or more symptoms associated with a disease or condition. In one embodiment, the term “treating” or “treating” means maintaining an FVIII trough level of at least about 1 IU / dL, 2 IU / dL, 3 IU / dL, 4 IU / dL, 5 IU / dL, 6 IU / dL, 7 IU / dL, 8 IU / dL, 9 IU / dL, 10 IU / dL, 11 IU / dL, 12 IU / dL, 13 IU / dL, 14 IU / dL, 15 IU / dL, 16 IU / dL, 17 IU / dL, 18 IU / dL, 19 IU / dL, or 20 IU / dL in a subject by administering the isolated nucleic acid molecule, isolated polypeptide, or vector of the present disclosure. In another embodiment, treating or treatment means maintaining an FVIII trough level of about 1 to about 20 IU / dL, about 2 to about 20 IU / dL, about 3 to about 20 IU / dL, about 4 to about 20 IU / dL, about 5 to about 20 IU / dL, about 6 to about 20 IU / dL, about 7 to about 20 IU / dL, about 8 to about 20 IU / dL, about 9 to about 20 IU / dL, or about 10 to about about 20 IU / dL. Treatment or treatment of the disease or condition may also involve maintaining FVIII activity in the subject at a level equivalent to at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of FVIII activity in the non-hemophilic subject. The minimum trough level required for treatment may be measured by one or more known methods and may be adjusted (increased or decreased) for each person.

[0138] As used herein, "administering" means giving a pharmaceutically acceptable Factor VIII-coding nucleic acid molecule, Factor VIII polypeptide, or a vector comprising the Factor VIII-coding nucleic acid molecule of this disclosure to a subject via a pharmaceutically acceptable route. The route of administration may be intravenous, e.g., intravenous injection and intravenous drip. Additional routes of administration include, e.g., subcutaneous, intramuscular, oral, nasal, and pulmonary administration. The nucleic acid molecule, polypeptide, and vector may be administered as part of a pharmaceutical composition comprising at least one excipient.

[0139] As used herein, the phrase “subjects requiring this” includes subjects who may benefit from the administration of the nucleic acid molecule, polypeptide, or vector of the present disclosure, for example, to improve hemostasis, such as mammalian subjects. In one embodiment, subjects include, but are not limited to, individuals having hemophilia. In another embodiment, subjects include, but are not limited to, individuals who do not generate FVIII inhibitors and thus require bypass treatment. Subjects are adults or minors (e.g. , It may be under 12 years of age.

[0140] As used herein, the term “coagulation factor” means a molecule, or an analogue thereof, produced naturally or by recombination, that prevents or reduces the duration of a hemorrhagic episode in a subject. That is, it means a molecule having coagulation-promoting activity, that is, responsible for converting fibrinogen into a mesh of insoluble fibrin to cause blood to coagulate or form a thrombus. “Activatable coagulation factor” is a coagulation factor in an inactive form (e.g., its zymogen form) that can be converted into an active form.

[0141] As used herein, coagulation activity means the ability to participate in a cascade of biochemical reactions that peak in the formation of fibrin clots and / or reduce the severity, duration, or frequency of major hemorrhages or hemorrhagic episodes.

[0142] As used herein, the terms “non-homologous” or “exogenous” refer to molecules that are not typically found in a given environment, e.g., a cell or polypeptide. For example, exogenous or non-homologous molecules may be introduced into a cell and exist only after the manipulation of the cell, e.g., by transfection or other forms of genetic engineering, or non-homologous amino acid sequences may exist in a protein that is not found in nature.

[0143] As used herein, the term “non-homologous nucleotide sequence” means a nucleotide sequence that does not occur in nature by a given polynucleotide sequence. In one embodiment, the non-homologous nucleotide sequence codes for a polypeptide capable of extending the half-life of FVIII. In another embodiment, the non-homologous nucleotide sequence codes for a polypeptide that increases the hydrodynamic radius of FVIII. In another embodiment, the non-homologous nucleotide sequence codes for a polypeptide that improves one or more pharmacokinetic properties of FVIII without significantly affecting its biological activity or function (e.g., its coagulating activity). In some embodiments, FVIII is bound to or linked by a linker to a polypeptide encoded by the non-homologous nucleotide sequence. Non-limiting examples of polypeptide moieties encoded by non-homologous nucleotide sequences include immunoglobulin constant regions or parts thereof, albumin or fragments thereof, albumin-binding moieties, transferrin, the PAS polypeptide of U.S. Patent Application No. 20100292130, HAP sequences, transferrin or fragments thereof, C-terminal peptide (CTP) of the β subunit of human chorionic gonadotropin, albumin-binding small molecules, XTEN sequences, FcRn-binding moieties (e.g., complete Fc regions or parts thereof that bind to FcRn), short-chain Fc regions (e.g., ScFc regions as described in U.S. No. 2008 / 0260738, WO No. 2008 / 012543, or WO No. 2008 / 1439545), polyglycine linkers, polyserine linkers, peptides, and among others. It comprises a short polypeptide of 6 to 40 amino acids of two types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), having varying degrees of secondary structure from less than 50% to more than 50%, or a combination of two or more of these.In some embodiments, a polypeptide encoded by a non-homologous nucleotide sequence is linked to a nonpolypeptide moiety. Non-limiting examples of the nonpolypeptide moiety include polyethylene glycol (PEG), albumin-linked small molecules, polysialic acid, hydroxyethyl starch (HES), derivatives thereof, or any combination thereof.

[0144] As used herein, the term “Fc region” is defined as a portion of a polypeptide corresponding to the Fc region of native Ig, that is, formed by the dimeric association of each Fc domain of its two heavy chains. The native Fc region forms a homodimer with another Fc region. Conversely, as used herein, the term “genetically fused Fc region” or “short-chain Fc region” (scFc region) refers to a synthetic dimeric Fc region consisting of Fc domains genetically linked (i.e. encoded in a single adjacent gene sequence) within a single polypeptide chain.

[0145] In one embodiment, the “Fc region” refers to a portion of a single Ig heavy chain that starts at the hinge region immediately upstream of the papain cleavage site (i.e., taking residue 216 of IgG and the first residue of the heavy chain constant region, 114) and ends at the C-terminus of the antibody. Thus, the complete Fc domain comprises at least a hinge domain, a CH2 domain, and a CH3 domain.

[0146] The Fc region of the Ig constant region may include CH2, CH3, and CH4 domains and a hinge region, depending on the Ig isotype. Chimeric proteins containing the Fc region of Ig exhibit increased stability, increased serum half-life (Reference [Capon et al., 1989, Nature[See 337:525]), and binding to an Fc receptor, such as the newborn Fc receptor (FcRn) (U.S. Patents No. 6,086,875, 6,485,726, 6,030,613; WO No. 03 / 077834; U.S. No. 2003-0235536A1) (the full text thereof is incorporated herein by reference) imparts some desired characteristics to a chimeric protein.

[0147] The “reference nucleotide sequence” is a polynucleotide sequence that is essentially identical to the nucleotide sequence of the present disclosure, except that the portion corresponding to the FVIII sequence is not optimized when used herein as a comparison to the nucleotide sequence of the present disclosure. For example, the reference nucleotide sequence for a nucleic acid molecule consisting of the codon-optimized BDD FVIII of SEQ ID NO. 1 and the non-homologous nucleotide sequence encoding the short-chain Fc region linked to SEQ ID NO. 1 at the 3’ end is a nucleic acid molecule consisting of the original (or “parent”) BDD FVIII of SEQ ID NO. 16 (Fig. 1i) and the same non-homologous nucleotide sequence encoding the short-chain Fc region linked to SEQ ID NO. 16 at the 3’ end.

[0148] As used herein, "codon adaptation index" refers to a measure of codon usage frequency bias. The codon adaptation index (CAI) measures the deviation of a given protein-coding gene sequence relative to a reference set of genes (Sharp PM and Li WH, Nucleic Acids Res. 15(3):1281-95 (1987). CAI is calculated by determining the geometric mean of the weights associated with each codon over the length of the gene sequence (measured at the codons):

[0149] (I)

[0150] For each amino acid, the weight of each of its codons in the CAI is calculated as the ratio between the observed frequency of the codon (fi) and the frequency of the synonymous codon (fj) for that amino acid:

[0151] Equation 2:

[0152] (II)

[0153] With respect to nucleotide sequences as used herein, the term “optimized” means a polynucleotide sequence encoding a polypeptide, and the polynucleotide sequence is mutated to enhance the characteristics of the polynucleotide sequence. In some embodiments, optimization is performed to increase the transcription level, increase the translation level, increase the steady-state mRNA level, increase or decrease the binding of regulatory proteins, such as common transcription factors, increase or decrease splicing, or increase the yield of the polypeptide produced by the polynucleotide sequence. Examples of modifications that may be made to optimize a polynucleotide sequence include codon optimization, G / C content optimization, removal of repetitive sequences, removal of AT-rich genetic elements, removal of cryptic slice regions, removal of cis-functional genetic elements that inhibit transcription or translation, addition or removal of poly-T or poly-A sequences, addition of sequences around transcription start sites that increase transcription, such as Kozak common sequences, removal of sequences forming stem loop structures, removal of destabilization sequences, and combinations of two or more of these.

[0154] Polynucleotide sequence encoding the FVIII protein

[0155] In some embodiments, the present disclosure relates to a codon-optimized nucleic acid molecule encoding a polypeptide having FVIII activity. In some embodiments, the polynucleotide codes for a full-length FVIII polypeptide. In other embodiments, the nucleic acid molecule codes for a B domain-deleted (BDD) FVIII polypeptide, where all or part of the B domain of FVIII is deleted. In one specific embodiment, the nucleic acid molecule codes for a polypeptide comprising an amino acid sequence having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with SEQ ID NO. 17 (Fig. 1j) or a fragment thereof. In one embodiment, the nucleic acid molecule codes for a polypeptide having the amino acid sequence of SEQ ID NO. 17 or a fragment thereof.

[0156] In some embodiments, the nucleic acid molecule of the present disclosure codes for an FVIII polypeptide comprising a signal peptide or a fragment thereof. In other embodiments, the nucleic acid molecule codes for an FVIII polypeptide lacking a signal peptide. In some embodiments, the signal peptide comprises amino acids 1 through 19 of SEQ ID NO. 17.

[0157] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 58 to 1791 of SEQ ID NO. 3 or (ii) nucleotides 58 to 1791 of SEQ ID NO. 4; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In one specific embodiment, the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 1791 of SEQ ID NO. 3. In another embodiment, the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 1791 of SEQ ID NO. 4. In another embodiment, the first nucleotide sequence comprises nucleotides 58 to 1791 of SEQ ID NO. 3 or nucleotides 58 to 1791 of SEQ ID NO. 4.

[0158] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1 to 1791 of SEQ ID NO. 3 or (ii) nucleotides 1 to 1791 of SEQ ID NO. 4; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In one embodiment, the first nucleotide sequence comprises nucleotides 1 to 1791 of SEQ ID NO. 3 or nucleotides 1 to 1791 of SEQ ID NO. 4. In another embodiment, the second nucleotide sequence has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 4374 of SEQ ID NO. 4. In one specific embodiment, the second nucleotide sequence comprises nucleotides 1792 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 4374 of SEQ ID NO. 4.In yet another embodiment, the second nucleotide sequence has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 3 or nucleotides 1792 to 4374 of sequence no. 4 that lack nucleotides encoding a B domain or a B domain fragment. In one specific embodiment, the second nucleotide sequence comprises nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 4 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 3 or nucleotides 1792 to 4374 of SEQ ID NO. 4 that lack nucleotides encoding the B domain or B domain fragment).

[0159] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1792 to 4374 of SEQ ID NO. 5 or (ii) nucleotides 1792 to 4374 of SEQ ID NO. 6; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In a given embodiment, the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 4374 of SEQ ID NO. 5. In another embodiment, the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 4374 of SEQ ID NO. 6. In one specific embodiment, the second nucleic acid sequence comprises nucleotides 1792 to 4374 of SEQ ID NO. 5 or nucleotides 1792 to 4374 of SEQ ID NO. 6. In some embodiments, the first nucleic acid sequence linked to the second nucleic acid sequence described above has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 1791 of sequence no. 5 or nucleotides 58 to 1791 of sequence no. 6.In another embodiment, the first nucleic acid sequence connected to the second nucleic acid sequence described above has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1 to 1791 of sequence no. 5 or nucleotides 1 to 1791 of sequence no. 6.

[0160] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 5 that do not contain nucleotides encoding a B domain or a B domain fragment) or (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 6 that do not contain nucleotides encoding a B domain or a B domain fragment) and at least 85%, at least 90%, at least It has 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In a given embodiment, the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 5 that lack nucleotides encoding the B domain or B domain fragment). In another embodiment, the second nucleic acid sequence has at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 6 (i.e., nucleotides 1792 to 4374 of sequence no. 6 that do not contain nucleotides encoding a B domain or a B domain fragment).In one specific embodiment, the second nucleic acid sequence comprises nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 5 or nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 6 (i.e., nucleotides 1792 to 4374 of sequence no. 5 or nucleotides 1792 to 4374 of sequence no. 6 that do not contain nucleotides encoding the B domain or B domain fragment). In some embodiments, the first nucleic acid sequence linked to the second nucleic acid sequence described above has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 1791 of SEQ ID NO. 5 or nucleotides 58 to 1791 of SEQ ID NO. 6. In other embodiments, the first nucleic acid sequence linked to the second nucleic acid sequence described above has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the nucleotide sequences 1 to 1791 of ID NO. 5 or nucleotides 1 to 1791 of SEQ ID NO. 6.

[0161] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 58 to 1791 of SEQ ID NO. 1, (ii) nucleotides 58 to 1791 of SEQ ID NO. 2, (iii) nucleotides 58 to 1791 of SEQ ID NO. 70, or (iv) nucleotides 58 to 1791 of SEQ ID NO. 71; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In another embodiment, the first nucleotide sequence comprises nucleotides 58 to 1791 of sequence no. 1, nucleotides 58 to 1791 of sequence no. 2, (iii) nucleotides 58 to 1791 of sequence no. 70, or (iv) nucleotides 58 to 1791 of sequence no. 71.

[0162] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1 to 1791 of SEQ ID NO. 1, (ii) nucleotides 1 to 1791 of SEQ ID NO. 2, (iii) nucleotides 1 to 1791 of SEQ ID NO. 70, or (iv) nucleotides 1 to 1791 of SEQ ID NO. 71; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In one embodiment, the first nucleotide sequence comprises nucleotides 1 to 1791 of sequence no. 1, nucleotides 1 to 1791 of sequence no. 2, (iii) nucleotides 1 to 1791 of sequence no. 70, or (iv) nucleotides 1 to 1791 of sequence no. 71. In another embodiment, the second nucleotide sequence connected to the first nucleotide sequence has at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 1792 to 4374 of sequence no. 1 of sequence no. 1 of sequence no. 2 of sequence no. 2 of sequence no. 2 of sequence no. 2 of sequence no. 3 of sequence no. 2 of sequence no. 3 of sequence no. 3 of sequence no. 1 of sequence no. 2 of sequence no. 3In one particular embodiment, the second nucleotide sequence linked to the first nucleotide sequence comprises (i) nucleotides 1792 to 4374 of SEQ ID NO. 1, (ii) nucleotides 1792 to 4374 of SEQ ID NO. 2, (iii) nucleotides 1792 to 4374 of SEQ ID NO. 70, or (iv) nucleotides 1792 to 4374 of SEQ ID NO. 71. In another embodiment, the second nucleotide sequence connected to the first nucleotide sequence is (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 1, (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 2, (iii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 70, or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 71 and at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of It has sequence identity. In one embodiment, the second nucleotide sequence comprises (i) nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 1, (ii) nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 2, (iii) nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 70, or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of sequence no. 71.

[0163] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with (i) nucleotides 1792 to 4374 of SEQ ID NO. 1, (ii) nucleotides 1792 to 4374 of SEQ ID NO. 2, (iii) nucleotides 1792 to 4374 of SEQ ID NO. 70, or (iv) nucleotides 1792 to 4374 of SEQ ID NO. 71; and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity. In one particular embodiment, the second nucleic acid sequence comprises (i) nucleotides 1792 to 4374 of sequence no. 1, (ii) nucleotides 1792 to 4374 of sequence no. 2, (iii) nucleotides 1792 to 4374 of sequence no. 70, or (iv) nucleotides 1792 to 4374 of sequence no. 71.In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 1, (ii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 2, (iii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 70, or (iv) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 71 (i.e., a B domain or B domain fragment). Nucleotides 1792 to 4374 of SEQ ID NO. 1, nucleotides 1792 to 4374 of SEQ ID NO. 2, nucleotides 1792 to 4374 of SEQ ID NO. 70, or nucleotides 1792 to 4374 of SEQ ID NO. 71) having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the coding nucleotides; the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.In one embodiment, the second nucleic acid sequence is (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 1, (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 2, (iii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 70, or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 71 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 1, nucleotides 1792 to 4374 of SEQ ID NO. 2 It includes nucleotides 1792 to 4374 of 70, or nucleotides 1792 to 4374 of sequence number 71.

[0164] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 1. In another embodiment, the nucleotide sequence comprises a nucleic acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 1 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 1 that do not contain a nucleotide encoding a B domain or a B domain fragment). In another embodiment, the nucleic acid sequence has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 1. In another embodiment, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 1 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 1 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 to 4374 of SEQ ID NO. 1. In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 1 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 1 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 1.

[0165] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 2. In other embodiments, the nucleotide sequence comprises a nucleic acid sequence having at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 2. In another embodiment, the nucleic acid sequence has at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 2. In another embodiment, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 2 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 2 that lack a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 to 4374 of SEQ ID NO. 2. In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 2 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 2 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 2.

[0166] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 70. In another embodiment, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 70 (i.e., nucleotides 58 to 4374 of sequence no. 70 that do not contain nucleotides encoding a B domain or a B domain fragment) and a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In another embodiment, the nucleic acid sequence has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ NO. 70. In another embodiment, the nucleotide sequence comprises nucleotides 58 through 2277 and 2320 through 4374 of SEQ NO. 70 (i.e., nucleotides 58 through 4374 of SEQ NO. 70 that lack a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 through 4374 of SEQ NO. 70.In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 70 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 70 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 70.

[0167] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 71. In another embodiment, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 71 (i.e., nucleotides 58 to 4374 of sequence no. 71 that do not contain nucleotides encoding a B domain or a B domain fragment) and a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In another embodiment, the nucleic acid sequence has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ NO. 71. In another embodiment, the nucleotide sequence comprises nucleotides 58 through 2277 and 2320 through 4374 of SEQ NO. 71 (i.e., nucleotides 58 through 4374 of SEQ NO. 71 that lack a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 through 4374 of SEQ NO. 71.In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 71 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 71 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 71.

[0168] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 3. In another embodiment, the nucleotide sequence comprises a nucleic acid sequence having at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 3 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 3 that do not contain a nucleotide encoding a B domain or a B domain fragment). In a given embodiment, the nucleic acid sequence has at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 3. In some embodiments, the nucleotide sequence comprises nucleotides 58 through 2277 and 2320 through 4374 of SEQ NO. 3 (i.e., nucleotides 58 through 4374 of SEQ NO. 3 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 through 4374 of SEQ NO. 3. In a further embodiment, the nucleotide sequence comprises nucleotides 58 through 2277 and 2320 through 4374 of SEQ NO. 3 (i.e., nucleotides 1 through 4374 of SEQ NO. 3 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 through 4374 of SEQ NO. 3.

[0169] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 4374 of SEQ ID NO. 4. In another embodiment, the nucleotide sequence comprises a nucleic acid sequence having at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 4 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 4 that lack nucleotides encoding a B domain or a B domain fragment). In another embodiment, the nucleic acid sequence has at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 4. In another embodiment, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 4 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 4 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 to 4374 of SEQ ID NO. 4. In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 4 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 4 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 4.

[0170] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 5. In another embodiment, the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 5 (i.e., nucleotides 58 through 4374 of SEQ ID NO. 5 that do not contain a nucleotide encoding a B domain or a B domain fragment). In a specific embodiment, the nucleic acid sequence has at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 5. In some embodiments, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 5 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 5 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 to 4374 of SEQ ID NO. 5.In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 5 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 5 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 5.

[0171] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 4374 of SEQ ID NO. 6. In another embodiment, the nucleotide sequence comprises a nucleic acid sequence having at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 6 that do not contain a nucleotide encoding a B domain or a B domain fragment). In a specific embodiment, the nucleic acid sequence has at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO. 6. In some embodiments, the nucleotide sequence comprises nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 58 to 4374 of SEQ ID NO. 6 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 58 to 4374 of SEQ ID NO. 6.In a further embodiment, the nucleotide sequence comprises nucleotides 1 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1 to 4374 of SEQ ID NO. 6 that do not contain a nucleotide encoding a B domain or a B domain fragment) or nucleotides 1 to 4374 of SEQ ID NO. 6.

[0172] In some embodiments, the nucleotide sequence comprises a nucleic acid sequence encoding a signal peptide. In some embodiments, the signal peptide is an FVIII signal peptide. In some embodiments, the nucleic acid sequence encoding the signal peptide is codon optimized. In one specific embodiment, the nucleic acid sequence encoding the signal peptide comprises (i) nucleotides 1 through 57 of SEQ ID NO. 1; (ii) nucleotides 1 through 57 of SEQ ID NO. 2; (iii) nucleotides 1 through 57 of SEQ ID NO. 3; (iv) nucleotides 1 through 57 of SEQ ID NO. 4; (v) nucleotides 1 through 57 of SEQ ID NO. 5; (vi) nucleotides 1 through 57 of SEQ ID NO. 6; (vii) nucleotides 1 through 57 of SEQ ID NO. 70; (viii) nucleotides 1 to 57 of sequence number 71; or (ix) having at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with nucleotides 1 to 57 of sequence number 68.

[0173] SEQ ID NOs 1 through 6, 70, and 71 are optimized versions of SEQ ID NO. 16, starting or “mother” or “wild-type” FVIII nucleotide sequences. SEQ ID NO. 16 codes for human FVIII with a B domain deletion. While SEQ ID NOs 1 through 6, 70, and 71 are derived from a specific B domain deletion form of FVIII (SEQ ID NO. 16), it should be understood that the present disclosure also relates to optimized versions of nucleic acids encoding other versions of FVIII. For example, other versions of FVIII may include full-length FVIII, other B domain deletions of FVIII (described below), or other fragments of FVIII containing FVIII activity.

[0174] As used herein, "polypeptide having FVIII activity" means a functional FVIII polypeptide in its normal role in coagulation, unless otherwise stated. The term polypeptide having FVIII activity includes its functional fragments, variants, analogs, or derivatives that possess the function of full-length wild-type Factor VIII in the coagulation pathway. "Polypeptide having FVIII activity" is used interchangeably with FVIII protein, FVIII polypeptide, or FVIII. Examples of FVIII function include the ability to activate coagulation, the ability to act as a carrier for Factor IX, or Ca 2 +It includes, but is not limited to, the ability to form a tenase complex with Factor IX (subsequently converting Factor X into the activated form Xa) in the presence of phospholipids. In one embodiment, the polypeptide having FVIII activity comprises two polypeptide chains: a first chain having an FVIII heavy chain and a second chain having an FVIII light chain. In another embodiment, the polypeptide having FVIII activity is a short-chain FVIII. The short-chain FVIII may contain one or more mutations or substitutions at amino acid residues 1645 and / or 1648 corresponding to the mature FVIII sequence. Refer to International Application PCT / US2012 / 045784 (the full text of which is incorporated herein by reference). The FVIII protein may be a human, porcine, dog, rat, or rodent FVIII protein. In addition, comparisons between FVIII from humans and other species have identified conserved residues that appear to be necessary for function (Cameron et al., Thromb. Haemost. 79:317-22 (1998); US No. 6,251,632).

[0175] As used herein, the “B domain” of FVIII is identical to a B domain known in the art, defined by internal amino acid sequence identity and the site of proteolytic cleavage by thrombin, e.g., residues Ser741-Arg1648 of full-length human FVIII. Other human FVIII domains are defined by the following amino acid residues: A1, residue Ala1-Arg372; A2, residue Ser373-Arg740; A3, residue Ser1690-Ile2032; C1, residue Arg2033-Asn2172; C2, residue Ser2173-Tyr2332. The A3-C1-C2 sequence contains residues Ser1690-Tyr2332. The remaining sequence, residues Glu1649-Arg1689, is commonly referred to as the FVIII light chain activating peptide. The location of the boundaries for all domains including the B domain for porcine, mouse, and canine FVIII is also known in the art. An example of BDD FVIII is REFACTO (registered trademark) Recombinant BDD FVIII (Wyeth Pharmaceuticals, Inc.).

[0176] "B domain deleted FVIII" may have a complete or partial deletion as disclosed in U.S. Patents No. 6,316,226, 6,346,513, 7,041,635, 5,789,203, 6,060,447, 5,595,886, 6,228,620, 5,972,885, 6,048,720, 5,543,502, 5,610,278, 5,171,844, 5,112,950, 4,868,112 and 6,458,563 (each of which is incorporated herein by reference in its entirety). In some embodiments, the B domain-deleted FVIII sequence of the present disclosure comprises any one of the deletions disclosed in column 4, lines 4 through 5, lines 28 of U.S. Patent No. 6,316,226 and Examples 1-5 (also in U.S. Patent No. 6,346,513). In some embodiments, the B domain-deleted FVIII of the present disclosure has the deletions disclosed in column 2, lines 26 through 51 of U.S. Patent No. 5,789,203 (also in U.S. Patents No. 6,060,447, U.S. Patent No. 5,595,886 and U.S. Patent No. 6,228,620) and Examples 5 through 8. In some embodiments, the B domain-deleted FVIII comprises column 1, lines 25 through 2, lines 40 of U.S. Patent No. 5,972,885; Column 6, lines 1 through 22 of U.S. Patent No. 6,048,720 and Example 1; Column 2, lines 17 through 46 of U.S. Patent No. 5,543,502; Column 4, lines 22 through Column 5, line 36 of U.S. Patent No. 5,171,844; Column 2, lines 55 through 68 of U.S. Patent No. 5,112,950, Fig. 2 and Example 1; Column 2, lines 2 through 9, line 21 of U.S. Patent No. 4,868,112 and Table 2; It has the results described in U.S. Patent No. 7,041,635, 2 columns, 1 to 3 columns, 19 lines, 3 columns, 40 to 4 columns, 67 lines, 7 columns, 43 to 8 columns, 26 lines and 11 columns, 5 to 13 columns, 39 lines; or 4 columns, 25 to 53 lines of U.S. Patent No. 6,458,563.In some embodiments, the B domain-deleted FVIII has a deletion of most of the B domain but still contains the amino-terminal sequence of the B domain essential for the in vivo proteolytic processing of the primary translation product into two polypeptide chains, as disclosed in WO No. 91 / 09122 (the full text of which is incorporated herein by reference). In some embodiments, the B domain-deleted FVIII is constructed by the deletion of amino acids 747 through 1638, i.e., a complete deletion of the B domain. Hoeben RC. et al. J. Biol . Chem . 265 (13): 7318-7323 (1990) (the full text thereof is incorporated herein by reference). FVIII with a B domain deletion may also contain deletions of amino acids 771 through 1666 or amino acids 868 through 1562 of FVIII. Meulien P., et al. Protein Eng .2(4): 301-6 (1988) (the full text of which is incorporated herein by reference). Additional B domain deletions that are part of this disclosure are, for example, Nos. 982 through 1562 or 760 through 1639 (Toole et al., Proc. Natl. Acad. Sci. USA (1986) 83, 5939-5942)), 797 through 1562 (Eaton, et al. Biochemistry (1986) 25:8343-8347)), 741 through 1646 (Kaufman (PCT Publication Application WO 87 / 04187)), 747 through 1560 (Sarver, et al., DNA (1987) 6:553-564)), 741 through 1648 (Pasek (PCT Application 88 / 00831)), 816 through 1598 or It includes deletions of amino acids 741 through 1689 (Lagner (Behring Inst. Mitt. (1988) No. 82:16-25, EP No. 295597)) (each of which is incorporated herein by reference in its entirety). Each of said deletions may be formed from any FVIII sequence.

[0177] Multiple functional FVIII molecules containing B domain deletions are US No. 6,316,226 and US No. 6,346,513 (both assigned to Baxter); US No. 7,041,635 (assigned to In2Gen); US No. 5,789,203, US No. 6,060,447, US No. 5,595,886 and US No. 6,228,620 (assigned to Chiron); US No. 5,972,885 and US No. 6,048,720 (assigned to Biovitrum), US No. 5,543,502 and US No. 5,610,278 (assigned to Novo Nordisk); US No. 5,171,844 (assigned to Immuno Ag); US No. 5,112,950 (assigned to Transgene SA); US Patent No. 4,868,112 (assigned to the Genetics Institute) (each of which is incorporated herein by reference in its entirety).

[0178] Codon optimization

[0179] In one embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleic acid sequence is codon-optimized. In another embodiment, the starting nucleic acid sequence encoding a polypeptide having FVIII activity and processed by codon optimization is SEQ ID NO. 16. In some embodiments, the sequence encoding a polypeptide having FVIII activity is codon-optimized for human expression. In other embodiments, the sequence encoding a polypeptide having FVIII activity is codon-optimized for mouse expression. SEQ ID NOs. 1 through 6, 70, and 71 are codon-optimized versions of SEQ ID NO. 16 optimized for human expression.

[0180] The term "codon-optimized" refers to a modification of codons in a gene or coding region of a nucleic acid molecule that reflects the host organism's usual codon usage frequency without altering the polypeptide encoded by DNA, where this refers to a gene or coding region of a nucleic acid molecule for the transformation of various hosts. Such optimization involves replacing at least one, more than one, or a significant number of codons with one or more codons that are more commonly used in the organism's gene.

[0181] Deviations in the nucleotide sequence containing codons coding for amino acids of any polypeptide chain allow for variations in the sequence coding for the gene. Since each codon consists of three nucleotides and the nucleotides containing DNA are restricted to four specific bases, there are 64 possible combinations of nucleotides, of which 61 code for amino acids (the remaining three codons code for signals that terminate translation). The "genetic code" showing which codons code for which amino acids is reproduced herein as Table 1. As a result, many amino acids are designated by more than one codon. For example, the amino acids alanine and proline are coded by four triplets, serine and arginine by six, while tryptophan and methionine are coded by only one triplet. This degeneracy causes the DNA base composition to vary over a wide range without altering the amino acid sequence of the protein coded by the DNA.

[0182]

[0183] Many organisms exhibit a bias toward the use of specific codons that code for the insertion of particular amino acids in growing peptide chains. Codon priority, or codon bias, which refers to differences in the frequency of codon usage among organisms, is conferred by the degeneracy of the genetic code and is well documented among many organisms. Codon bias is generally correlated with the efficiency of messenger RNA (mRNA) translation, which is believed to ultimately depend on the characteristics of the codon being translated and the availability of specific transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons most commonly used in peptide synthesis. Therefore, genes can be tuned for optimal gene expression in a given organism based on codon optimization.

[0184] Considering the large number of available gene sequences for a wide variety of animal, plant, and microbial species, the relative frequencies of codon usage are calculated. Codon usage tables are available in the "Codon Usage Database," available, for example, at www.kazusa.or.jp / codon / (visited June 18, 2012). Refer to the literature [Nakamura, Y., et al. Nucl. Acids Res. 28:292 (2000)].

[0185] Randomizing codons at optimized frequencies to code a given polypeptide sequence can be performed manually by calculating the codon frequency for each amino acid and then randomly assigning codons to the polypeptide sequence. Additionally, various algorithms and computer software programs can be used to calculate the optimal sequence.

[0186] In some embodiments, the nucleic acid molecule comprises one or more characteristics: (a) the nucleic acid molecule or a part thereof has an increased human codon adaptation index for SEQ NO. 16; (b) the nucleotide sequence or a part thereof has an increased frequency of optimal codons for SEQ NO. 16; (c) the nucleotide sequence or a part thereof contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in SEQ NO. 16; (d) the nucleotide sequence or a part thereof has an increased frequency of relative synonymous codon use for SEQ NO. 16; (e) the nucleotide sequence or a part thereof has a decreased number of effective codons for SEQ NO. 16; (f) the nucleotide sequence contains fewer MARS / ARS sequences (SEQ NOs 21 and 22) for SEQ NO. 16; (g) the nucleotide sequence contains fewer destabilized genetic elements (SEQ NOs 23 and 24) for SEQ NO. 16; (i) the nucleotide sequence does not contain a poly-T sequence, (j) the nucleotide sequence does not contain a poly-A sequence; or (k) any combination thereof. In some embodiments, the nucleic acid molecule contains at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or 10 features of (a) to (j).

[0187] Codon Adaptation Index

[0188] In one embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity as described herein, and the human codon adaptation index is increased for SEQ ID NO. 16. For example, the nucleotide sequence is at least about 0.75 (75%), at least about 0.76 (76%), at least about 0.77 (77%), at least about 0.78 (78%), at least about 0.79 (79%), at least about 0.80 (80%), at least about 0.81 (81%), at least about 0.82 (82%), at least about 0.83 (83%), at least about 0.84 (84%), at least about 0.85 (85%), at least about 0.86 (86%), at least about 0.87 (87%), at least about 0.88 (88%), at least about 0.89 (89%), at least about 0.90 (90%), at least about 0.91 (91%), at least about 0.92 (92%), at least about 0.93 (93%), and at least about It may have a human codon adaptation index of 0.94 (94%), at least about 0.95 (95%), at least about 0.96 (96%), at least about 0.97 (97%), at least about 0.98 (98%), or at least about 0.99 (99%). In some embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.88 (88%). In other embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.91 (91%). In other embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.91 (97%).

[0189] In one particular embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4, having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the human codon adaptation index of the nucleotide sequence is increased for sequence number 16. In some embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.75 (75%), at least about 0.76 (76%), at least about 0.77 (77%), at least about 0.78 (78%), at least about 0.79 (79%), at least about 0.80 (80%), at least about 0.81 (81%), at least about 0.82 (82%), at least about 0.83 (83%), at least about 0.84 (84%), at least about 0.85 (85%), at least about 0.86 (86%), at least about 0.87 (87%), at least about 0.88 (88%), at least about 0.89 (89%), at least about 0.90 (90%), or at least about 0.91 (91%). In one specific detail, the nucleotide sequence has a human codon adaptation index of at least about 0.88 (88%). In another embodiment, the nucleotide sequence has at least about 0.It has a human codon adaptation index of 91 (91%).

[0190] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 or (ii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about It has 97%, at least about 98%, or at least about 99% sequence identity, and the N-terminal and C-terminal portions together have FVIII polypeptide activity, and the human codon adaptation index of the nucleotide sequence is increased for sequence number 16. In some embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.75 (75%), at least about 0.76 (76%), at least about 0.77 (77%), at least about 0.78 (78%), at least about 0.79 (79%), at least about 0.80 (80%), at least about 0.81 (81%), at least about 0.82 (82%), at least about 0.83 (83%), at least about 0.84 (84%), at least about 0.85 (85%), at least about 0.86 (86%), at least about 0.87 (87%), or at least about 0.88 (88%). In one specific specification, the nucleotide sequence has a human codon adaptation index of at least about 0.83 (83%). In another embodiment, the nucleotide sequence has a human codon adaptation index of at least about 0.88 (88%).

[0191] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about The nucleotide sequence comprises a nucleic acid sequence having 98% or at least about 99% sequence identity, and the human codon adaptation index of the nucleotide sequence increases for SEQ NO. 16. In some embodiments, the nucleotide sequence has a human codon adaptation index of at least about 0.75 (75%), at least about 0.76 (76%), at least about 0.77 (77%), at least about 0.78 (78%), at least about 0.79 (79%), at least about 0.80 (80%), at least about 0.81 (81%), at least about 0.82 (82%), at least about 0.83 (83%), at least about 0.84 (84%), at least about 0.85 (85%), at least about 0.86 (86%), at least about 0.87 (87%), or at least about 0.88 (88%). In one specific detail, the nucleotide sequence has a human codon adaptation index of at least about 0.75 (75%). In another embodiment, the nucleotide sequence has a human codon adaptation index of at least about 0.83 (83%). In another embodiment, the nucleotide sequence has a human codon adaptation index of at least about 0.88 (88%). In another embodiment, the nucleotide sequence has at least about 0.It has a human codon adaptation index of 91 (91%). In another embodiment, the nucleotide sequence has a human codon adaptation index of at least about 0.97 (97%).

[0192] In some embodiments, the isolated nucleic acid molecule of the present disclosure has an increased optimal codon frequency (FOP) for SEQ ID NO. 16. In some embodiments, the FOP of the isolated nucleic acid molecule is at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 64, at least about 65, at least about 70, at least about 75, at least about 79, at least about 80, at least about 85, or at least about 90.

[0193] In other embodiments, the isolated nucleic acid molecule of the present disclosure has an increased relative codon usage frequency (RCSU) for SEQ ID NO. 16. In some embodiments, the RCSU of the isolated nucleic acid molecule is greater than 1.5. In other embodiments, the RCSU of the isolated nucleic acid molecule is greater than 2.0. In certain embodiments, the RCSU of the isolated nucleic acid molecule is at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2.0, at least about 2.1, at least about 2.2, at least about 2.3, at least about 2.4, at least about 2.5, at least about 2.6, or at least about 2.7.

[0194] In a further embodiment, the isolated nucleic acid molecule of the present disclosure has a reduced number of codons for SEQ ID NO. 16. In some embodiments, the isolated nucleic acid molecule has a number of codons less than about 50, less than about 45, less than about 40, less than about 35, less than about 30, or less than about 25. In one particular embodiment, the isolated nucleic acid molecule has a number of codons of about 40, about 35, about 30, about 25, or about 20.

[0195] Optimization of G / C content

[0196] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity as described herein, wherein the nucleotide sequence contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in SEQ NO. 16. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, or at least about 60%.

[0197] In one particular embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in sequence number 16. In some embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, or at least about 58%. In one specific embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 58%.

[0198] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 to 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 to 4374 of SEQ ID NO. 6; (iii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 5 that lack a nucleotide encoding a B domain or a B domain fragment), or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 6 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about Having sequence identity of 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in Sequence No. 16. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity has a G / C content of at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, or at least about 57%.In one specific embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity has a G / C content of at least about 52%. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity has a G / C content of at least about 55%. In yet another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity has a G / C content of at least about 57%.

[0199] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ ID NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ ID NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about It comprises a nucleic acid sequence having 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence contains a higher percentage of G / C nucleotides compared to the percentage of G / C nucleotides in Sequence No. 16. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 45%. In one specific embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 52%. In yet another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 55%. In yet another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 57%. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 58%.In yet another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity has a G / C content of at least about 60%.

[0200] "G / C content (or guanine-cytosine content)" or "percentage of G / C nucleotides" refers to the percentage of nitrogenous bases in a DNA molecule that are guanine or cytosine. G / C content can be calculated using the following formula:

[0201] (III)

[0202] Human genes are highly heterogeneous in their G / C content, with some genes having a G / C content as low as 20% and others having a G / C content as high as 95%. Generally, G / C-rich genes are more highly expressed. In fact, it has been shown that increasing the G / C content of a gene can lead to increased gene expression, mostly due to increased transcription and higher steady-state mRNA levels. See the literature [Kudla et al., PLoS Biol., 4(6): e180 (2006)].

[0203] Matrix attachment region similar sequence

[0204] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity as described herein, wherein the nucleotide sequence contains fewer MARS / ARS sequences than that of SEQ ID NO. 16. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 6, up to 5, up to 4, up to 3, or up to 2 MARS / ARS sequences. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 1 MARS / ARS sequence. In even other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain a MARS / ARS sequence.

[0205] In one particular embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of SEQ ID NO. 4, or (iv) nucleotides 1 to 1791 of SEQ ID NO. 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains less MARS / ARS sequence compared to SEQ ID NO. 16. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 6, up to 5, up to 4, up to 3, or up to 2 MARS / ARS sequences. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 1 MARS / ARS sequence. In a further embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity does not contain a MARS / ARS sequence.

[0206] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 through 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 through 4374 of SEQ ID NO. 6; and (iii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 through 4374 of SEQ ID NO. 5 that lack nucleotides encoding the B domain or B domain fragment). or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 6 that lack nucleotides encoding the B domain or B domain fragment) having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, wherein the N-terminal and C-terminal portions together possess FVIII polypeptide activity, and the nucleotide sequences have fewer MARS / ARS sequences compared to SEQ ID NO. 16 It contains. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 6, up to 5, up to 4, up to 3, or up to 2 MARS / ARS sequences. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 1 MARS / ARS sequence.In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain a MARS / ARS sequence.

[0207] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NOs 1, 2, 3, 4, 5, 6, 70, or 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NOs 1, 2, 3, 4, 5, 6, 70, or 71 (i.e., nucleotides 58 through 4374 of SEQ ID NOs 1, 2, 3, 4, 5, 6, 70, or 71 that lack nucleotides encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about 90%, or at least about It comprises a nucleic acid sequence having 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence contains fewer MARS / ARS sequences compared to SEQ ID NO. 16. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 6, up to 5, up to 4, up to 3, or up to 2 MARS / ARS sequences. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 1 MARS / ARS sequence. In a further embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity does not contain a MARS / ARS sequence.

[0208] An AT-rich genetic element in the human FVIII nucleotide sequence was identified that has sequence similarity to the autonomous replication sequence (ARS) and nuclear-matrix attachment region (MAR) of Saccharomyces cerevisiae (Fallux et al., Mol . Cell. Biol . 16:4264-4272 (1996)). One of these genetic factors was shown to bind to nuclear factors in vitro and inhibit the expression of the chloramphenicol acetylconvertase (CAT) reporter gene. Id. It is assumed that this sequence may contribute to the transcriptional repression of the human FVIII gene. Accordingly, in one embodiment, all MAR / ARS sequences are abolished from the FVIII gene of the present disclosure. Four MAR / ARS ATATTT sequences (Sequence No. 21) and three MAR / ARS AAATAT sequences (Sequence No. 22) exist in the parent FVIII sequence (Sequence No. 16). All of these sites are mutated to disrupt the MAR / ARS sequences in the optimized FVIII sequences (Sequence Nos. 1 to 6). The respective positions of these genetic elements and the sequences of the corresponding nucleotides in the optimized sequences are listed in Table 2 below.

[0209]

[0210]

[0211] Destabilization order

[0212] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity as described herein, wherein the nucleotide sequence contains fewer destabilizing genetic elements than that of SEQ NO. 16. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 destabilizing genetic elements. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 destabilizing genetic element. In even other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain any destabilizing genetic elements.

[0213] In one particular embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains fewer destabilizing genetic elements compared to sequence number 16. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 destabilizing genetic elements. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 destabilizing genetic element. In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain destabilizing genetic elements.

[0214] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 through 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 through 4374 of SEQ ID NO. 6; and (iii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 through 4374 of SEQ ID NO. 5 that lack nucleotides encoding the B domain or B domain fragment). or (iv) having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with the nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 6 that lack nucleotides encoding the B domain or B domain fragment), at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the N-terminal and C-terminal portions together possess FVIII polypeptide activity, and the nucleotide sequence has fewer destabilizing genetic elements compared to SEQ ID NO. 16 It contains. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 destabilized genetic elements. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 destabilized genetic element.In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain a destabilizing genetic element.

[0215] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It comprises a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence contains fewer destabilized genetic elements than SEQ NO. 16. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 destabilized genetic elements. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 destabilized genetic element. In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain any destabilized genetic elements.

[0216] Ten destabilized genetic elements in the parent FVIII sequence (Sequence No. 16): three ATTTA sequences (Sequence No. 23) and four TAAAT sequences (Sequence No. 24) are present. In one embodiment, the sequences of these sites are mutated to disrupt the destabilized genetic elements in the optimized FVIII sequences No. 1 to 6, 70, and 71. The respective positions of these genetic elements and the sequences of the corresponding nucleotides in the optimized sequences are listed in Table 2.

[0217] Potential facilitator binding site

[0218] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity as described herein, wherein the nucleotide sequence contains fewer potential promoter binding sites than that of SEQ ID NO. 16. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 potential promoter binding sites. In other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 potential promoter binding site. In even other embodiments, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain any potential promoter binding sites.

[0219] In one particular embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains fewer potential promoter binding sites compared to sequence number 16. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 potential promoter binding sites. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 potential promoter binding site. In a further embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity does not contain any potential promoter binding sites.

[0220] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 through 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 through 4374 of SEQ ID NO. 6; and (iii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 through 4374 of SEQ ID NO. 5 that lack nucleotides encoding the B domain or B domain fragment). or (iv) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e. nucleotides 1792 to 4374 of SEQ ID NO. 6 that lack nucleotides encoding a B domain or a B domain fragment) have at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence contains fewer potential promoter binding sites compared to SEQ ID NO. 16. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 potential promoter binding sites. In another embodiment, the nucleotide sequence encoding the polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 potential promoter binding site.In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain a potential promoter binding site.

[0221] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It comprises a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence contains fewer potential promoter binding sites compared to Sequence No. 16. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 9, up to 8, up to 7, up to 6, or up to 5 potential promoter binding sites. In another embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity contains up to 4, up to 3, up to 2, or up to 1 potential promoter binding site. In a further embodiment, the nucleotide sequence encoding a polypeptide having FVIII activity does not contain any potential promoter binding sites.

[0222] The TATA box is a regulatory sequence typically found in the promoter region of eukaryotes. It acts as a binding site for the common transcription factor TATA-binding protein (TBP). The TATA box usually contains the sequence TATAA (Sequence No. 28) or a closely related variant. However, the TATA box within the coding sequence can inhibit the translation of the full-length protein. Ten potential promoter binding sequences exist in the wild-type BDD FVIII sequence (Sequence No. 16), which consists of five TATAA sequences (Sequence No. 28) and five TTATA sequences (Sequence No. 29). In some embodiments, at least one, at least two, at least three, or at least four of the promoter binding sites are abolished in the FVIII gene of the present disclosure. In some embodiments, at least five of the promoter binding sites are abolished in the FVIII gene of the present disclosure. In another embodiment, at least 6, at least 7, or at least 8 promoter binding sites are abolished in the FVIII gene of the present disclosure. In one embodiment, at least 9 promoter binding sites are abolished in the FVIII gene of the present disclosure. In one specific embodiment, all promoter binding sites are abolished in the FVIII gene of the present disclosure. The locations of each potential promoter binding site and the sequences of the corresponding nucleotides in the optimized sequences are listed in Table 2.

[0223] Other cis-activating voice regulatory genetic elements

[0224] In addition to the MAR / ARS sequence, destabilization elements, and potential promoter sites described above, several additional potential inhibiting sequences can be identified in the wild-type BDD FVIII sequence (Sequence No. 16). Two AU-enriched sequence elements (AREs) can be identified in the unoptimized BDD FVIII sequence along with a poly-A site (AAAAAA; Sequence No. 26), a poly-T site (TTTTTT; Sequence No. 25), and a slice site (GGTGAT; Sequence No. 27) (ATTTTATT (Sequence No. 30); and ATTTTTAA (Sequence No. 31)). One or more of these elements can be removed from the optimized FVIII sequence. The respective positions of these sites and the sequences of the corresponding nucleotides in the optimized sequence are listed in Table 2.

[0225] In a given embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 to 1791 of SEQ ID NO. 3; (ii) nucleotides 1 to 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of SEQ ID NO. 4, or (iv) nucleotides 1 to 1791 of SEQ ID NO. 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence does not contain one or more cis-functional negative regulatory genetic elements, e.g., slice portion, poly-T sequence, poly-A sequence, ARE sequence, or any combination thereof.

[0226] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 through 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 through 4374 of SEQ ID NO. 6; and (iii) nucleotides 1792 through 2277 and 2320 through 4374 of SEQ ID NO. 5 (i.e., nucleotides 1792 through 4374 of SEQ ID NO. 5 that lack nucleotides encoding the B domain or B domain fragment). or (iv) having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 6 (i.e., nucleotides 1792 to 4374 of SEQ ID NO. 6 that lack nucleotides encoding a B domain or a B domain fragment), at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% with respect to the N-terminal portion and the C-terminal portion together having FVIII polypeptide activity, and the nucleotide sequence having one or more cis-functional negative regulatory elements, e.g., slice regions, It does not contain poly-T sequences, poly-A sequences, ARE sequences, or any combination thereof.

[0227] In another embodiment, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It comprises a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence does not contain one or more cis-functional negative regulatory genetic elements, e.g., slice sites, poly-T sequences, poly-A sequences, ARE sequences, or any combination thereof.

[0228] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of SEQ ID NO. 4, or (iv) nucleotides 1 to 1791 of SEQ ID NO. 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence does not contain the slice site GGTGAT (SEQ ID NO. 27).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence does not contain a poly-T sequence (sequence number 25).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of sequence number 4, or (iv) nucleotides 1 to 1791 of sequence number 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence does not contain a poly-A sequence (sequence number 26).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence comprises (i) nucleotides 58 through 1791 of SEQ ID NO. 3; (ii) nucleotides 1 through 1791 of SEQ ID NO. 3; (iii) nucleotides 58 to 1791 of SEQ ID NO. 4, or (iv) nucleotides 1 to 1791 of SEQ ID NO. 4 and at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity, and the nucleotide sequence does not contain the ARE gene element (SEQ ID NO. 30 or SEQ ID NO. 31).

[0229] In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It comprises a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity; the nucleotide sequence does not contain the slice site GGTGAT (sequence number 27).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It includes a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence does not contain a poly-T sequence (sequence number 25).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It includes a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence does not contain a poly-A sequence (sequence number 26).In some embodiments, the present disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 or (ii) nucleotides 58 through 2277 and 2320 through 4374 of an amino acid sequence selected from SEQ NOs 1, 2, 3, 4, 5, 6, 70 and 71 (i.e., nucleotides 58 through 4374 of SEQ NOs 1, 2, 3, 4, 5, 6, 70 or 71 that lack a nucleotide encoding a B domain or a B domain fragment) and at least about 80%, at least about 85%, at least about 89%, at least about It comprises a nucleic acid sequence having 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, and the nucleotide sequence does not contain the ARE genetic element (sequence number 30 or sequence number 31).

[0230] In another embodiment, the optimized FVIII sequence of the present disclosure does not include one or more of an antiviral motif, a stem-loop structure, and a repeat sequence.

[0231] In a further embodiment, the nucleotides surrounding the transcription start site are the Kozak common sequence (GCCGCCACC). ATG It changes to C (sequence number 32), where the underlined nucleotide is the starting codon). In other embodiments, the restriction site may be added or removed to facilitate the cloning process.

[0232] Non-homologous nucleotide sequences

[0233] In some embodiments, the isolated nucleic acid molecule of the present disclosure further comprises a non-homologous nucleotide sequence. In some embodiments, the isolated nucleic acid molecule of the present disclosure further comprises at least one non-homologous nucleotide sequence. The non-homologous nucleotide sequence may be connected to the optimized BDD-FVIII nucleotide sequence of the present disclosure at the 5' end or the 3' end, or inserted into the middle of the optimized BDD-FVIII nucleotide sequence. Thus, in some embodiments, the non-homologous amino acid sequence encoded by the non-homologous nucleotide sequence is connected to the N-end or C-end of the FVIII amino acid sequence encoded by the nucleotide sequence, or inserted between two amino acids in the FVIII amino acid sequence. In some embodiments, the non-homologous amino acid sequence may be inserted between two amino acids at one or more insertion sites selected from Table 3. In some embodiments, non-homologous amino acid sequences may be inserted into an FVIII polypeptide encoded by the nucleic acid molecule of the present disclosure at any site disclosed in International Publication WO No. 2013 / 123457 A1, WO No. 2015 / 106052 A1 or U.S. Publication No. 2015 / 0158929 A1 (the full text thereof is incorporated herein by reference).

[0234] In some embodiments, a non-homologous amino acid sequence encoded by a non-homologous nucleotide sequence is inserted into the B domain or a fragment thereof. In some embodiments, the non-homologous amino acid sequence is inserted into FVIII immediately downstream of the amino acid corresponding to amino acid 745 of mature human FVIII (SEQ No. 15). In one specific embodiment, FVIII comprises a deletion of amino acids 746 through 1646 corresponding to mature human FVIII (SEQ No. 15), and the non-homologous amino acid sequence encoded by the non-homologous nucleotide sequence is inserted immediately downstream of amino acid 745 corresponding to mature human FVIII (SEQ No. 15).

[0235]

[0236] In other embodiments, the isolated nucleic acid molecule of the present disclosure further comprises two, three, four, five, six, seven, or eight non-homologous nucleotide sequences. In some embodiments, all non-homologous nucleotide sequences are identical. In some embodiments, at least one non-homologous nucleotide sequence is different from other non-homologous nucleotide sequences. In some embodiments, the present disclosure may comprise tandem non-homologous nucleotide sequences of two, three, four, five, six, or more than seven.

[0237] In some embodiments, a non-homologous nucleotide sequence codes for an amino acid sequence. In some embodiments, the amino acid sequence encoded by the non-homologous nucleotide sequence is a non-homologous moiety ("half-life extender") capable of increasing the half-life of the FVIII molecule.

[0238] In some embodiments, the non-homologous moiety is a peptide or polypeptide having unstructured or structured features associated with an extension of the in vivo half-life when introduced into the protein of the present disclosure. Non-limiting examples include albumin, albumin fragments, Fc fragments of immunoglobulin, C-terminal peptide (CTP) of the β subunit of human chorionic gonadotropin, HAP sequences, XTEN sequences, transferrin or fragments thereof, PAS polypeptides, polyglycine linkers, polyserine linkers, albumin-binding moietys, or any fragments, derivatives, variants, or combinations of these polypeptides. In one specific embodiment, the non-homologous amino acid sequence is an immunoglobulin constant region or a portion thereof, transferrin, albumin, or PAS sequence. In some aspects, the non-homologous moiety includes von Willebrand factor or a fragment thereof. In another related embodiment, the non-homologous moiety has an attachment site for the non-polypeptide moiety (e.g., , It may include cysteine ​​amino acids, such as polyethylene glycol (PEG), hydroxyethyl starch (HES), polysialic acid, or any derivatives, variants, or combinations of these genetic elements. In some embodiments, the non-homologous moiety comprises cysteine ​​amino acids, such as polyethylene glycol (PEG), hydroxyethyl starch (HES), polysialic acid, or any derivatives, variants, or combinations of these genetic elements, which act as attachment sites for the non-polypeptide moiety.

[0239] In one specific embodiment, a first non-homologous nucleotide sequence codes for a first non-homologous moiety which is a half-life extending molecule known in the art, and a second non-homologous nucleotide sequence codes for a second non-homologous moiety which is also known in the art and may be a half-life extending molecule. In a given embodiment, the first non-homologous moiety (e.g., a first Fc moiety) and the second non-homologous moiety (e.g., a second Fc moiety) are associated with each other to form a dimer. In one embodiment, the second non-homologous moiety is a second Fc moiety, and the second Fc moiety is connected to or associated with the first non-homologous moiety, e.g., the first Fc moiety. For example, a second non-homologous moiety (e.g., a second Fc moiety) may be connected to a first non-homologous moiety (e.g., a first Fc moiety) by a linker or may be associated with the first non-homologous moiety by a covalent or non-covalent bond.

[0240] In some embodiments, the non-homologous moiety is a polypeptide comprising, or essentially composed of, or composed of, at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600, at least about 1700, at least about 1800, at least about 1900, at least about 2000, at least about 2500, at least about 3000, or at least about 4000 amino acids. In another embodiment, the non-homologous moiety comprises about 100 to about 200 amino acids, about 200 to about 300 amino acids, about 300 to about 400 amino acids, about 400 to about 500 amino acids, about 500 to about 600 amino acids, about 600 to about 700 amino acids, about 700 to about 800 amino acids, about 800 to about 900 amino acids, or about 900 to about 1000 amino acids, is essentially composed of these, or is a polypeptide composed of these.

[0241] In a given embodiment, the non-homologous moiety improves one or more pharmacokinetic properties of the FVIII protein without significantly affecting its biological activity or function.

[0242] In a given embodiment, the non-homologous moiety increases the in vivo and / or in vitro half-life of the FVIII protein of the present disclosure. In another embodiment, the non-homologous moiety facilitates the visualization or localization of the FVIII protein of the present disclosure or a fragment thereof (e.g., a fragment containing the non-homologous moiety after proteolytic cleavage of the FVIII protein). The visualization and / or localization of the FVIII protein of the present disclosure or a fragment thereof may be in vivo, in vitro, extracellular, or a combination thereof.

[0243] In other embodiments, non-homologous moiety increases the stability of the FVIII protein of the present disclosure or a fragment thereof (e.g., a fragment containing a non-homologous moiety after proteolytic cleavage of the FVIII protein). As used herein, the term “stability” means a field-recognized measure of the retention of one or more physical properties of the FVIII protein in response to environmental conditions (e.g., elevated or lowered temperature). In a given embodiment, the physical property may be the retention of the covalent structure of the FVIII protein (e.g., absence of proteolytic cleavage, unwanted oxidation, or deamidation). In another embodiment, the physical property may also be the presence of the FVIII protein in a properly folded state (e.g., absence of soluble or insoluble aggregates or precipitates). In one embodiment, the stability of the FVIII protein is measured by evaluating the biophysical properties of the FVIII protein, e.g., thermal stability, pH unfolded profile, stable removal of glycosylation, solubility, biochemical function (e.g., ability to bind to proteins, receptors, or ligands), and / or combinations thereof. In another embodiment, biochemical function is demonstrated by the binding affinity of interactions. In one embodiment, a measure of protein stability is thermal stability, i.e., resistance to thermal attack. Stability may be measured using methods known in the art, such as HPLC (High Performance Liquid Chromatography), SEC (Size Exclusion Chromatography), DLS (Dynamic Light Scattering), etc. Methods for measuring thermal stability include, but are not limited to, differential scanning calorimetry (DSC), differential scanning fluorescence (DSF), circular dichroism (CD), and thermal attack assays.

[0244] In a given embodiment, the FVIII protein encoded by the nucleic acid molecule of the present disclosure comprises at least one half-life extender, namely a non-homologous moiety that increases the in vivo half-life of the FVIII protein in relation to the in vivo half-life of the corresponding FVIII protein lacking such non-homologous moiety. The in vivo half-life of the FVIII protein may be determined by any method known to those skilled in the art, for example, an activity assay (colorimetric assay or one-step coagulation aPTT assay), ELISA, ROTEM (trademark), etc.

[0245] In some embodiments, the presence of one or more half-life extenders results in an increased half-life of the FVIII protein compared to the half-life of the corresponding protein lacking such one or more half-life extenders. The half-life of the FVIII protein containing the half-life extenders is at least about 1.5 times, at least about 2 times, at least about 2.5 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, or at least about 12 times longer than the in vivo half-life of the corresponding FVIII protein lacking such half-life extenders.

[0246] In one embodiment, the half-life of an FVIII protein containing a half-life extender is about 1.5 to about 20 times, about 1.5 to about 15 times, or about 1.5 to about 10 times longer than the in vivo half-life of a corresponding protein lacking such a half-life extender. In another embodiment, the half-life of an FVIII protein containing a half-life extender is about 2 to about 10 times, about 2 to about 9 times, about 2 to about 8 times, about 2 to about 7 times, about 2 to about 6 times, about 2 to about 5 times, about 2 to about 4 times, about 2 to about 3 times, about 2.5 to about 10 times, about 2.5 to about 9 times, about 2.5 to about 8 times, about 2.5 to about 7 times, about 2.5 to about 6 times, about 2.5 to about 5 times, about 2.5 to about 4 times, about 2.5 to about 3 times, about 3 to about 10 times, about 3 to about 9 times, about 3 to about 8 times, compared to the in vivo half-life of a corresponding protein lacking such a half-life extender. It is extended by about 3 to about 7 times, about 3 to about 6 times, about 3 to about 5 times, about 3 to about 4 times, about 4 to about 6 times, about 5 to about 7 times, or about 6 to about 8 times.

[0247] In another embodiment, the half-life of the FVIII protein containing a half-life extender is at least about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24 hours, at least about 25 hours, at least about 26 hours, at least about 27 hours, at least about 28 hours, at least about 29 hours, at least about 30 hours, at least about 31 hours, at least about 32 hours, at least about 33 hours, at least about 34 hours, at least about 35 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96 hours, or at least about 108 hours.

[0248] In a further embodiment, the half-life of the FVIII protein containing a half-life extender is about 15 hours to about 2 weeks, about 16 hours to about 1 week, about 17 hours to about 1 week, about 18 hours to about 1 week, about 19 hours to about 1 week, about 20 hours to about 1 week, about 21 hours to about 1 week, about 22 hours to about 1 week, about 23 hours to about 1 week, about 24 hours to about 1 week, about 36 hours to about 1 week, about 48 hours to about 1 week, about 60 hours to about 1 week, about 24 hours to about 6 days, about 24 hours to about 5 days, about 24 hours to about 4 days, about 24 hours to about 3 days, or about 24 hours to about 2 days.

[0249] In some embodiments, the average half-life per subject of the FVIII protein containing a half-life extender is about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours (1 day), about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 40 hours, about 44 hours, about 48 hours (2 days), about 54 hours, about 60 hours, about 72 hours (3 days), about 84 hours, about 96 hours (4 days), about 108 hours, about 120 hours (5 days), about 6 days, about 7 days (1 week), about It is 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

[0250] One or more half-life extenders may be fused to the C-terminus or N-terminus of FVIII or inserted into FVIII.

[0251] 1. Immunoglobulin constant region or part thereof

[0252] In another aspect, the non-homologous moiety comprises one or more immunoglobulin constant regions or parts thereof (e.g., Fc regions). In one embodiment, the isolated nucleic acid molecule of the present disclosure further comprises a non-homologous nucleic acid sequence encoding an immunoglobulin constant region or a part thereof. In some embodiments, the immunoglobulin constant region or a part thereof is the Fc region.

[0253] The immunoglobulin constant region consists of domains referred to as CH (constant heavy chain) domains (CH1, CH2, etc.). Depending on the isotype (i.e., IgG, IgM, IgA, IgD, or IgE), the constant region may consist of three or four CH domains. The constant region of some isotypes (e.g., IgG) also contains a hinge region. [Janeway] et al. 2001, Immunobiology Refer to , Garland Publishing, NY, NY.

[0254] The immunoglobulin constant region or a portion thereof for producing the FVIII protein of the present disclosure may be obtained from a number of different sources. In one embodiment, the immunoglobulin constant region or a portion thereof is derived from human immunoglobulin. However, it is understood that the immunoglobulin constant region or a portion thereof may be derived from immunoglobulin of other mammalian species, including, for example, rodent species (e.g., mouse, rat, rabbit, guinea pig) or non-human primate species (e.g., chimpanzee, macaque). Furthermore, the immunoglobulin constant region or a portion thereof may be derived from any immunoglobulin class, including IgM, IgG, IgD, IgA, and IgE, and any immunoglobulin isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, human isotype IgG1 is used.

[0255] Various immunoglobulin constant region gene sequences (e.g., human constant region gene sequences) are available in the form of publicly accessible deposits. The constant region domain sequences may be selected to have specific effector functions (or lack specific effector functions) or specific modifications to reduce immunogenicity. Many sequences of antibodies and antibody-coding genes are disclosed, and suitable Ig constant region sequences (e.g., hinge, CH2, and / or CH3 sequences, or parts thereof) may be derived from these sequences using field-recognized techniques. Subsequently, the genetic material obtained by any of the above methods may be modified or synthesized to obtain the polypeptide of the present disclosure. It will be further understood that the scope of the present disclosure includes alleles, variants, and mutations of the constant region DNA sequence.

[0256] For example, the sequence of the immunoglobulin constant region or a portion thereof can be cloned using a polymerase chain reaction and primers selected to amplify the domain of interest. To clone the sequence of the immunoglobulin constant region or a portion thereof from an antibody, mRNA can be isolated from hybridoma, spleen, or lymphocytes, reverse transcribed into DNA, and antibody gene amplified by PCR. PCR amplification methods are described in U.S. Patents No. 4,683,195; No. 4,683,202; No. 4,800,159; No. 4,965,188; and, for example, in the literature ["PCR Protocols: A Guide to Methods and Applications" Innis et al. eds., Academic Press, San Diego, CA (1990); Ho et al. 1989. Gene 77:51; Horton et al. 1993. Methods Enzymol .This is described in detail in [217:270]. PCR can be initiated by common constant region primers or more specific primers based on the disclosed heavy and light chain DNA and amino acid sequences. PCR can also be used to isolate DNA clones encoding antibody light and heavy chains. In this case, the library can be screened by common primers or greater homology probes, such as mouse constant region probes. Many sets of primers suitable for the amplification of antibody genes are known in the art (e.g., 5' primers based on the N-terminal sequence of a purified antibody (Benhar and Pastan. 1994). Protein Engineering 7:1509); rapid amplification of cDNA ends (Ruberti, F. et al. 1994. J. Immunol . Methods 173:33); antibody leader sequence (Larrick et al. 1989 Biochem . Biophys . Res. Commun . 160:1250)). The cloning of the antibody sequence is further described in U.S. Patent No. 5,658,570 of Newman et al., filed January 25, 1995 (incorporated herein by reference).

[0257] As used herein, the immunoglobulin constant region may include all domains and hinge regions or parts thereof. In one embodiment, the immunoglobulin constant region or parts thereof includes a CH2 domain, a CH3 domain, and a hinge region, i.e., an Fc region or an FcRn binding partner.

[0258] As used herein, the term “Fc region” is defined as a portion of a polypeptide corresponding to the Fc region of native Ig, that is, formed by the dimeric association of each Fc domain of its two heavy chains. The native Fc region forms a homodimer with another Fc region. Conversely, as used herein, the terms “genetically fused Fc region” or “short-chain Fc region” (scFc region) refer to a synthetic dimeric Fc region consisting of Fc domains genetically linked (i.e. encoded in a single adjacent gene sequence) within a single polypeptide chain. See International Publication WO No. 2012 / 006635 (the full text of which is incorporated herein by reference).

[0259] In one embodiment, the “Fc region” refers to a portion of a single Ig heavy chain that starts at a hinge region immediately upstream of the papain cleavage site (i.e., residue 216 in IgG, taking the first residue of the heavy chain constant region at 114) and ends at the C-terminus of the antibody. Therefore, the complete Fc region includes at least a hinge domain, a CH2 domain, and a CH3 domain.

[0260] An immunoglobulin constant region or a portion thereof may be an FcRn binding partner. FcRn is active in adult epithelial tissues and is expressed in the lumens of the intestine, pulmonary airways, nasal surfaces, vaginal surfaces, colon, and rectal surfaces (U.S. Patent No. 6,485,726). An FcRn binding partner is a portion of immunoglobulin that binds to FcRn.

[0261] FcRn receptors are isolated from several mammalian species, including humans. The sequences of human FcRn, monkey FcRn, rat FcRn, and mouse FcRn are known (Story et al. 1994, J. Exp. Med. 180:2377). FcRn receptors bind IgG (not other immunoglobulin types, e.g., IgA, IgM, IgD, and IgE) at relatively low pH, actively transport IgG via cells from the lumen toward the serosa, and then release IgG at the relatively high pH found in interstitial fluid. This is expressed in lung and intestinal epithelium (Israel et al. 1997, Immunology 92:69), renal tubular epithelium (Kobayashi et al. 2002, Am. J. Physiol. Renal Physiol. 282:F358), and adult epithelial tissues including nasal epithelium, vaginal surface and bile duct surface (U.S. Patents No. 6,485,726, 6,030,613, 6,086,875; WO No. 03 / 077834; U.S. No. 2003-0235536A1).

[0262] FcRn binding partners useful in this disclosure include molecules capable of specifically binding to the FcRn receptor, comprising whole IgG, the Fc fragment of IgG, and other fragments containing the complete binding region of the FcRn receptor. The region of the Fc portion of IgG binding to the FcRn receptor is described based on X-ray crystallography (Burmeister et al. 1994, Nature 372:379). The major contact sites between Fc and FcRn are close to the junction of the CH2 and CH3 domains. All Fc-FcRn contacts are located within a single Ig heavy chain. FcRn binding partners include whole IgG, the Fc fragment of IgG, and other fragments of IgG containing the complete binding region of FcRn. The major contact sites include amino acid residues 248, 250 to 257, 272, 285, 288, 290 to 291, 308 to 311, and 314 of the CH2 domain and amino acid residues 385 to 387, 428, and 433 to 436 of the CH3 domain. All references made to the amino acid numbering of the immunoglobulin or the immunoglobulin fragment or region are based on the literature [Kabat et al. 1991, Sequences of Proteins of Immunological Interest, US Department of Public Health, Bethesda, Md].

[0263] An Fc region or FcRn binding partner bound to FcRn can be effectively shuttled across the epithelial barrier by FcRn, thereby providing a non-invasive means for systemic administration of desired therapeutic molecules. Additionally, a fusion protein containing an Fc region or FcRn binding partner is endocytosed by cells expressing FcRn. However, instead of being indicated for degradation, this fusion protein is recycled back into circulation to increase the in vivo half-life of this protein. In a given embodiment, a portion of the immunoglobulin constant region is an Fc region or FcRn binding partner that typically associates with another Fc region or another FcRn binding partner to form dimers and higher-order polymers through disulfide bonds and other non-specific interactions.

[0264] Two FcRn receptors can bind a single Fc molecule. Crystallographic data suggest that each FcRn molecule binds a single polypeptide of an Fc homodimer. In one embodiment, attaching an FcRn binding partner, e.g., an Fc fragment of IgG, to a biologically active molecule provides a means of delivering the biologically active molecule orally, buccally, sublingually, rectally, vaginally, or via an aerosol administered nasally, or via a pulmonary route, or via an intraocular route. In another embodiment, the FVIII protein may be administered invasively, e.g. subcutaneously or intravenously.

[0265] The FcRn binding partner region is a molecule or part thereof that can be specifically bound by an FcRn receptor, resulting in active transport by the FcRn receptor of the Fc region. "Specifically bound" refers to two molecules that form a relatively stable complex under physiological conditions. Specific binding is distinguished from non-specific binding, which typically has low affinity along with moderate to high capacity, and is characterized by high affinity and low to moderate capacity. Typically, binding is characterized by an affinity constant KA of 10 6 M -1 Exceeding or 10 8 M -1 It is considered specific when exceeded. If necessary, non-specific binding can be reduced by changing binding conditions without substantially affecting specific binding. Appropriate binding conditions, such as molecular concentration, solution ion concentration, temperature, allowed time for binding, and concentration of blockers (e.g., serum albumin, milk casein), can be optimized by a person skilled in the field using routine techniques.

[0266] In a given embodiment, the FVIII protein encoded by the nucleic acid molecule of the present disclosure comprises one or more truncated Fc regions sufficient to confer Fc receptor (FcR) binding properties to the Fc region. For example, the portion of the Fc region that binds to FcRn (i.e., the FcRn binding portion) comprises amino acids 282 through 438 of IgG1 with EU numbering (the primary contact sites are amino acids 248, 250 through 257, 272, 285, 288, 290 through 291, 308 through 311 and 314 of the CH2 domain and amino acid residues 385 through 387, 428 and 433 through 436 of the CH3 domain). Thus, the Fc region of the present disclosure may comprise or be composed of the FcRn binding portion. The FcRn binding portion may be derived from heavy chains of any isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, the FcRn binding portion from an antibody of human isotype IgG1 is used. In another embodiment, the FcRn binding portion from an antibody of human isotype IgG4 is used.

[0267] The Fc region may be obtained from a number of different sources. In one embodiment, the Fc region of the polypeptide is derived from human immunoglobulin. However, it is understood that the Fc moiety may be derived from immunoglobulin of other mammalian species, including, for example, rodent species (e.g., mouse, rat, rabbit, guinea pig) or non-human primate species (e.g., chimpanzee, macaque). Furthermore, the polypeptide of the Fc domain or a portion thereof may be derived from any immunoglobulin class including IgM, IgG, IgD, IgA, and IgE, and any immunoglobulin isotype including IgG1, IgG2, IgG3, and IgG4. In another embodiment, human isotype IgG1 is used.

[0268] In a given embodiment, the Fc variant confers a modification of at least one effector function conferred by the Fc moiety comprising the wild-type Fc domain (e.g., an improvement or reduction in the ability of the Fc region to bind to an Fc receptor (e.g., FcγRI, FcγRII, or FcγRIII) or a complement protein (e.g., C1q), or to trigger antibody-dependent cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDCC). In another embodiment, the Fc variant provides a engineered cysteine ​​residue.

[0269] The Fc region of the present disclosure may use field-recognized Fc variants known to impart an effector function and / or a change (e.g., increase or decrease) in the FcR or FcRn bond.Specifically, the Fc section of the present disclosure is International PCT Publication WO 88 / 07089A1, WO 96 / 14339A1, WO 98 / 05787A1, WO 98 / 23289A1, WO 99 / 51642A1, WO 99 / 58572A1, WO 00 / 09560A2, WO 00 / 32767A1, WO 00 / 42072A2, WO 02 / 44215A2, WO 02 / 060919A2, WO 03 / 074569A2, WO 04 / 016750A2, WO 04 / 029207A2, WO 04 / 035752A2, WO 04 / 063351A2, WO WO No. 04 / 074455A2, WO No. 04 / 099249A2, WO No. 05 / 040217A2, WO No. 04 / 044859, WO No. 05 / 070963A1, WO No. 05 / 077981A2, WO No. 05 / 092925A2, WO No. 05 / 123780A2, WO No. 06 / 019447A1, WO No. 06 / 047350A2 and WO No. 06 / 085967A2; U.S. Patent Publication US No. 2007 / 0231329, US No. 2007 / 0231329, US No. 2007 / 0237765, US No. 2007 / 0237766, US No. 2007 / 0237767, US No. 2007 / 0243188, US No. 20070248603, US No. 20070286859, US No. 20080057056; or U.S. Patent No. 5,648,260; No. 5,739,277; No. 5,834,250; No. 5,869,046; No. 6,096,871; No. 6,121,022; No. 6,194,551; No. 6,242,195; Changes (e.g., substitutions) at one or more amino acid positions disclosed in 6,277,375; 6,528,624; 6,538,124; 6,737,056; 6,821,505; 6,998,253; 7,083,784; 7,404,956 and 7,317,091 (each of which is incorporated herein by reference) may be included.In one embodiment, a specific modification (e.g., a specific substitution of one or more amino acids disclosed in the art) may be made at one or more disclosed amino acid positions. In another embodiment, a different modification at one or more disclosed amino acid positions (e.g., a different substitution of one or more amino acid positions disclosed in the art) may be made.

[0270] The Fc region of IgG or the FcRn binding partner may be modified according to well-recognized procedures, such as site-specific mutagenesis, to generate modified IgG or Fc fragments or parts thereof bound to FcRn. Such modifications include modifications far from the FcRn contact site and modifications within the contact site that preserve or even enhance binding to FcRn.For example, the following single amino acid residue (Fcγ1) in human IgG1 Fc can be substituted without a significant loss of Fc binding affinity for FcRn: P238A, S239A, K246A, K248A, D249A, M252A, T256A, E258A, T260A, D265A, S267A, H268A, E269A, D270A, E272A, L274A, N276A, Y278A, D280A, V282A, E283A, H285A, N286A, T289A, K290A, R292A, E293A, E294A, Q295A, Y296F, N297A, S298A, Y300F, R301A, V303A, V305A, T307A, L309A, Q311A, D312A, N315A, K317A, E318A, K320A, K322A, S324A, K326A, A327Q, P329A, A330Q, P331A, E333A, K334A, T335A, S337A, K338A, K340A, Q342A, R344A, E345A, Q347A, R355A, E356A, M358A, T359A, K360A, N361A, Q362A, Y373A, S375A, D376A, A378Q, E380A, E382A, S383A, N384A, Q386A, E388A, N389A, N390A, Y391F, K392A, L398A, S400A, D401A, D413A, K414A, R416A, Q418A, Q419A, N421A, V422A, S424A, E430A, N434A, T437A, Q438A, K439A, S440A, S444A, and K447A (wherein, for example, P238A represents wild-type proline substituted by alanine at position 238). As an example, a specific embodiment introduces the N297A mutation which removes a highly conserved N-glycosylation site. In addition to alanine, other amino acids may be substituted for the wild-type amino acid at the aforementioned positions.Mutations can be introduced as Fc alone to generate more than 100 Fc regions distinct from native Fc. Additionally, combinations of two, three, or more of these individual mutations can be introduced together to generate more than hundreds of Fc regions.

[0271] The aforementioned mutation may confer a new functional group to the Fc region or the FcRn binding partner. For example, one embodiment introduces N297A, which removes a highly conserved N-glycosylation site. The effect of this mutation is to reduce immunogenicity, thereby increasing the circulating half-life of the Fc region and preventing the Fc region from binding to FcγRI, FcγRIIA, FcγRIIB, and FcγRIIIA without impairing the affinity for FcRn (Routledge et al. 1995, Transplantation 60:847; Friend et al. 1999, Transplantation 68:1632; Shields et al. 1995, J. Biol. Chem. 276:6591). As an example of the addition of a new functional group resulting from the mutation described above, the affinity for FcRn may increase beyond that of the wild type in some cases. This increased affinity may reflect an increased "binding" constant, a decreased "dissociation" constant, or both an increased "binding" constant and a decreased "dissociation" constant. Examples of mutations thought to confer increased affinity for FcRn include, but are not limited to, T256A, T307A, E380A, and N434A (Shields et al. 2001, J. Biol. Chem. 276:6591).

[0272] Additionally, at least three human Fc gamma receptors appear to recognize binding sites on IgG in the down-hinge region, generally within amino acids 234 through 237. Thus, another example of a novel functional group and potential reduced immunogenicity may arise from mutations in this region, for instance, by substituting amino acids 233 through 236 of human IgG1 "ELLG" (Sequence No. 45) with the corresponding sequence from IgG2 "PVA" (which has a one-amino acid deletion). It was found that when such mutations are introduced, FcγRI, FcγRII, and FcγRIII, which mediate various effector functions, do not bind to IgG1 (Ward and Ghetie 1995, Therapeutic Immunology 2:77 and Armour et al. 1999, Eur. J. Immunol. 29:2613).

[0273] In another embodiment, the immunoglobulin constant region or a portion thereof comprises an amino acid sequence in a hinge region or a portion thereof that forms one or more disulfide bonds with the second immunoglobulin constant region or a portion thereof. The second immunoglobulin constant region or a portion thereof may be linked to the second polypeptide so that the FVIII protein and the second polypeptide may be together. In some embodiments, the second polypeptide is an enhancer moiety. As used herein, the term “enhancer moiety” means a molecule, fragment, or component of the polypeptide capable of enhancing the coagulating activity of FVIII. The enhancer moiety may be a carrier, such as a soluble tissue factor (sTF) or a coagulating peptide. Thus, upon activation of FVIII, the enhancer moiety is available to enhance FVIII activity.

[0274] In a given embodiment, the FVIII protein encoded by the nucleic acid molecule of the present disclosure has an antigen-independent effector function of the Ig constant region, in particular an immunoglobulin constant region or a portion thereof that alters the cyclic half-life of the protein (e.g. , It includes amino acid substitutions for the Fc variant.

[0275] 2. scFc area

[0276] In another aspect, the non-homologous moiety comprises a scFc (short-chain Fc) region. In one embodiment, the isolated nucleic acid molecule of the present disclosure further comprises a non-homologous nucleic acid sequence encoding a scFc region. The scFc region comprises at least two immunoglobulin constant regions or parts thereof (e.g., intramolecular or intermolecular folding) within the same linear polypeptide chain that can be folded (e.g., intramolecular or intermolecular folding) to form a single functional scFc region linked by an Fc peptide linker. , It comprises Fc moiety or domains (e.g., 2, 3, 4, 5, 6, or more Fc moiety or domains). For example, in one embodiment, the polypeptide of the present disclosure may bind to at least one Fc receptor (e.g., FcRn, FcγR receptor (e.g., FcγRIII), or complement protein (e.g., C1q)) through its scFc region to improve half-life or trigger immune effector function (e.g., antibody-dependent cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDCC)) and / or improve manufacturability.

[0277] 3. CTP

[0278] In another embodiment, the non-homologous moiety comprises one C-terminal peptide (CTP) of the β-subunit of human chorionic gonadotropin or a fragment, variant, or derivative thereof. It is known that one or more CTP peptides inserted into a recombinant protein increase the in vivo half-life of the protein. For example, see U.S. Patent No. 5,712,122 (the full text of which is incorporated herein by reference).

[0279] Exemplary CTP peptides include DPRFQDSSSSKAPPPSLPSPSRLPGPSDTPIL (SEQ No. 33) or SSSSKAPPPSLPSPSRLPGPSDTPILPQ (SEQ No. 34). For example, refer to U.S. Patent Application No. 2009 / 0087411 A1 (incorporated by reference).

[0280] 4. XTEN sequence

[0281] In some embodiments, the non-homologous moiety comprises one or more XTEN sequences, fragments, variants, or derivatives thereof. As used herein, "XTEN sequence" refers to an extended-length polypeptide having a naturally non-generating, substantially non-repeating sequence composed mainly of small hydrophilic amino acids, and the sequence has little to no secondary or tertiary structure under physiological conditions. As a non-homologous moiety, XTEN can act as a half-life extending moiety. Additionally, XTEN can provide desired properties including (but not limited to) enhanced pharmacokinetic parameters and solubility characteristics.

[0282] Introduction of a non-homologous moiety comprising the XTEN sequence of the present disclosure into a protein may confer one or more of the following advantageous properties to the protein: stereotype flexibility, increased aqueous solubility, a high degree of protease resistance, low immunogenicity, low binding to mammalian receptors, or increased hydrodynamic (or Stokes) radius.

[0283] In a given embodiment, the XTEN sequence can increase pharmacokinetic properties, such as a longer in vivo half-life or an increased area under the curve (AUC), so that the protein of the present disclosure remains in vivo and has coagulation-promoting activity for an increased period of time compared to a protein having the XTEN non-homologous moiety, except that the protein does not have the XTEN non-homologous moiety.

[0284] In some embodiments, the XTEN sequence useful for the present disclosure is a peptide or polypeptide having more than about 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1400, 1600, 1800, or 2000 amino acid residues. In a given embodiment, XTEN is a peptide or polypeptide having more than about 20 to about 3,000 amino acid residues, more than 30 to about 2,500 residues, more than 40 to about 2,000 residues, more than 50 to about 1,500 residues, more than 60 to about 1,000 residues, more than 70 to about 900 residues, more than 80 to about 800 residues, more than 90 to about 700 residues, more than 100 to about 600 residues, more than 110 to about 500 residues, or more than 120 to about 400 residues. In one specific embodiment, XTEN comprises an amino acid sequence with an amino acid length longer than 42 and shorter than 144.

[0285] The XTEN sequence of the present disclosure may comprise one or more sequence motifs of 5 to 14 (e.g., 9 to 14) amino acid residues or amino acid sequences that are at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence motif, wherein the motif comprises, is essentially composed of, or consists of, 4 to 6 types of amino acids (e.g., 5 amino acids) selected from the group consisting of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P). Refer to US No. 2010-0239554 A1.

[0286] In some embodiments, XTEN comprises non-overlapping sequence motifs, wherein about 80% or at least about 85% or at least about 90% or about 91% or about 92% or about 93% or about 94% or about 95% or about 96% or about 97% or about 98% or about 99% or about 100% of the sequence is composed of multiple units of non-overlapping sequences selected from single motif families selected from Table 4 to form a family sequence. As used herein, “family” means that XTEN has only motifs selected from single motif categories from Table 4; namely, AD, AE, AF, AG, AM, AQ, BC, or BD XTEN, and any other amino acid in XTEN not from the family motif is selected to achieve the required properties, such as allowing the introduction of a restriction site by a coding nucleotide, the introduction of a cleavage sequence, or to achieve a better linkage to FVIII. In some embodiments of the XTEN family, the XTEN sequence comprises multiple units of non-overlapping sequence motifs of the AD motif family, the AE motif family, the AF motif family, the AG motif family, the AM motif family, the AQ motif family, the BC family, or the BD family, and the resulting XTEN exhibits the range of homology described above. In other embodiments, the XTEN comprises multiple units of motif sequences from two or more motif families of Table 2A. This sequence may be selected to achieve desired physical / chemical features, including characteristics such as net charge, hydrophilicity, lack of secondary structure, or lack of repeatability, imparted by the amino acid composition of the motifs described in more detail below. In the embodiments described in this paragraph, the motifs introduced into the XTEN may be selected and assembled using the methods described herein to achieve an XTEN of about 36 to about 3000 amino acid residues.

[0287]

[0288] Examples of XTEN sequences that may be used as non-homologous moiety in the chimeric proteins of the present disclosure are, for example, U.S. Patent Publication No. 2010 / 0239554 A1, No. 2010 / 0323956 A1, No. 2011 / 0046060 A1, No. 2011 / 0046061 A1, No. 2011 / 0077199 A1 or No. 2011 / 0172146 A1, or International Patent Publication WO No. 2010091122 A1, WO No. 2010144502 A2, WO No. 2010144508 A1, WO No. 2011028228 A1, WO No. 2011028229 A1 or WO No. 2011028344 A2 (each of which is in its entirety by reference to this specification). It is disclosed in (included).

[0289] XTEN may have various lengths for insertion into FVIII or linkage thereto. In one embodiment, the length of the XTEN sequence(s) is selected based on the characteristic or function to be achieved in the fusion protein. Depending on the intended characteristic or function, XTEN may be a short or medium-length sequence or a longer sequence capable of acting as a carrier. In a given embodiment, XTEN comprises a short segment of about 6 to about 99 amino acid residues, a medium length of about 100 to about 399 amino acid residues, and a longer length of about 400 to about 1000 and about 3000 or fewer amino acid residues. Accordingly, XTEN inserted into or connected to FVIII may have a length of about 6, about 12, about 36, about 40, about 42, about 72, about 96, about 144, about 288, about 400, about 500, about 576, about 600, about 700, about 800, about 864, about 900, about 1000, about 1500, about 2000, about 2500, or about 3000 or fewer amino acid residues. In another embodiment, the XTEN sequence is of length from about 6 to about 50, about 50 to about 100, about 100 to 150, about 150 to 250, about 250 to 400, about 400 to about 500, about 500 to about 900, about 900 to 1500, about 1500 to 2000, or about 2000 to about 3000 amino acid residues. The exact length of the XTEN inserted into or linked to FVIII may vary without negatively affecting the activity of FVIII. In one embodiment, one or more XTENs used herein have a length of 42 amino acids, 72 amino acids, 144 amino acids, 288 amino acids, 576 amino acids, or 864 amino acids, and are one or more XTEN family sequences; i.e. ,It can be selected from AD, AE, AF, AG, AM, AQ, BC, or BD.

[0290] In some embodiments, the XTEN sequences used in this disclosure are AE42, AG42, AE48, AM48, AE72, AG72, AE108, AG108, AE144, AF144, AG144, AE180, AG180, AE216, AG216, AE252, AG252, AE288, AG288, AE324, AG324, AE360, AG360, AE396, AG396, AE432, AG432, AE468, AG468, AE504, AG504, AF504, AE540, AG540, AF540, AD576, AE576, AF576, AG576, AE612, AG612, AE624, AE648, AG648, AG684, AE720, AG720, AE756, AG756, AE792, AG792, AE828, AG828, AD836, AE864, AF864, AG864, AM875, AE912, AM923, AM1318, BC864, BD864, AE948, AE1044, AE1140, AE1236, AE1332, AE1428, AE1524, AE1620, AE1716, AE1812, AE1908, AE2004A, AG948, AG1044, AG1140, AG1236, It is at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from the group consisting of AG1332, AG1428, AG1524, AG1620, AG1716, AG1812, AG1908, AG2004, and any combination thereof. See US No. 2010-0239554 A1. In one particular embodiment, XTEN comprises AE42, AE72, AE144, AE288, AE576, AE864, AG 42, AG72, AG144, AG288, AG576, AG864, or any combination thereof.

[0291] Exemplary XTEN sequences that can be used as non-homologous moiety in the chimeric proteins of the present disclosure are XTEN AE42-4 (coded by sequence no. 46 and sequence no. 47; FIG. 11c and FIG. 11d, respectively), XTEN 144-2A (coded by sequence no. 48 and sequence no. 49; FIG. 11e and FIG. 11f, respectively), XTEN A144-3B (coded by sequence no. 50 and sequence no. 51; FIG. 11g and FIG. 11h, respectively), XTEN AE144-4A (coded by sequence no. 52 and sequence no. 53; FIG. 11i and FIG. 11j, respectively), XTEN AE144-5A (coded by sequence no. 54 and sequence no. 55; FIG. 11k and FIG. 11l, respectively), XTEN AE144-6B (sequence no. 56, sequence no. Includes XTEN AG144-1 (coded by 57; FIG. 11m and FIG. 11n, respectively), XTEN AG144-1 (coded by sequence number 58, sequence number 59; FIG. 11o and FIG. 11p, respectively), XTEN AG144-A (coded by sequence number 60, sequence number 61; FIG. 11q and FIG. 11r, respectively), XTEN AG144-B (coded by sequence number 62, sequence number 63; FIG. 11s and FIG. 11t, respectively), XTEN AG144-C (coded by sequence number 64, sequence number 65; FIG. 11u and FIG. 11v, respectively) and XTEN AG144-F (coded by sequence number 66, sequence number 67; FIG. 11w and FIG. 11x, respectively). In one particular embodiment, XTEN is coded by sequence number 18.

[0292] In some embodiments, less than 100% of the amino acids of XTEN are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P), or less than 100% of the sequence consists of sequence motifs from Table 2A or the XTEN sequence provided herein. In these embodiments, the remaining amino acid residues of XTEN are selected from any 14 other natural L-amino acids but may be preferentially selected from hydrophilic amino acids, so that the XTEN sequence contains at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% hydrophilic amino acids. The content of hydrophobic amino acids in XTEN used in the conjugated composition may be less than 5%, less than 2%, or less than 1% of hydrophobic amino acid content. Less favorable hydrophobic residues in the composition of XTEN include tryptophan, phenylalanine, tyrosine, leucine, isoleucine, valine, and methionine. Additionally, the XTEN sequence may contain or not contain less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the following amino acids: methionine (e.g., to avoid oxidation), or asparagine and glutamine (to avoid desamidation).

[0293] One or more XTEN sequences may be inserted at the C-terminus or N-terminus of the amino acid sequence encoded by the nucleotide sequence, or between two amino acids in the amino acid sequence encoded by the nucleotide sequence. For example, XTEN may be inserted between two amino acids at one or more insertion sites selected from Table 3. Examples of sites within FVIII acceptable for XTEN insertion may be found, for example, in International Publication WO No. 2013 / 123457 A1 or U.S. Publication No. 2015 / 0158929 A1 (the full text thereof is incorporated herein by reference).

[0294] 5. Albumin, or a fragment, derivative, or thereof variant

[0295] In some embodiments, the non-homologous moiety comprises albumin or a functional fragment thereof. Human serum albumin (HSA, or HA), a 609-amino acid protein in its full-length form, is responsible for a significant proportion of the serum's osmotic pressure and also acts as a carrier for endogenous and exogenous ligands. As used herein, the term "albumin" includes full-length albumin or a functional fragment, variant, derivative, or analog thereof. Examples of albumin or fragments or variants thereof are disclosed in U.S. Patent Publication No. 2008 / 0194481 A1, No. 2008 / 0004206 A1, No. 2008 / 0161243 A1, No. 2008 / 0261877 A1 or No. 2008 / 0153751 A1, or PCT Application Publication No. 2008 / 033413 A2, No. 2009 / 058322 A1 or No. 2007 / 021494 A2 (the full text thereof is incorporated herein by reference).

[0296] In one embodiment, the FVIII protein encoded by the nucleic acid molecule of the present disclosure is an immunoglobulin constant region or a part thereof (e.g., , It includes albumin, a fragment or variant thereof, additionally linked to a second non-homologous moiety selected from the group consisting of Fc region), PAS sequence, HES, and PEG.

[0297] 6. Albumin binding Moiety

[0298] In a given embodiment, the non-homologous moiety is an albumin-binding moiety comprising an albumin-binding peptide, a bacterial albumin-binding domain, an albumin-binding antibody fragment, or any combination thereof.

[0299] For example, the albumin-binding protein may be a bacterial albumin-binding protein, antibody, or antibody fragment comprising a domain antibody (see U.S. Patent No. 6,696,245). The albumin-binding protein may be, for example, one of a bacterial albumin-binding domain, such as Streptococcus protein G (Konig, T. and Skerra, A. (1998) J. Immunol. Methods 218, 73-83). Other examples of albumin-binding peptides that can be used as conjugation partners are, for example, U.S. Patent Application No. 2003 / 0069395 or Dennis et al. (Dennis et al. (2002) J. Biol . Chem .  It has the Cys-Xaa1-Xaa2-Xaa3-Xaa4-Cys common sequence as described in 277, 35035-35043) (wherein Xaa1 is Asp, Asn, Ser, Thr, or Trp; Xaa2 is Asn, Gln, His, Ile, Leu, or Lys; Xaa3 is Ala, Asp, Phe, Trp, or Tyr; and Xaa4 is Asp, Gly, Leu, Phe, Ser, or Thr).

[0300] Domain 3 from Streptococcus protein G, such as that described by Kraulis et al. in FEBS Lett. 378:190-194 (1996) and Linhult et al. in Protein Sci. 11:206-213 (2002), is an example of a bacterial albumin-binding domain. Examples of albumin-binding peptides include a series of peptides having the core sequence DICLPRWGCLW (Sequence No. 35). For example, the literature [Dennis et al.See , J. Biol. Chem. 2002, 277: 35035-35043 (2002)]. For examples of albumin-binding antibody fragments, refer to the literature [Muller and Kontermann, Curr. Opin. Mol. Ther. 9:319-326 (2007); Roovers et al. , Cancer Immunol. Immunother. 56:303-317 (2007), and Holt. et al. This is disclosed in Prot. Eng. Design Sci., 21:283-288 (2008) (the full text thereof is incorporated herein by reference). An example of such an albumin-binding moiety is 2-(3-maleimidopropaneamido)-6-(4-(4-iodophenyl)butanamido) hexanoate ("Albu" tag) as disclosed by Trussel et al. Bioconjugate Chem. 20:2286-2292 (2009).

[0301] Fatty acids, particularly long-chain fatty acids (LCFAs) and long-chain fatty acid-like albumin-binding compounds, may be used to extend the in vivo half-life of the FVIII protein of the present disclosure. An example of an LCFA-like albumin-binding compound is 16-(1-(3-(9-(((2,5-dioxopyrrolidine-l-yloxy)carbonyloxy)-methyl)-7-sulfo-9H-fluorene-2-ylamino)-3-oxopropyl)-2,5-dioxopyrrolidine-3-ylthio)hexadecanoic acid (see, for example, WO 2010 / 140148).

[0302] 7. PAS sequence

[0303] In another embodiment, the non-homologous moiety is a PAS sequence. As used herein, a PAS sequence refers to an amino acid sequence that mainly comprises alanine and serine residues or mainly comprises alanine, serine, and proline residues, and the amino acid sequence forms a random coiled structure under physiological conditions. Thus, a PAS sequence is a building block, amino acid polymer, or sequence cassette that comprises, is essentially composed of, or consists of alanine, serine, and proline, which can be used as part of a non-homologous moiety in a chimeric protein. Thereby, those skilled in the art will know that when residues other than alanine, serine, and proline are added as minor components to the PAS sequence, the amino acid polymer may also form a random coiled structure. As used herein, the term “minor component” means that amino acids other than alanine, serine, and proline can be added to the PAS sequence to a predetermined degree, for example, about 12% or less, i.e., about 12 amino acids out of 100 of the PAS sequence; about 10% or less, i.e., about 10 amino acids out of 100 of the PAS sequence; about 9% or less, i.e., about 9 amino acids out of 100; about 8% or less, i.e., about 8 amino acids out of 100; about 6%, i.e., about 6 amino acids out of 100; about 5%, i.e., about 5 amino acids out of 100; about 4%, i.e., about 4 amino acids out of 100; about 3%, i.e., about 3 amino acids out of 100; about 2%, i.e., about 2 amino acids out of 100; and about 1%, i.e., about 1 amino acid out of 100. Alanine, serine, proline, and other amino acids can be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val.

[0304] Under physiological conditions, the PAS sequence stretch forms a random coil structure and thereby can mediate increased in vivo and / or in vitro stability for the FVIII protein. Since the random coil domain does not adopt a stable structure or function of its own, the biological activity mediated by the FVIII protein is essentially conserved. In another embodiment, the PAS sequence forming the random coil domain is biologically inactive, particularly with respect to proteolysis in blood plasma, immunogenicity, isoelectric / electrostatic behavior, and binding or internalization to cell surface receptors, but is still biodegradable, which provides a clear advantage over synthetic polymers, e.g., PEG.

[0305] Non-limiting examples of PAS sequences forming a random coiled stereostructure include amino acid sequences selected from the group consisting of ASPAAPAPASPAAPAPSAPA (SEQ No. 36), AAPASPAPAAPSAPAPAAPS (SEQ No. 37), APSSPSPSAPSSPSPASPSS (SEQ No. 38), APSSPSPSAPSSPSPASPS (SEQ No. 39), SSPSAPSPSSPASPSPSSPA (SEQ No. 40), AASPAAPSAPPAAASPAAPSAPPA (SEQ No. 41), and ASAAAPAAASAAASAPSAAA (SEQ No. 42), or any combination thereof. Additional examples of PAS sequences are known, for example, from U.S. Patent Publication No. 2010 / 0292130 A1 and PCT Application Publication WO No. 2008 / 155134 A1.

[0306] 8. HAP sequence

[0307] In a given embodiment, the non-homologous moiety is a glycine-rich homo-amino acid polymer (HAP). The HAP sequence may comprise a repeat sequence of glycine having a length of at least 50 amino acids, at least 100 amino acids, 120 amino acids, 140 amino acids, 160 amino acids, 180 amino acids, 200 amino acids, 250 amino acids, 300 amino acids, 350 amino acids, 400 amino acids, 450 amino acids, or 500 amino acids. In one embodiment, the HAP sequence may extend the half-life of the moiety fused to or linked to the HAP sequence. Non-limiting examples of the HAP sequence are (Gly) n , (Gly4Ser) n or S(Gly4Ser) n (Here, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) but is not limited to these. In one embodiment, n is 20, 21, 22, 23, 24, 25, 26, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40. In another embodiment, n is 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200.

[0308] 9. Transferrin or a fragment thereof

[0309] In a given embodiment, the non-homologous moiety is transferrin or a fragment thereof. Any transferrin may be used to make the FVIII protein of the present disclosure. For example, wild-type human TF (TF) is a 679-amino acid protein of approximately 75 kDa (glycosylation not described) having two major domains, N (about 330 amino acids) and C (about 340 amino acids), which appear to originate from a gene duplication. Refer to Gene Bank accession numbers NM001063, XM002793, M12530, XM039845, XM039847 and S95936 (www.ncbi.nlm.nih.gov / ) (the full text of which is incorporated herein by reference). Transferrin comprises two domains, an N domain and a C domain. The N domain includes two subdomains, the N1 domain and the N2 domain, and the C domain includes two subdomains, the C1 domain and the C2 domain.

[0310] In one embodiment, the transferrin non-homologous moiety comprises a transferrin slice variant. In one example, the transferrin slice variant may be a slice variant of human transferrin, for example, Gene Bank accession number AAA61140. In another embodiment, the transferrin portion of the chimeric protein comprises one or more domains of the transferrin sequence, for example, an N domain, a C domain, an N1 domain, an N2 domain, a C1 domain, a C2 domain, or any combination thereof.

[0311] 10. Gap receptors

[0312] In a given embodiment, the non-homologous moiety is a clearance receptor, a fragment, variant, or derivative thereof. LRP1 is a 600 kDa inner membrane protein involved in receptor-mediated clearance of various proteins, such as factor X. For example, see the literature [Narita et al., Blood 91:555-560 (1998)].

[0313] 11. The von Willebrand factor or a fragment thereof

[0314] In a given embodiment, the non-homogeneous moiety is a von Willebrand factor (VWF) or one or more fragments thereof.

[0315] VWF (also known as F8VWF) is a large polymeric glycoprotein present in blood plasma and constitutively produced in the endothelium (in Vibel-Felard bodies), megakaryocytes (α-granules of platelets), and subendothelial connective tissue. The basic VWF monomer is a 2,813-amino acid protein. All monomers contain a number of specific domains with specific functions, D' and D3 domains (together binding to Factor VIII), A1 domain (binding to platelet GPIb-receptor, heparin, and / or possibly collagen), A3 domain (binding to collagen), C1 domain (where the RGD domain binds to platelet integrin αIIbβ3 when activated) and a "cysteine ​​knot" domain at the C-terminal end of the protein (VWF shares with platelet-derived growth factor (PDGF), transforming growth factor-β (TGFβ) and β-human chorionic gonadotropin (βHCG)).

[0316] The 2,813 monomeric amino acid sequence for human VWF is reported in the Gene Bank under accession number NP000543.2. The nucleotide sequence encoding human VWF is reported in the Gene Bank under accession number NM000552.3. Sequence number 44 (Fig. 11b) is the amino acid sequence encoded by sequence number 43. The D' domain contains amino acids 764 through 866 of sequence number 44. The D3 domain contains amino acids 867 through 1240 of sequence number 44.

[0317] In plasma, 95% to 98% of FVIII circulates as a tight, non-covalent complex with full-length VWF. The formation of this complex is important for maintaining adequate plasma levels of FVIIII in vivo. Lenting et al ., Blood. 92(11): 3983-96 (1998); Lenting et al ., J. Thromb. Haemost . 5(7): 1353-60 (2007). When FVIII is activated by proteolysis at positions 372 and 740 in the heavy chain and at position 1689 in the light chain, VWF bound to FVIII is removed from the activated FVIII.

[0318] In a given embodiment, the non-homologous moiety is a full-length von Willebrand factor. In another embodiment, the non-homologous moiety is a von Willebrand factor fragment. As used herein, the term “VWF fragment” or “VWF fragment” means any VWF fragment that interacts with FVIII and possesses at least one characteristic typically provided to FVIII by full-length VWF, e.g., prevention of premature activation to FVIIIa, prevention of premature proteolysis, prevention of association with a phospholipid membrane that may cause premature clearance, prevention of binding to an FVIII gap receptor that may bind naked FVIII rather than VWF-bound FVIII, and / or stabilization of FVIII heavy chain and light chain interactions. In a specific embodiment, the non-homologous moiety is a (VWF) fragment comprising a D' domain and a D3 domain of VWF. A VWF fragment comprising a D' domain and a D3 domain may further comprise a VWF domain selected from the group consisting of an A1 domain, an A2 domain, an A3 domain, a D1 domain, a D2 domain, a D4 domain, a B1 domain, a B2 domain, a B3 domain, a C1 domain, a C2 domain, a CK domain, one or more fragments thereof, and any combination thereof. Further examples of polypeptides having FVIII activity fused to a VWF fragment are disclosed in U.S. Provisional Patent Application No. 61 / 667,901 (filed July 3, 2012) and U.S. Publication No. 2015 / 0023959 A1 (both incorporated herein by reference in their entirety).

[0319] 12. Linker Moiety

[0320] In a given embodiment, the non-homologous moiety is a peptide linker.

[0321] As used herein, the terms “peptide linker” or “linker moiety” mean a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) that links two domains in a linear amino acid sequence of a polypeptide chain.

[0322] In some embodiments, a non-homologous nucleotide sequence encoding a peptide linker may be inserted between the optimized FVIII polynucleotide sequence of the present disclosure and a non-homologous nucleotide sequence encoding one of the non-homologous moiety described above, for example, albumin. The peptide linker may provide flexibility to the chimeric polypeptide molecule. The linker is typically not cleaved, and such cleavage may be desirable. In one embodiment, the linker is not removed during processing.

[0323] The type of linker that may be present in the chimeric protein of the present disclosure is a protease-cleavable linker that comprises a cleavable site (i.e., a protease cleavage site substrate, e.g., factor XIa, factor Xa, or thrombin cleavage site) and may comprise additional linkers at the N-terminus or C-terminus or on both sides of the cleavage site. When this cleavable linker is introduced into the composition of the present disclosure, it produces a chimeric molecule having non-homologous cleavage sites.

[0324] In one embodiment, an FVIII polypeptide encoded by a nucleic acid molecule of the present disclosure comprises two or more Fc domains or moietyes linked via a cscFc linker to form an Fc region contained in a single polypeptide chain. The cscFc linker is flanked by at least one intracellular processing site, i.e., a site cleaved by an intracellular enzyme. Cleaving of the polypeptide at at least one intracellular processing site results in a polypeptide comprising at least two polypeptide chains.

[0325] Other peptide linkers may be optionally used in the compositions of the present disclosure, for example, to link an FVIII protein to an Fc region. Some exemplary linkers that may be used in conjunction with the present disclosure include, for example, polypeptides comprising GlySer amino acids described in more detail below.

[0326] In one embodiment, the peptide linker is synthetic, i.e., naturally occurring. In one embodiment, the peptide linker comprises a peptide (or polypeptide) (which may or may not be naturally occurring) comprising an amino acid sequence that links or genetically fuses a first linear sequence of amino acids to a second linear sequence of amino acids that is not naturally linked or is naturally genetically fused. For example, in one embodiment, the peptide linker is a modified form of a naturally occurring polypeptide (e.g. , It may include a naturally occurring polypeptide that is a mutation (e.g., including addition, substitution, or deletion). In another embodiment, the peptide linker may include a naturally occurring amino acid. In another embodiment, the peptide linker may include a naturally occurring amino acid that occurs in a linear sequence that does not occur in nature. In yet another embodiment, the peptide linker may include a naturally occurring polypeptide sequence.

[0327] For example, in a given embodiment, a peptide linker may be used to fuse identical Fc moietyes to form a homodimeric scFc region. In another embodiment, a peptide linker may be used to fuse different Fc moietyes (e.g., a wild-type Fc moiety and an Fc moiety variant) to form a heterodimeric scFc region.

[0328] In another embodiment, the peptide linker comprises or consists of a gly-ser linker. In one embodiment, the scFc or cscFc linker comprises an immunoglobulin hinge and at least a portion of the gly-ser linker. As used herein, the term “gly-ser linker” means a peptide composed of glycine and serine residues. In a given embodiment, the gly-ser linker may be inserted between two different sequences of the peptide linker. In another embodiment, the gly-ser linker is attached to one or both ends of another sequence of the peptide linker. In a further embodiment, two or more gly-ser linkers are introduced in series in the peptide linker. In one embodiment, the peptide linker of this disclosure comprises at least a portion of the upper hinge region (e.g., derived from an IgG1, IgG2, IgG3, or IgG4 molecule), at least a portion of the middle hinge region (e.g. , It includes a series of gly / ser amino acid residues derived from IgG1, IgG2, IgG3, or IgG4 molecules.

[0329] The peptide linker of the present disclosure is at least one amino acid length and may be of various lengths. In one embodiment, the peptide linker of the present disclosure is about 1 to about 50 amino acid lengths. As used in this context, the term “about” indicates ±2 amino acid residues. Since the linker length must be a positive integer, a length of about 1 to about 50 amino acids means a length of 1 to 3 to 48 to 52 amino acids. In another embodiment, the peptide linker of the present disclosure is about 10 to about 20 amino acid lengths. In another embodiment, the peptide linker of the present disclosure is about 15 to about 50 amino acid lengths. In another embodiment, the peptide linker of the present disclosure is about 20 to about 45 amino acid lengths. In another embodiment, the peptide linker of the present disclosure is about 15 to about 35 amino acids long or about 20 to about 30 amino acids. In another embodiment, the peptide linker of the present disclosure is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 500, 1000, or 2000 amino acids long. In one embodiment, the peptide linker of the present disclosure is 20 or 30 amino acids long.

[0330] In some embodiments, the peptide linker may comprise at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acids. In other embodiments, the peptide linker may comprise at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1,000 amino acids. In some embodiments, the peptide linker may comprise at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids. The peptide linker may include 1 to 5 amino acids, 1 to 10 amino acids, 1 to 20 amino acids, 10 to 50 amino acids, 50 to 100 amino acids, 100 to 200 amino acids, 200 to 300 amino acids, 300 to 400 amino acids, 400 to 500 amino acids, 500 to 600 amino acids, 600 to 700 amino acids, 700 to 800 amino acids, 800 to 900 amino acids, or 900 to 1000 amino acids.

[0331] The peptide linker can be introduced into the polypeptide sequence using techniques known in the art. Modifications can be identified by DNA sequencing analysis. Plasmid DNA can be used in transformed host cells for the stable production of the prepared polypeptide.

[0332] Monomer-dimer hybrid

[0333] In some embodiments, the isolated nucleic acid molecule of the present disclosure further comprising a non-homologous nucleotide sequence codes for a monomer-dimer hybrid molecule comprising FVIII.

[0334] As used herein, the term “monomer-dimer hybrid” means a chimeric protein comprising a first polypeptide chain and a second polypeptide chain associated with each other by disulfide bonds, wherein the first chain comprises factor VIII and a first Fc region, and the second chain comprises a second Fc region without FVIII, or is essentially composed of, or is composed of. Accordingly, the monomer-dimer hybrid construct is a hybrid comprising a monomeric mode having at least one coagulation factor and a dimeric mode having two Fc regions.

[0335] Genetic elements controlling expression

[0336] In some embodiments, the nucleic acid molecule or vector of the present disclosure further comprises at least one expression control sequence. An expression control sequence as used herein is any regulatory nucleotide sequence, such as a promoter sequence or a promoter-enhancer combination, that promotes the efficient transcription and translation of the coding nucleic acid to which it is operatively linked. For example, the isolated nucleic acid molecule of the present disclosure may be operatively linked to at least one transcription control sequence. The gene expression control sequence may be, for example, a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, promoters for the following genes: hypoxanthine phosphoribosyl convertase (HPRT), adenosine deaminase, pyruvate kinase, beta-actin promoter, and other constitutive promoters. Exemplary viral promoters that act constitutively in eukaryotic cells include, for example, cytomegalovirus (CMV), primate virus (e.g., SV40), papillomavirus, adenovirus, human immunodeficiency virus (HIV), Rouss sarcoma virus, cytomegalovirus, long terminal repeats (LTRs) of Molony leukemia virus and other retroviruses, and thymidine kinase promoters of herpes simplex virus. Other constituent promoters are known to those skilled in the art. Promoters useful as gene expression sequences of the present disclosure also include inducible promoters. Inducible promoters are expressed in the presence of an inducer. For example, metallothionein promoters are induced to promote transcription and translation in the presence of a specific metal ion. Other inducible promoters are known to those skilled in the art.

[0337] In one embodiment, the present disclosure comprises the expression of a transgenic gene under the control of a tissue-specific promoter and / or enhancer. In another embodiment, the promoter or other expression control sequence selectively enhances the expression of the transgenic gene in liver cells. Examples of liver-specific promoters include, but are not limited to, mouse tyretin promoter (mTTR), endogenous human factor VIII promoter (F8), human alpha-1-antitrypsin promoter (hAAT), human albumin minimal promoter, and mouse albumin promoter. In certain embodiments, the promoter includes an mTTR promoter. The mTTR promoter is described in the literature [RH Costa et al., 1986, Mol. Cell. Biol. 6:4697]. The F8 promoter is described in the literature [Figueiredo and Brownlee, 1995, J. Biol. Chem. 270:11828-11838].

[0338] Expression levels may be further enhanced to achieve therapeutic efficacy using one or more enhancers. One or more enhancers may be provided alone or together with one or more promoter genes. Typically, the expression control sequence comprises multiple enhancer genes and tissue-specific promoters. In one embodiment, the enhancer comprises one or more copies of an α-1-microglobulin / vicunin enhancer (Rouet et al., 1992, J. Biol. Chem. 267:20765-20773; Rouet et al., 1995, Nucleic Acids Res. 23:395-404; Rouet et al., 1998, Biochem. J. 334:577-584; Ill et al., 1997, Blood Coagulation Fibrinolysis 8:S23-S30). In another embodiment, the enhancer is derived from liver-specific transcription factor binding sites including HNF1, (sense)-HNF3, (sense)-HNF4, (antisense)-HNF1, (antisense)-HNF6, (sense)-EBP, (antisense)-HNF4(antisense), e.g., EBP, DBP, HNF1, HNF3, HNF4, HNF6, and Enh1.

[0339] In a specific example, a promoter useful for the present disclosure includes Sequence No. 69, also known as Gene Bank No. AY661265 (i.e., ET promoter; FIG. 11y). Also, the literature [Vigna et al., Molecular Therapy 11(5) See [763 (2005)]. Examples of other suitable vectors and gene-regulating genetic elements are described in WO No. 02 / 092134, EP1395293, or U.S. Patents No. 6,808,905, 7,745,179, or 7,179,903 (the full text of which is incorporated herein by reference).

[0340] Generally, the expression control sequence should include, as necessary, 5' non-transcription and 5' non-translation sequences involved in the initiation of transcription and translation, respectively, such as TATA boxes, capping sequences, CAAT sequences, etc. In particular, these 5' non-transcription sequences will include a promoter region containing a promoter sequence for the transcriptional control of operatively linked coding nucleic acids. The gene expression sequence may optionally include an enhancer sequence or an upstream activator sequence as desired.

[0341] Vector system

[0342] Some embodiments of the present disclosure relate to a vector comprising one or more codon-optimized nucleic acid molecules encoding a polypeptide having FVIII activity as described herein, a host cell comprising the vector, and a method for treating a bleeding disorder using the vector. The present disclosure meets a significant need in the field by providing a vector comprising an optimized FVIII sequence that demonstrates increased expression in subjects and potentially generates greater therapeutic efficacy when used in gene therapy methods.

[0343] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the first nucleic acid sequence has at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with (i) nucleotides 58 through 1791 of SEQ ID NO. 3 or (ii) nucleotides 58 through 1791 of SEQ ID NO. 4, and the N-terminal portion and the C-terminal portion Together, they have FVIII polypeptide activity.In another embodiment, the nucleic acid molecule comprises a nucleotide sequence comprising a first nucleic acid sequence encoding the N-terminal portion of an FVIII polypeptide and a second nucleic acid sequence encoding the C-terminal portion of an FVIII polypeptide, wherein the second nucleic acid sequence comprises (i) nucleotides 1792 to 4374 of SEQ ID NO. 5; (ii) nucleotides 1792 to 4374 of SEQ ID NO. 6; and (iii) nucleotides 1792 to 2277 and 2320 to 4374 of SEQ ID NO. 5; or (iv) having at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity with nucleotides 1792 to 2277 and 2320 to 4374 of sequence number 6, and the N-terminal portion and the C-terminal portion together have FVIII polypeptide activity.

[0344] In some embodiments, the present disclosure provides a vector comprising a nucleotide molecule isolated from a polypeptide encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 1 or (ii) a nucleic acid sequence having at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 1, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence number 1 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence number 1.

[0345] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 2 or (ii) a nucleic acid sequence having at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 2, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence number 2 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence number 2.

[0346] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 70 or (ii) a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 70, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence number 70 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence number 70.

[0347] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 71 or (ii) a nucleic acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 71, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence number 71 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence number 71.

[0348] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 3 or (ii) a nucleic acid sequence having at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 3, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence no. 3 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 3.

[0349] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 4 or (ii) a nucleic acid sequence having at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 4, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence no. 4 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 4.

[0350] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 5 or (ii) a nucleic acid sequence having at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 5, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence no. 5 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence no. 5.

[0351] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises (i) nucleotides 58 through 4374 of SEQ ID NO. 6 or (ii) a nucleic acid sequence having at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with nucleotides 58 through 2277 and 2320 through 4374 of SEQ ID NO. 6, and is operatively linked to a promoter, a target sequence, or both. In another embodiment, the nucleic acid sequence comprises (i) nucleotides 58 to 4374 of sequence number 6 or (ii) nucleotides 58 to 2277 and 2320 to 4374 of sequence number 6.

[0352] Vectors suitable for the present disclosure include expression vectors, viral vectors, and plasmid vectors. In one embodiment, the vector is a viral vector.

[0353] As used herein, an expression vector means any nucleic acid construct comprising a genetic element necessary for transcription and translation of an inserted coding sequence, or, in the case of an RNA virus vector, a genetic element necessary for replication and translation when introduced into a suitable host cell. An expression vector may include plasmids, phagesid, viruses, and derivatives thereof.

[0354] The expression vector of the present disclosure will comprise an optimized polynucleotide encoding the BDD FVIII protein described herein. In one embodiment, the optimized coding sequence for the BDD FVIII protein is operatively linked to an expression control sequence. As used herein, two nucleic acid sequences are operatively linked when they are covalently linked in such a way that each component nucleic acid sequence allows its functionality. It is said that the coding sequence and the gene expression control sequence are operatively linked when they are covalently linked in such a way that the expression or transcription and / or translation of the coding sequence is under the influence or control of the gene expression control sequence. It is said that two DNA sequences are operatively linked when the induction of a promoter in the 5' gene expression sequence causes transcription of the coding sequence, and the nature of the linkage between the two DNA sequences does not (1) cause the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region directing the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Therefore, the gene expression sequence will be operatively linked to the coding nucleic acid sequence if the gene expression sequence can execute the transcription of that coding nucleic acid sequence so that the generated transcript is translated into a desired protein or polypeptide.

[0355] Viral vectors contain nucleic acid sequences from the following viruses, but are not limited to: retroviruses, e.g., Moloney's rodent leukemia virus, Harvey's rodent sarcoma virus, rodent mammary tumor virus, and Rous's sarcoma virus; lentiviruses; adenoviruses; adeno-associated viruses; SV40 type viruses; polyomaviruses; Epstein-Barr virus; papillomaviruses; herpesviruses; vacciniaviruses; polioviruses; and RNA viruses, e.g., retroviruses. Other vectors widely known in the art may be readily used. A given viral vector is based on a non-cytomorphic eukaryotic virus in which a non-essential gene is replaced by the gene of interest. Non-cytomorphic viruses include retroviruses (whose life cycle involves the reverse transcription of genomic viral RNA into DNA, along with subsequent proviral integration into host cell DNA). Retroviruses have been approved for human gene therapy experiments. Replication-deficient retroviruses (i.e., capable of directing the synthesis of a desired protein but unable to produce infectious particles) are most useful. These genetically modified retroviral expression vectors have general utility for the high-efficiency transduction of genes in vivo. Standard protocols for producing replication-deficient retroviruses (including the steps of introducing exogenous genetic material into a plasmid, transduction of a packaging cell line by the plasmid, production of a recombinant retrovirus by the packaging cell line, collection of viral particles from tissue culture media, and infection of target cells by viral particles) are described in the literature [Kriegler, M., Gene Transfer and Expression, A Laboratory Manual, WH Freeman Co., New York (1990) and Murry, EJ, Methods in Molecular Biology, Vol. 7, Humana Press, Inc., Cliffton, NJIt is provided in (1991).

[0356] In one embodiment, the virus is an adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be non-replicating and can infect a wide range of cell types and species. This has additional advantages such as thermal and lipid solvent stability; a high transduction frequency in cells of various lineages, including hematopoietic cells; and the absence of superinfection inhibition (thereby allowing multiple series of transductions). It has been reported that the adeno-associated virus can integrate into human cell DNA in a site-specific manner, thereby minimizing the potential for insertion mutagenesis and the variability of inserted gene expression characteristics in retroviral infections. Furthermore, wild-type adeno-associated virus infection persists in tissue culture for more than 100 passages in the absence of selective pressure, suggesting that adeno-associated virus genome integration is a relatively stable event. The adeno-associated virus can also act in an extrachromosomal manner.

[0357] In another embodiment, the viral vector is an adeno-associated virus (AAV) engineered to carry a polynucleotide encoding an FVIII protein as disclosed herein. General methods for obtaining recombinant AAV (rAAV) are disclosed. For example, refer to USP No. 8,734,809, No. 2013 / 0195801, and the references cited herein. In some embodiments, the rAAV vector comprises one or more AAV inverted terminal repeats (ITRs) and a transfer gene of interest (e.g., an optimized FVIII polynucleotide sequence). In a given embodiment, a method for producing rAAV involves culturing a desired host cell containing a nucleic acid sequence or a fragment thereof encoding an AAV capsid protein; a functional rep gene; an rAAV vector comprising the AAV inverted terminal repeat (ITR) and the transfer gene of interest; and a helper function sufficient to allow packaging of the recombinant AAV vector with the AAV capsid protein. Materials and methods for carrying out these and related procedures are disclosed, for example, in USP No. 8,734,809, No. 2013 / 0195801, PCT / US1997 / 015692, PCT / US2002 / 033692, PCT / US2002 / 033630, WO No. 2007 / 148971, WO No. 00 / 20561, WO No. 03 / 042361 and WO No. 2007 / 04670.

[0358] One or more different AAV vector sequences derived from almost any serotype may be used in accordance with the present disclosure. The selection of a specific AAV vector sequence will be guided by known parameters, such as the tropism of the target of interest, the required vector yield, etc. In general, AAV serotypes have genomic sequences of significant homology at the amino acid and nucleic acid levels, provide an associated set of gene functions, generate associated virions, and replicate and assemble similarly. For a review of the genomic sequences and genomic similarities of various AAV serotypes, see, for example, Gene Bank Accession No. U89790; Gene Bank Accession No. J01901; Gene Bank Accession No. AF043303; Gene Bank Accession No. AF085716; [Chlorini et al. (1997, J. Vir. 71: 6823-33); Srivastava et al. (1983, J. Vir. 45:555-64); Chlorini et al. Refer to [1999, J. Vir. 73:1309-1319; Rutledge et al. (1998, J. Vir. 72:309-319); and Wu et al. (2000, J. Vir. 74: 8635-47)]. AAV serotypes 1, 2, 3, 4, and 5 are exemplary sources of AAV nucleotide sequences for use in the context of this disclosure. For example, AAV6, AAV7, AAV8, or AAV9 or newly developed AAV-like particles obtained by capsid shuffling techniques and AAV capsid libraries or from newly designed, developed, or deployed ITRs are also suitable for the given disclosure application. References [Dalkara, D et al. (2013), Sci. Transl. Med. 5(189): 189ra76; Kotterman, MA Nat. Rev. Genet. See

[2014] 15(7):455].

[0359] However, in certain embodiments, an AAV vector having significant tropism in the liver and related tissues will be of interest for expressing the FVIII protein disclosed herein. Non-limiting examples include AAV serotypes 1, 2, 6, and 8. For example, refer to [Torres-Torranteras et al. (2014) 22: 901] and the literature cited herein.

[0360] In another embodiment, the vector is derived from a lentivirus. In a given embodiment, the vector is a vector of a recombinant lentivirus capable of infecting non-dividing cells.

[0361] Lentivirus genomes and proviral DNA typically possess three genes found in retroviruses—gag, pol, and env—flanked by two long end-terminal (LTR) sequences. The gag gene codes for internal structure proteins (matrix, capsid, and nucleocapsid); the pol gene codes for RNA-directed DNA polymerase (reverse transcriptase), protease, and integrase; and the env gene codes for viral envelope glycoproteins. The 5' and 3' LTRs function to promote the transcription and polyadenylation of virion RNA. The LTRs contain all other cis-functional sequences required for viral replication. Lentiviruses possess additional genes (in HIV-1, HIV-2, and / or SIV), including vif, vpr, tat, rev, vpu, nef, and vpx.

[0362] The sequences required for reverse transcription of the genome (tRNA primer binding site) and efficient translocation of viral RNA into particles (Psi site) are adjacent to the 5' LTR. If the sequence required for translocation (or packaging of retroviral RNA into infectious virions) is missing from the viral genome, the cis defect prevents the translocation of genomic RNA.

[0363] However, the generated mutant is capable of directing the synthesis of all virion proteins. The present disclosure provides a method for producing a recombinant lentivirus capable of infecting non-dividing cells, comprising transfecting a suitable host cell with two or more vectors having packaging functions, namely gag, pol, and env, and rev and tat. As disclosed herein, a vector lacking the functional tat gene is preferred in a given field. Thus, for example, a first vector may provide nucleic acids encoding viral gag and viral pol, and another vector may provide nucleic acids encoding viral env that generates packaging cells. Introducing a vector providing the non-homologous gene identified herein as a carrier vector into the packaging cell generates a producer cell that releases an infectious viral particle containing the foreign gene of interest.

[0364] Depending on the configuration of the vector and the foreign gene indicated above, the second vector may provide nucleic acid encoding a viral envelope (env) gene. The env gene may be derived from almost any suitable virus, including retroviruses. In some embodiments, the env protein is an amphotropic envelope protein that allows transduction into cells of human and other species.

[0365] Examples of retrovirus-derived env genes include, but are not limited to, Molony rodent leukemia virus (MoMuLV or MMLV), Harvey rodent sarcoma virus (HaMuSV or HSV), rodent mammary tumor virus (MuMTV or MMTV), gibbon leukemia virus (GaLV or GALV), human immunodeficiency virus (HIV), and Rous sarcoma virus (RSV). Other env genes, such as those of vesicular stomatitis virus (VSV) protein G (VSV G), hepatitis virus, and influenza, may also be used.

[0366] A vector providing a viral env nucleic acid sequence is operatively associated with a regulatory sequence otherwise described herein.

[0367] In a given embodiment, the vector comprises a lentivirus vector in which the HIV virulence genes env, vif, vpr, vpu, and nef are deleted without impairing the vector's ability to transduce non-dividing cells.

[0368] In some embodiments, the vector comprises a lentivirus vector containing a deletion of the U3 region of the 3' LTR. The deletion of the U3 region may be a complete deletion or a partial deletion.

[0369] In some embodiments, a lentiviral vector of the present disclosure comprising an FVIII nucleotide sequence described herein may be transfected in cells by (a) a first nucleotide sequence comprising a gag, pol, or gag and pol gene and (b) a second nucleotide sequence comprising a non-homologous env gene; and the lentiviral vector lacks a functional tat gene. In other embodiments, the cells are further transfected by a fourth nucleotide sequence comprising a rev gene. In certain embodiments, the lentiviral vector lacks a functional gene selected from vif, vpr, vpu, vpx, and nef, or a combination thereof.

[0370] In a given embodiment, the lentivirus vector comprises one or more nucleotide sequences encoding a gag protein, a Rev-responsive genetic element, a central polypurine track (cPPT), or any combination thereof.

[0371] Examples of lentivirus vectors are disclosed in WO 9931251, W0 9712622, W0 9817815, W0 9817816 and WO 9818934 (the full text of which is incorporated herein by reference).

[0372] Other vectors include plasmid vectors. Plasmid vectors are extensively described in the field and are widely known to those skilled in the art. For example, the literature [Sambrook et al Refer to [Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989]. In recent years, plasmid vectors have been found to be particularly advantageous for delivering genes into in vivo cells due to their inability to replicate and integrate into the host genome. However, these plasmids, which possess promoters compatible with host cells, can express peptides from genes operatively encoded within the plasmid. Some commonly used plasmids available from commercial suppliers include pBR322, pUC18, pUC19, various pcDNA plasmids, pRC / CMV, various pCMV plasmids, pSV40, and pBlueScript. Additional examples of specific plasmids include pcDNA3.1, Catalog V79020; pcDNA3.1 / hygro, Catalog V87020; pcDNA4 / myc-His, Catalog V86320; and pBudCE4.1, Catalog V53220 (all available from Invitrogen, Carlsbad, California). Other plasmids are widely known to those skilled in the art. Additionally, plasmids may be custom-designed using standard molecular biology techniques to remove and / or add specific fragments of DNA.

[0373] Tissue-specific expression

[0374] In certain embodiments, it may be useful to include one or more miRNA target sequences within the vector that are operatively linked to, for example, an optimized FVIII transposable gene. Accordingly, the present disclosure also provides at least one miRNA sequence target that is operatively linked to an optimized FVIII nucleotide sequence or otherwise inserted into the vector. More than one copy of the miRNA target sequence included in the vector may increase the effectiveness of the system. Different miRNA target sequences are also included. For example, a vector expressing more than one transposable gene may have the transposable gene under the control of more than one miRNA target sequence, which may be the same or different. The miRNA target sequences may be tandem, but other arrangements are also included. A transposable gene expression cassette containing miRNA target sequences may also be inserted into the vector in an antisense orientation. Antisense orientation may be useful in the production of viral particles to avoid the expression of gene products that may otherwise be toxic to producer cells. In other embodiments, the vector comprises one, two, three, four, five, six, seven, or eight copies of the same or different miRNA target sequences. However, in certain other embodiments, the vector will not comprise any miRNA target sequences. The choice of whether or not to comprise miRNA target sequences (and how much) will be guided by known parameters, such as the intended tissue target and the required level of expression.

[0375] In one embodiment, the target sequence is the miR-223 target, which has been reported to block expression most effectively in myeloid-only progenitor cells and at least partially more primitive HSPCs. The miR-223 target can block expression in differentiated myeloid cells, including granulocytes, monocytes, macrophages, and myeloid dendritic cells. The miR-223 target may also be suitable for gene therapy applications that rely on robust transgene expression in lymphocyte or erythrocyte lineages. The miR-223 target can also block expression very effectively in human HSCs.

[0376] In another embodiment, the target sequence is the miR142 target (tccataaagt aggaaacact aca (sequence number 43)). In one embodiment, the vector contains four copies of the miR-142 target sequence. In a given embodiment, the complementary sequence of a hematopoietic-specific microRNA, such as miR-142 (142T), is introduced into the 3' untranslated region of a vector, such as a lentiviral vector (LV), so that the transgenic coding transcript becomes susceptible to miRNA-mediated downregulation. By this method, transgenic expression can be maintained in non-hematopoietic cells while being prevented in hematopoietic lineage antigen-presenting cells (APCs) (Brown et al., Nat Med 2006). This strategy allows for strict post-transcriptional control of transgenic expression and thus enables stable delivery and long-term expression of the transgenic. In some embodiments, miR-142 regulation prevents immune-mediated clearance of transduced cells and / or induces antigen-specific regulatory T cells (T reg) and mediates robust immunological tolerance to transgenic coding antigens.

[0377] In some embodiments, the target sequence is a miR181 target. The literature [Chen CZ and Lodish H, Seminars in Immunology (2005) 17(2):155-165] discloses miR-181, a miRNA specifically expressed in B cells within mouse bone marrow (Chen and Lodish, 2005). This also discloses that some human miRNAs are linked to leukemia.

[0378] The target sequence may be fully or partially complementary to the miRNA. The term "fully complementary" means that the target sequence has a nucleic acid sequence that is 100% complementary to the sequence of the miRNA that recognizes it. The term "partially complementary" means that the target sequence is only partially complementary to the sequence of the miRNA that recognizes it (thereby, the partially complementary sequence is still recognized by the miRNA). That is, in the context of this disclosure, a partially complementary target sequence is effective in preventing or reducing transgenic expression in cells that recognize the corresponding miRNA and express that miRNA. Examples of miRNA target sequences are described in WO 2007 / 000668, WO 2004 / 094642, WO 2010 / 055413, or WO 2010 / 125471 (the full text of which is incorporated herein by reference).

[0379] host cell

[0380] The present disclosure also provides a host cell comprising the nucleic acid molecule or vector of the present disclosure. As used herein, the term “transformation” should be used to mean the introduction of DNA into a recipient host cell that alters the genotype and consequently causes changes in the recipient cell.

[0381] "Host cell" means a cell constructed using recombinant DNA techniques and transformed by a vector encoding at least one non-homologous gene. The host cells of this disclosure are preferably of mammalian origin; most preferably of human or mouse origin. The ability to preferentially determine a particular host cell line best suited for this purpose is the credit of those skilled in the art. Exemplary host cell lines include, but are not limited to, CHO, DG44 and DUXB11 (Chinese hamster ovary line, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (derivative of CVI with SV40 T antigen), R1610 (Chinese hamster fibroblast), BALBC / 3T3 (mouse fibroblast), HAK (hamster kidney line), SP2 / O (mouse myeloma), P3.times.63-Ag3.653 (mouse myeloma), BFA-1c1BPT (bovine endothelial cell), RAJI (human lymphocyte), PER.C6 (registered trademark), NS0, CAP, BHK21 and HEK 293 (human kidney). In one particular embodiment, the host cell is selected from the group consisting of CHO cells, HEK293 cells, BHK21 cells, PER.C6 (trademark) cells, NS0 cells, and CAP cells. Host cell lines are typically available from commercial services, the American Tissue Culture Collection, or public literature.

[0382] Introduction of the isolated nucleic acid molecules or vectors of the present disclosure into host cells can be achieved by various techniques widely known to those skilled in the art. This includes, but is not limited to, transfection (including electroporation and electroporation), protoplast fusion, calcium phosphate precipitation, cell fusion with envelope DNA, microinjection, and infection by intact viruses. Reference [Ridgway, AAG] Mammalian Expression VectorsRefer to Chapter 24.2, pp. 470-472 Vectors, Rodriguez and Denhardt, Eds. (Butterworths, Boston, Mass. 1988). Most preferably, plasmid introduction into the host is performed via electroporation. Transformed cells are grown under conditions suitable for the production of light and heavy chains and evaluated for heavy and / or light chain protein synthesis. Exemplary assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or fluorescence-activated cell sorting assay (FACS), immunohistochemistry, etc.

[0383] Host cells containing the isolated nucleic acid molecule or vector of the present disclosure are grown in a suitable growth medium. As used herein, the term “suitable growth medium” means a medium containing nutrients necessary for cell growth. Nutrients necessary for cell growth may include carbon sources, nitrogen sources, essential amino acids, vitamins, minerals, and growth factors. Optionally, the medium may contain one or more selectors. Optionally, the medium may contain bovine calf serum or fetal calf serum (FCS). In one embodiment, the medium is substantially free of IgG. The growth medium will select cells generally containing the DNA construct, for example, by supplementing with selectable markers in the DNA construct or by drug selection for deficiencies in essential nutrients co-transfected by the DNA construct. Cultured mammalian cells are generally grown in commercially available serum-containing or serum-free media (e.g., MEM, DMEM, DMEM / F12). In one embodiment, the medium is CDoptiCHO (Invitrogen (Carlsbad, California)). In another embodiment, the medium is CD17 (Invitrogen (Carlsbad, California)). The selection of a medium appropriate for the specific cell line used is within the level of a person skilled in the art.

[0384] Preparation of polypeptides

[0385] The present disclosure also provides a polypeptide encoded by a nucleic acid molecule of the present disclosure. In another embodiment, the polypeptide of the present disclosure is encoded by a vector comprising an isolated nucleic acid molecule of the present disclosure. In a further embodiment, the polypeptide of the present disclosure is produced by a host cell comprising an isolated nucleic acid molecule of the present disclosure.

[0386] In another embodiment, the present disclosure also provides a method for producing a polypeptide having FVIII activity, comprising the steps of culturing a host cell of the present disclosure under conditions in which a polypeptide having FVIII activity is produced, and recovering the polypeptide having FVIII activity. In some embodiments, the expression of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions, except that the reference nucleotide sequence comprises SEQ ID NO. 16, which is the parent FVIII gene sequence.

[0387] In another embodiment, the present disclosure provides a method for increasing the expression of a polypeptide having FVIII activity, comprising the step of culturing a host cell of the present disclosure under conditions in which the polypeptide having FVIII activity is expressed by a nucleic acid molecule, wherein the expression of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ ID NO. 16.

[0388] In another embodiment, the present disclosure provides a method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing a host cell under conditions in which the polypeptide having FVIII activity is produced by a nucleic acid molecule, wherein the yield of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ ID NO. 16.

[0389] In another embodiment, the present disclosure provides a method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing a host cell comprising a nucleotide sequence encoding the polypeptide, wherein the codon adaptation index of the 3' portion of the nucleotide sequence is increased compared to the 5' portion of the nucleotide sequence; and the yield of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ NO. 16. In some embodiments, the codon adaptation index of the 5' portion of the nucleotide sequence is not increased, decreased, or changed compared to the codon optimization index of SEQ NO. 16.

[0390] In another embodiment, the present disclosure provides a method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing a host cell comprising a nucleotide sequence encoding the polypeptide, wherein the codon adaptation index of the 5' portion of the nucleotide sequence is increased compared to the 3' portion of the nucleotide sequence; and the yield of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ NO. 16. In some embodiments, the codon adaptation index of the 3' portion of the nucleotide sequence is increased, decreased, or unchanged compared to the codon optimization index of SEQ NO. 16.

[0391] In another embodiment, the present disclosure provides a method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing a host cell comprising a nucleotide sequence encoding the polypeptide, wherein the codon adaptation index of the nucleotide portion encoding the C-terminal portion of the polypeptide is increased compared to the nucleotide portion encoding the N-terminal portion of the polypeptide; and the yield of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ NO. 16. In some embodiments, the codon adaptation index of the nucleotide portion encoding the N-terminal portion of the polypeptide is increased, decreased, or unchanged compared to the codon optimization index of SEQ NO. 16.

[0392] In another embodiment, the present disclosure provides a method for improving the yield of a polypeptide having FVIII activity, comprising the step of culturing a host cell comprising a nucleotide sequence encoding the polypeptide, wherein the codon adaptation index of the portion of nucleotides encoding the N-terminal portion of the polypeptide is increased compared to the portion of nucleotides encoding the C-terminal portion of the polypeptide; and the yield of the polypeptide having FVIII activity is increased compared to a host cell cultured under the same conditions comprising a reference nucleic acid molecule comprising SEQ NO. 16. In some embodiments, the codon adaptation index of the portion of nucleotides encoding the C-terminal portion of the polypeptide is increased, decreased, or unchanged compared to the codon optimization index of SEQ NO. 16.

[0393] In a specific embodiment of improving the yield of a polypeptide having FVIII activity, the 5' portion of the nucleotide sequence corresponds, when properly aligned, to nucleotides about 1 to 1791 of SEQ ID NO. 1, nucleotides 58 to 1791 of SEQ ID NO. 1, or a fragment thereof. In another embodiment, the polypeptide encoded by the 5' portion of the nucleotide corresponds, when properly aligned, to amino acids about 1 to 497 of SEQ ID NO. 17, amino acids 20 to 497 of SEQ ID NO. 17, or a fragment thereof. In a specific embodiment, the portion of the nucleotide sequence encoding the N-terminal portion of the polypeptide corresponds, when properly aligned, to nucleotides about 1 to 1791 of SEQ ID NO. 1, nucleotides 58 to 1791 of SEQ ID NO. 1, or a fragment thereof. In some embodiments, the 3' portion of the nucleotide sequence corresponds to nucleotides approximately 1792 through 4374 of SEQ ID NO. 1 or fragments thereof when properly aligned. In other embodiments, the polypeptide encoded by the 3' portion of the nucleotide corresponds to amino acids approximately 498 through 1458 of SEQ ID NO. 17 or fragments thereof when properly aligned. In some embodiments, the portion of the nucleotide sequence encoding the C-terminal portion of the polypeptide corresponds to nucleotides approximately 1792 through 4374 of SEQ ID NO. 1 or fragments thereof when properly aligned.

[0394] In some embodiments, the expression of FVIII polypeptide is increased by at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, at least about 150 times, or at least about 200 times compared to host cells cultured under the same conditions containing a reference nucleic acid sequence including SEQ No. 16.

[0395] Various methods are available to recombinantly produce FVIII proteins from the optimized nucleic acid molecules of the present disclosure. Polynucleotides of the desired sequence may be produced by nascent solid-phase DNA synthesis or by PCR mutagenesis of previously produced polynucleotides. Oligonucleotide-mediated mutagenesis is one method for preparing substitutions, insertions, deletions, or alterations (e.g., altered codons) in a nucleotide sequence. For example, the starting DNA is altered by hybridizing an oligonucleotide encoding the desired mutation into a single-stranded DNA template. After hybridization, a DNA polymerase is used to synthesize the entire second complementary strand of the template into which the oligonucleotide primer is introduced. In one embodiment, genetic manipulation, e.g., primer-based PCR mutagenesis, is sufficient to introduce the alteration as defined herein to produce the polynucleotides of the present disclosure.

[0396] For the production of a recombinant protein, the optimized polynucleotide sequence of the present disclosure encoding the FVIII protein is inserted into a suitable expression vehicle, that is, a vector containing the genetic elements necessary for transcription and translation of the inserted coding sequence, or, in the case of an RNA virus vector, the genetic elements necessary for replication and translation.

[0397] The polynucleotide sequence of the present disclosure is inserted into a vector in an appropriate reading frame. Subsequently, the expression vector is transfected into suitable target cells expressing the polypeptide. Transfection techniques known in the art include calcium phosphate precipitation (Wigler et al. 1978, Cell 14: 725) and electroporation (Neumann et al. 1982, EMBO , J. Various host-expression vector systems may be used to express the FVIII protein described herein in eukaryotic cells. In one embodiment, the eukaryotic cell is an animal cell, including mammalian cells (e.g., HEK293 cells, PER.C6 (registered trademark), CHO, BHK, Cos, HeLa cells). The polynucleotide sequence of the present disclosure may also code for a signal sequence that allows the FVIII protein to be secreted. Those skilled in the art will understand that as the FVIII protein is translated, the signal sequence is cleaved by the cell to form a mature protein. Various signal sequences, e.g., native Factor VII signal sequence, native Factor IX signal sequence, and mouse IgK light chain signal sequence, are known in the art. Alternatively, where no signal sequence is included, the FVIII protein may be recovered by lysing the cell.

[0398] The FVIII protein of the present disclosure may be synthesized in transgenic animals, such as rodents, goats, sheep, pigs, or cattle. The term “transgenic animal” means a non-human animal into which an exogenous gene has been introduced into its genome. Since this gene is present in the germline tissue, it is passed from parents to offspring. The exogenous gene is introduced into a single-cell embryo (Brinster et al. 1985, Proc. Natl. Acad. Sci. USA 82:4438). Methods for producing transgenic animals, including transformations that produce immunoglobulin molecules, are known in the art (Wagner et al. 1981, Proc. Natl. Acad. Sci. USA 78: 6376; ​​McKnight et al. 1983, Cell 34: 335; Brinster et al. 1983, Nature 306: 332; Ritchie et al. 1984, Nature 312: 517; Baldassarre et al. 2003, Theriogenology 59: 831; Robl et al. 2003, Theriogenology 59: 107; Malassagne et al. 2003, Xenotransplantation 10 (3): 267).

[0399] Expression vectors may encode tags that allow for the easy purification or identification of proteins produced by recombinant production. Examples include, but are not limited to, the vector pUR278 (Ruther et al. 1983, EMBO J. 2: 1791) (wherein the sequence encoding the FVIII protein described herein can be ligated to the vector as a frame with the lac Z coding region to produce a hybrid protein); pGEX vectors may be used to express proteins having a glutathione S-convertase (GST) tag. These proteins are typically soluble and can be easily purified from cells by adsorption onto glutathione-agarose beads, followed by elution in the presence of free glutathione. The vector may include cleavage sites (e.g.,) for easy removal of the tag after purification. , Precission Protease Includes (Pharmacia (New Jersey Pharmacist)).

[0400] For the purposes of the present disclosure, many expression vector systems may be used. These expression vectors are typically replicable in a host organism as an integrated portion of episomal or host chromosomal DNA. The expression vector may include expression control sequences, for example, promoters (e.g., naturally related or non-homologous promoters), enhancers, signal sequences, slice signals, enhancer genetic elements, and transcription termination sequences (but not limited thereto). Preferably, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. The expression vector may also utilize DNA genetic elements derived from animal viruses, such as bovine papillomavirus, polyomavirus, adenovirus, vaccinia virus, baculovirus, retrovirus (RSV, MMTV, or MOMLV), cytomegalovirus (CMV), or SV40 virus. Others involve the use of polycistronic systems having internal ribosomal binding sites.

[0401] Often, expression vectors contain selection markers (e.g., ampicillin resistance, hygromycin resistance, tetracycline resistance, or neomycin resistance) to allow the detection of cells transformed by the desired DNA sequence (e.g., Itakura et al (See U.S. Patent No. 4,704,362). Cells that have incorporated DNA into the chromosome may be selected by introducing one or more markers that allow selection of the transfused host cell. The markers may provide basic prototrophy, resistance to biocides (e.g., antibiotics), or resistance to heavy metals, such as copper, to the trophic host. The selectable marker gene may be directly linked to the DNA sequence to be expressed or may be introduced into the same cell by co-transformation.

[0402] An example of a vector useful for expressing an optimized FVIII sequence is NEOSPLA (U.S. Patent No. 6,159,730). This vector contains a cytomegalovirus promoter / enhancer, a mouse beta-globin major promoter, an SV40 replication origin, a bovine growth hormone polyadenylation sequence, neomycin phosphoconvertase exons 1 and 2, a dihydrofolate reductase gene, and a leader sequence. This vector has been found to result in very high levels of antibody expression upon the introduction of variable and constant region genes, transfection into cells, subsequent selection in G418-containing medium, and methotrexate amplification. Vector systems are also taught in U.S. Patents No. 5,736,137 and No. 5,658,570 (the full text of which is incorporated herein by reference). These systems provide high expression levels, for example, greater than 30 pg / cell / day. Other exemplary vector systems are disclosed, for example, in U.S. Patent No. 6,413,777.

[0403] In another embodiment, the polypeptide of the present disclosure may be expressed using a polyci...

Claims

Claim 1 An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence comprising nucleotides 58 to 2277 and 2320 to 4374 of SEQ ID NO.

71. Claim 2 In claim 1, the nucleotide sequence further comprises a nucleic acid sequence encoding a signal peptide, wherein the nucleic acid sequence encoding the signal peptide comprises (i) nucleotides 1 to 57 of SEQ ID NO. 1; (ii) nucleotides 1 to 57 of SEQ ID NO. 2; (iii) nucleotides 1 to 57 of SEQ ID NO. 3; (iv) nucleotides 1 to 57 of SEQ ID NO. 4; (v) nucleotides 1 to 57 of SEQ ID NO. 5; (vi) nucleotides 1 to 57 of SEQ ID NO. 6; (vii) nucleotides 1 to 57 of SEQ ID NO. 70; and (viii) nucleotides 1 to 57 of SEQ ID NO.

71. or (ix) an isolated nucleic acid molecule having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with nucleotides 1 to 57 of sequence number 68. Claim 3 In claim 1, the nucleic acid molecule comprises: (a) an increase in the human codon adaptation index of the nucleic acid molecule or a part thereof compared to SEQ NO. 16; (b) an increase in the frequency of optimal codons of the nucleotide sequence or a part thereof compared to SEQ NO. 16; (c) a higher percentage of G and C nucleotides compared to the percentage of G and C nucleotides in SEQ NO. 16; (d) an increase in the frequency of relative synonymous codon use of the nucleotide sequence or a part thereof compared to SEQ NO. 16; (e) a decrease in the effective number of codons of the nucleotide sequence or a part thereof compared to SEQ NO. 16; (f) a lower matrix attachment-like sequence of the nucleotide sequence compared to SEQ NO. 16; and (g) a lower destabilizing genetic element of the nucleotide sequence compared to SEQ NO.

16. and (h) an isolated nucleic acid molecule comprising one or more characteristics selected from the group consisting of any combination thereof. Claim 4 An isolated nucleic acid molecule according to claim 1, further comprising a non-homologous nucleotide sequence encoding a non-homologous amino acid sequence. Claim 5 In paragraph 4, the above-mentioned non-homologous amino acid sequence is an isolated nucleic acid molecule that is an immunoglobulin constant region or a part thereof, XTEN, transferrin, albumin, or PAS sequence. Claim 6 In claim 5, the nucleotide sequence is an isolated nucleic acid molecule comprising sequence number 72. Claim 7 In claim 4, the isolated nucleic acid molecule is connected to the N-terminus or C-terminus of the amino acid sequence encoded by the nucleotide sequence, or inserted between two amino acids in the amino acid sequence encoded by the nucleotide sequence at one or more insertion sites. Claim 8 A vector comprising a nucleic acid molecule according to claim 1. Claim 9 In paragraph 8, the vector is a lentivirus vector. Claim 10 A host cell comprising a nucleic acid molecule according to paragraph 1 or 6. Claim 11 A host cell comprising a vector according to paragraph 8 or 9. Claim 12 A method for producing a polypeptide having FVIII activity, comprising the steps of culturing the host cell of claim 10 under conditions in which the polypeptide having FVIII activity is produced, and recovering the polypeptide having FVIII activity. Claim 13 A composition for use in a method for treating a bleeding disorder, comprising a nucleic acid molecule of claim 1 or 6. Claim 14 A composition for use in a method for treating a bleeding disorder, wherein the method comprises administering the vector of claim 8 to a subject. Claim 15 Isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide having FVIII activity, wherein the nucleotide sequence comprises a nucleic acid sequence comprising nucleotides 58 to 4374 of SEQ ID NO.

71. Claim 16 delete

Citation Information

Patent Citations

  • Recombinant factor viii proteins

    KR1020140134291A

  • Optimised coding sequence and promoter

    US20130024960A1